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General introduction  
 
Epidemiology and etiology of esophageal cancer 
The incidence of esophageal cancer (EC) has increased over the past few decades.1, 2 EC is 
the eight most common cancer and the sixth most common cause of death worldwide.3 The 
incidence of EC was approximately 2,500 in the Netherlands, in 2018.2 
������ ���� ���� ����� ������ ��� ��;� ����������� ��������� ����� ���������� ������� ����
����������� ��������������� ������� ��������� ����� ��� ��������� ������� �����������type 
worldwide, EAC predominates in the Netherlands.2 Likewise, EAC is the most common type 
in West and North Euro����������������������������4 ���������������������������������������
highest in East Asia and Africa.4 
These two types of EC differ in certain �����������������������������������������������������
middle part of the esophagus while EAC is located in the lower part of the esophagus and the 
gastroesophageal junction (GEJ). In developed countries, smoking and alcohol are risk factors 
���������5 Besides smoking and alcohol, poor nutritional status (low intake of vegetables and 
fruits) and drinking high temperature beverages are thought to be risk factors ��������� ���
Asian countries.6 Common risk factors for EAC are obesity, smoking, and the presence of 
Barrett’s esophagus (BE).7, 8 ���������������������������������ted as a risk factor for EAC.9 
Clinical presentation, diagnosis and treatment of esophageal cancer 
Patients with EC often present with weight loss and progressive dysphagia.8 Asymptomatic 
patients might present with iron deficiency anemia due to chronic gastrointestinal blood loss 
from EC.8 However, patients with early stage EC usualy do not present with any symptoms 
and EC is therefore often diagnosed in an advanced stage.8, 10 �����������������������-year 
survival rate of EC is only 19%.11 When EC is detected in an early stage, curative treatment 
is possible with less morbidity and mortality.8 A study by Pech et al. about the long-term folow-
up results of 1,000 patients who underwent endoscopic mucosal resection (EMR) for early 
EAC, showed a long-term complete remission rate of 93.8% and a 10-year survival rate of 
75%.12 
Esophagoduodenoscopy (EGD) is the gold standard for EC diagnosis.8, 13 EGD alows the 
gastroenterologist to visualize the tumor and take biopsies to confirm EC diagnosis.8 During 
EGD, the endoscopist can macroscopicaly assess the tumor for morphology according to the 
Paris classification, location, size, and whether EC is suitable for endoscopic resection (ER).14, 
15 The latter, however, has to be performed by an endoscopist with experience in assessing 
endoscopic resectability of the tumor. 
EC staging is based on the American Joint Committee on Cancer’s TNM system.16 Degree of 
tumor invasion (T), regional lymph node involvement (N), and the presence of distant 
metastasis (M) are described in this system.16 Different tumor stages of EC are presented in 
Figure 1. To determine the TNM-classification for a specific esophageal carcinoma, guidelines 
recommend endos����������������� ���������������� ����������� ������������������������
emission tomography (PET).8, 13 ���� ��� ����� ������ ����� ���� ������ �������� �������� ��� ���







Figure 1. Esophageal cancer tumor staging [from Rubenstein JH, Shaheen NJ. “Epidemiology, 
diagnosis and management of esophageal adenocarcinoma.” ����������������� ����;� ����������, 
Copyright Elsevier;������������������������������].�� 
��� ��������� ����� ����� ���� ��� ��������� ��� �������� ��� ���� ��� EAC, but less accurate in 
���������������������������������������������-55%, specificity 80-�����20, 21 As a result, many 
����������������������������������������������������������������������������������������
invasive treatment.�� Accurate tumor staging i���������������������������������������������������
����������� 
��������� ����� ����� ������ ���������� ������ �� ���������-in-����� ������ ��� ���� �� ����� ��� ����
������� ������������� ����� ���� ������� ����������� ���������������������� ������ ��-����22 
Therefore, ER with���� ��������� ����� ���� ��� ���������� ��� ������ ������������� ���� �� When EAC 
������������������������������������������������������;�����������25-�� However, when pT1b 
EAC is limited to the upper part of the submucosa (sm1: ≤500 μm) without poor histologic 
fe�����������������������������������������������������������������������������������������������
���������������������������������������������������������������������������������������������
these patients.��  
������������������������������ ���������������� ����������������������� ����������������
���������� ���� ����� ���� ���������� ���� ���������� ����������� ����� ����������omy.�� Current 
����������� ���������� �������������� ����� ����-��������� ������ ����� ����������� ������ ���
without neo-��������� �����-�������������� ��� ���ients with pT1b EAC with submucosal 
invasion ≥sm2 (>500 μ������������������������������������� 
��������� ���� ������ �������� ����� ����� ���� ��������� ����� ��������� ���������
����������������������������������������������������������������������������������������inical 






improve estimation of LNM risk. A clinical tool is needed for shared decision making whether 
or not to undergo adjuvant treatment after ER of pT1b EAC. 
Esophageal squamous cell carcinoma and the risk of second primary tumors in the 
upper aerodigestive tract 
In patients with ESCC, multiple primary tumors (MPTs) frequently develop.33 Likewise, MPTs 
can also develop in patients with head and neck squamous cel carcinoma (HNSCC).34, 35 
These MPTs are particularly located in the upper aerodigestive tract (UADT), consisting of the 
head and neck region, esophagus and lungs.36 The stomach is another important region at 
risk for MPT development.37  
The occurrence of MPTs can be explained by the field cancerization theory, which was first 
described by Slaughter et al., in 1953.38 Premalignant histologic and genetic changes can 
occur around the primary tumor due to carcinogen exposure, such as alcohol and tobacco.38 
These subtle histologic and genetic changes might increase the risk of synchronous and 
metachronous MPTs.38 Common risk factors for cancers in the UADT might play a role in the 
development of MPTs.37 When MPTs develop within 6 months after diagnosis of the primary 
tumor, it is defined synchronous. MPTs that develop ≥ 6 months after primary tumor diagnosis 
are defined metachronous. 
Previous studies have reported an MPT incidence in the UADT up to 19.3% in patients with 
primary ESCC.33, 39-42 Most of these studies have been performed in Asian populations and 
data on Western incidences are currently not known. The head and neck region is especialy 
at risk for developing MPTs in patients with ESCC.37, 42 Although the prognosis of EC is poor 
because most tumors are diagnosed in an advanced stage, this prognosis is even worse when 
head and neck second primary tumors (HNSPTs) are detected.8, 43 A previous study reported 
a 5-year survival rate of 21.0% in patients with ESCC compared to 9.2% in ESCC patients 
with HNSPT.43 Early detection of MPTs is therefore vitaly important. Nowadays, The 
European Society for Medical Oncology Clinical Practice Guidelines for EC recommends head 
and neck and lung screening to detect MPTs in patients with ESCC who use chronic tobacco 
and alcohol.44 However, screening is usualy not performed in daily clinical practice and no 
Western screening studies have been published to date. 
MPTs that develop in patients with HNSCC are particularly located in the esophagus.35, 45 The 
prevalence of these esophageal MPTs is reported up to 22% in retrospective studies.46 Early 
detection of esophageal MPTs is very important since early EC can be treated with minimaly 
invasive ER instead of surgery or (neo-adjuvant) chemo-radiotherapy, which is associated 
with higher morbidity and decreased quality of life.47, 48 Although several esophageal screening 
studies have been performed in Asian patients with HNSCC, there is a lack of screening 







Endoscopic detection techniques 
EGD is the gold standard for the detection of (early) EC. EGD can be performed with white 
light high resolution endoscopy (WLE), narrow band imaging (NBI) and Lugol 
chromoendoscopy (LCE). Early EC, in particular ESCC, are characterized by flat lesions and 
these lesions are easily missed with WLE.49 
LCE is considered by many the gold standard for the detection of superficial ESCC.50 Lugol 
iodine binds to glycogen and is applied during EGD to stain the esophagus.51 Glycogen is 
abundant in normal epithelium and diminished or absent in dysplastic or neoplastic tissue.51 
Iodine-unstained areas, also caled Lugol-voiding lesions (LVL), are therefore characteristic 
for dysplastic and neoplastic lesions.49, 51 However, non-dysplastic lesions such as 
inflammation can also appear unstained wherefore LCE is not very specific.49 In addition, LCE 
can cause several side effects, such as chest discomfort, nausea, heartburn and pulmonary 
aspiration.52, 53 
NBI is a real-time optical chromoendoscopy technique that was first described in 2004.54 In 
contrast to LCE, NBI can be used by simply pressing a button on the endoscope.52 
Intraepithelial papilary capilary loop (IPCL) patterns can be visualized with NBI.55, 56 
Figure 2 shows the IPCL pattern classification. IPCL type I-III corresponds to benign pathology 
and low grade neoplasia (LGIN).56, 57 IPCL type IV corresponds to LGIN or high grade 
neoplasia (HGIN).56 IPCL pattern V is a malignant pattern and is classified into four 
categories.56 The recommended treatment for these different IPCL patterns is outlined in the 
last column of Figure 2. 
�������������������������������������������� ���� ��;����������������-2 in the left picture 
with NBI and LVL in the right picture with LCE. Since endoscopic imaging techniques have 
improved over time and LCE has several side effects, the question arises whether LCE is stil 






Figure 2. IPCL pattern classification IPCL, ������������������������������������ ����;�����, low grade 
���������;� ����, ����� ������ ���������;� ���, ����������� �������� ���������;� ���, endoscopic 
����������� ����������;� ��, ����������� ���������;� ���, chemoradiotherapy. [from ������� ��� ����














Endoscopic resection of early esophageal cancer 
ER can be used to remove early EC. ER is mostly performed with either endoscopic mucosal 
resection (EMR) or endoscopic submucosal dissection (ESD).  
The EMR-cap technique and the EMR band ligation technique are often used for EC resection. 
EMR-cap: the lesion is sucked into the cap after fluid injection into the submucosa, and the 
snare is closed at the base of the tumor. EMR band ligation: a rubber band is placed at the 
base of the tumor to create a ‘pseudo polyp’, the snare is tightened below the rubber band 
and the ‘pseudo polyp’ is subsequently removed.58 
ESD has a higher curative resection rate than EMR and is used when submucosal invasion of 
the lesion is suspected.59, 60 During ESD, a fluid solution with blue dye, usualy indigo carmine 
is injected in the submucosal layer to elevate the lesion from the muscular layer.58 Afterwards, 
a circumferential incision is made around the target lesion folowed by dissection of the 
submucosal layer.58 ESD is a time-consuming procedure that can result in pain and discomfort 
for the patient.61, 62 Adequate sedation and analgesia are required to limit complications.63-65 
Although guidelines do not recommend a preferred sedation method during ESD, general 
anesthesia with endotracheal intubation is most often used during this procedure because of 
the continuous airway protection which may lead to fewer respiratory problems.63, 66, 67 
However, disadvantages of general anesthesia are higher procedural costs, the need for an 
anesthesiologist, and prolonged post-procedural hospital stay.63, 67 
Strictures rates after endoscopic resection 
A major disadvantage after ER of large esophageal tumors is the high esophageal stricture 
rate.68, 69 This risk is especialy high when the mucosal defect after ER is more than three 
quarters of the esophageal circumference. Strictures can result in dysphagia with the need for 
endoscopic dilations that might decrease patients quality of life.70 Several methods have been 
described to prevent these strictures (e.g. preventive baloon dilation, triamcinolone injections, 
oral prednisolone).68, 71-73 However, these methods al have several side effects. The optimal 
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Aims and outline of this thesis  
 
AIMS 
This thesis aims to provide insights in the incidence and risk of second and multiple primary 
tumors (MPTs) in the upper aerodigestive tract (UADT) in patients with esophageal squamous 
cel carcinoma (ESCC) and in patients with head and neck squamous cel carcinoma 
(HNSCC). The second aim of this thesis is to investigate whether screening for these MPTs 
is recommended. 
The third aim of this thesis is to optimize clinical staging and endoscopic resection (ER) of 
early esophageal cancer (EC) and to develop a prediction model that estimates the risk of 
lymph node metastasis (LNM) in individual patients with submucosal (pT1b) esophageal 
adenocarcinoma (EAC). 
OUTLINE OF THE THESIS  
This thesis is divided into four parts. Part I contains the general introduction (Chapter 1.1) 
and the aims and outline of this thesis (Chapter 1.2). In Chapter 1.1, a general introduction 
on EC is outlined including epidemiology, etiology, clinical presentation, diagnosis and 
treatment of early EC, risk factors for LNM, the risk for second primary tumors (SPTs) in the 
UADT in patients with ESCC and HNSCC, endoscopic detection techniques, ER techniques, 
and the prevention of esophageal strictures after ER. Chapter 1.2 describes the aims and 
outline of this thesis.  
Part II of this thesis focusses on screening and diagnosis of MPTs in the UADT in patients 
with ESCC and HNSCC. Part II starts with an overview of the prevalence of MPTs in patients 
with ESCC in the Netherlands, in Chapter 2. In this chapter, the risk of MPTs in patients with 
ESCC is compared with the general population.  
It is currently known that Asian patients with ESCC have a high risk of developing MPTs, 
compared to the general population. The head and neck region is especialy at risk for 
developing MPTs. Several screening studies have been performed to screen for head and 
neck SPTs in patients with ESCC. Chapter 3 describes a systematic review and meta-analysis 
of studies in which head and neck screening was performed in patients with ESCC. 
Conversely, patients with HNSCC are also at risk for developing SPTs in the esophagus. 
Chapter 4 describes a systematic review and meta-analysis of studies in which esophageal 
screening was performed by Lugol chromoendoscopy (LCE) to screen for esophageal SPTs 
in patients with HNSCC.  
Most screening studies are performed in the Asian population and there is a lack of wel-
defined screening studies in the Western population. Chapter 5 describes a prospective 
screening study in which patients with HNSCC are screened with 
esophagogastroduodenoscopy (EGD) for esophageal SPTs. EGD is performed with white 
light high resolution endoscopy (WLE), narrow-band imaging (NBI) and LCE. LCE is 
considered by many the gold standard for the detection of early ESCC. However, endoscopic 
imaging techniques have drasticaly improved over time. In addition, LCE is associated with 






when LCE is stil necessary for the detection of ESCC. Chapter 6 concerns an editorial 
whether Lugol is stil necessary for ESCC detection to date.  
While Part II of this thesis is about ESCC, Part III mainly focusses on early EAC. Endoscopic 
ultrasound (EUS) is used for clinical staging of early EAC. It is known that the accuracy of 
EUS is low in differentiating T1 from T2 EAC. Chapter 7 describes a multicenter prospective 
cohort study of patients with a clinical (c)T2 EAC. These patients underwent endoscopic 
reassessment by an experienced interventional endoscopist in order to assess the proportion 
of cT2 EAC that were downstaged to cT1 EAC.  
Early EC can be treated with ER. Endoscopic mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD) are both appropriate ER methods. ESD has a higher curative 
resection rate than EMR and is used when submucosal invasion of the tumor is suspected or 
when the tumor cannot be removed by EMR. ESD is, however, time-consuming and minimal 
patient movement is preferred during the procedure. Therefore, appropriate sedation and 
analgesia are required to perform a successful ESD. Chapter 8 describes a retrospective 
cohort study of patient who underwent ESD for early esophageal or gastric cancer. In this 
study, analgosedation using propofol and remifentanil without endotracheal intubation was 
used and endoscopy- and anesthesia-related complications were reported.  
When ER is performed in the esophagus, there is a risk of developing esophageal strictures 
after the procedure. This risk is especialy high when the mucosal defect after ER is more than 
three quarters of the esophageal circumference. Several methods have been described to 
prevent these strictures. Chapter 9 describes the effectiveness of a treatment with topical 
Budesonide for the prevention of esophageal strictures after ESD for EC (both ESCC and 
EAC).  
After ER, the ER specimen is assessed by the pathologist. Adjuvant therapy, such as 
esophagectomy, is only required when the risk of LNM outweighs the risk for mortality 
associated with esophagectomy. Although many studies have described separate 
histopathological risk factors associated with LNM, no clinical tool is available that incorporates 
these histopathological parameters to predict the LNM risk on an individual basis. Chapter 
10.1 describes a multicenter retrospective cohort study of patients with submucosal (pT1b) 
EAC that underwent ER or primary surgery. A prediction model was developed, and internaly 
validated, that incorporated al accepted prognostic parameters to accurately predict the LNM 
risk on an individual basis. 
Currently, lymphovascular invasion (LVI) is classified as either present or absent. Chapter 
10.2 describes a multicenter retrospective cohort study that determines whether quantification 
of LVI provides additional prognostic information for the development of LNM in patients with 
pT1b EAC.  
Part IV starts with Chapter 11.1, in which the summary of the main findings is outlined. 
Chapter 11.2 includes the general discussion and recommendations for further research. The 
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Background: Patients with primary esophageal squamous cel carcinoma are at risk of 
developing multiple primary tumors in the upper aerodigestive tract. To date, most studies are 
performed in the Asian population. We aimed to evaluate the risk of multiple primary tumors 
in the upper aerodigestive tract and stomach in patients with esophageal squamous cel 
carcinoma in a Western population. 
 
Methods: We performed a nationwide, retrospective cohort study in colaboration with the 
Netherlands Cancer Registry. Patients with primary esophageal squamous cel carcinoma, 
diagnosed between 2000 and 2016, were included. Primary endpoints were synchronous and 
metachronous multiple primary tumor risk. 
 
Results: The cohort consisted of 9,058 patients, diagnosed with esophageal squamous cel 
carcinoma (male: 57.3%, median age 67 years). In 476 patients (5.3%), 545 multiple primary 
tumors have been diagnosed. Most of them were located in the head and neck region (49.5%). 
Among al multiple primary tumors, 329 (60.4%) were diagnosed synchronously (<6 months 
after esophageal squamous cell carcinoma diagnosis) and 216 (39.6%) metachronously (≥6 
months). Patients with esophageal squamous cel carcinoma had a significantly increased risk 
of both synchronous (standardized incidence ratio 10.95, 99% confidence interval 9.40-12.53) 
and metachronous multiple primary tumors (standardized incidence ratio 4.36, 99% 
confidence interval 3.56-5.10), compared to the general population. The median interval to 
metachronous second primary tumor diagnosis was 3.0 years (interquartile range 1.8-5.9). 
 
Conclusion: Approximately one in 20 patients with primary esophageal squamous cel 
carcinoma have a second primary tumor in the upper aerodigestive tract or stomach, either at 
the time of esophageal squamous cel carcinoma diagnosis or at a later stage. As second 
primary tumors occur at an increased risk compared to the general population, prospective 
studies are necessary to investigate the yield and survival benefit of screening for second 








Squamous cel carcinoma is the most common histologic type of esophageal cancer 
worldwide, and has the highest incidence in Eastern Asia.1, 2 Multiple primary tumors (MPTs) 
frequently develop in patients with esophageal squamous cel carcinoma (ESCC), especialy 
in the upper aerodigestive tract (UADT).3, 4 
Since survival of patients with esophageal cancer has improved over the last years due to 
better treatment options, the risk of developing MPTs may increase.5 These MPTs affect the 
prognosis and survival of patients with ESCC, and the choice of ESCC treatment in case of 
synchronous second primary tumor (SPT) detection.6 It is therefore important to detect MPTs 
at an early stage, when curative treatment is stil possible. 
The development of MPTs in the UADT particularly occurs in patients with squamous cel 
carcinomas, and can be explained by the ‘field cancerization’ theory.7 This theory states that 
premalignant epithelial changes can occur around the primary tumor, due to exposure to 
common carcinogens.7 Wel-known carcinogens for the development of both ESCC and 
MPTs, especialy in the head and neck region and lungs, are tobacco and alcohol.8, 9 
In retrospective studies, up to 19.3% of patients with primary ESCC develop MPTs in the 
UADT.3, 10-13 Most studies consider the head and neck region, lungs, and esophagus as the 
UADT, the stomach is another important region to be at risk for MPT development.3, 12, 14, 15 
Most studies about MPT development, however, are performed in Asian populations. There is 
a lack of Western studies about MPT incidence in ESCC patients.  
We therefore conducted a nationwide, retrospective, registry study of patients with primary 
ESCC to determine the risk of developing MPTs in the UADT and stomach, in a Western 
country. 
 
MATERIALS AND METHODS 
 
Patient and study design 
We conducted a nationwide, retrospective, registry study in colaboration with the Netherlands 
Cancer Re������� ����;� ����������� ��������� ��� ���� ���������� ������ ��������� ���������� �����
ESCC between 1 January 2000 and 31 December 2016 were selected from the NCR. Patients 
�����������������������������������������������;��������������������������������������
or stomach which was diagnosed >180 days prior to ESCC diagnosis. This study was 
approved by the Medical Ethical Review Committee of the Erasmus Medical Centre [MEC-
2018-1631] on 7 January 2019. The study protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki as reflected in a priori approval by the institution's Human 
Research Committee. 
Data collection 
Anonymous patient data were obtained from the NCR. The folowing data were available and 
colected: year and age at ESCC diagnosis, sex, ESCC tumor characteristics, the presence of 
metastases, and ESCC treatment. Tumor characteristics included histology, location in the 
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����������� ��� ������������ ���� ���������� ������ ���� ����� ����� ��������� ������ ��-scan, 
����������������������������������������������������������������������������������������
��������� ���������� ������������������ ������� ������� ��������������������������������������
(��� ����� ��� ���������� ����� ���� ������ ������ ��� ������� �������� ���� �c�� ���� ���� ��� ��
�������������������������������� ��������������������������������������������������������
6 months before or after ESCC diagnosis, and as metachronous when it developed ≥6 months 
������������������������������� ��������-���������������������� ������������������������ ���
������������������������20-22 ��������������������������������������������������������������
���������� ��������������� ��� ���� ��� ���� ������� �������������� ������������ �������������




general populati���� ���������� ���������� ����;� ���� ���� ������������� ��� ���� ����� ����
�����������������������������c��������������������������������������������������������d) 
�����������������������������������e��������������������������������������������������������
���� ������� �������� ���� ����� ������� �������� ������ ������������� ������ ���� ���� ����� ��������
��������������������������������� 
Statistics 
���������� ���������� ����� ���������� ��� ����� ��� ��������� ���������� ������ ���� �������
(interqua������ ������ ������ ���� ������� ���� ��������� ���� ������� ������������ �����������
������������������������������������������ ������������ ������������������������ ����� ���������
������� ������� ������ ���� ���� ����������� ���������� ������ ����� �� �� �-dependent covariate 
�������-��� �� �� ������ ������������ ��� ��� ����� ������ ��� ���� ����� ����� ��� ������-���� �����
�������������������������� 
�������������� ���������������������������� ��������������s������������incidence ra����������
��������������������������������������������������������������������������������������������
��� ��������� ��� ������������������������������������������� �������������������������������
���������������������������������������������������������������������������������������������
age, gender, year and ty���������������������������������������������������������������������






incidence data from the general population were acquired from the NCR. The cumulative 
incidence of SPTs was estimated with death as competing risk. STATA (v. 14) was used for 
this analysis.  
Survival analysis was determined by Kaplan-Meier analysis, and we performed log-rank 
analysis using SPSS. SIRs were calculated with SAS 9.2 software (SAS Institute Inc., Cary, 
North Caroline, USA), al other analysis were carried out using IBM SPSS version 25. For 
SIRs, a two-sided test with a p-value of <0.01 was considered significant. For al other 





We identified a total of 9,810 patients with ESCC diagnosis between 1 January 2000 and 31 
December 2016 in the NCR. In total, 752 patients were excluded because ESCC was not the 
index tumor (Figure 1). The study cohort consisted of 9,058 patients with primary ESCC. The 
median age at ESCC diagnosis was 67 years (IQR 60-75), most patients were male (57.3%) 
(baseline characteristics are shown in Table 1). The total folow-up consisted of 17,072 
person-years with a median folow-up time of 9.8 months (IQR 4.2-23.8 months). The median 
survival after ESCC diagnosis was 9.9 months (IQR 9.6-10.3). The overal five-year survival 
rate of the total cohort was 15.9%. 
 
Figure 1. Flow-chart patient selection and MPT development 
ESCC, esophageal squamous ��������������;������������������;���������������� ���������;�
UADT, upper aerodigestive tract.
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Table 1. Baseline and tumor characteristics of patients with esophageal squamous cell 
carcinoma 
 
Characteristics (N=9,058)  
Gender, n(%)  
Male 5,193 (57.3%) 
Median age (years) (IQR)  67 (60-75) 
Follow-up 
Person-years at risk (years) 










Median overall survival after ESCC diagnosis (months) (95% CI) 9.9 (9.6-10.3) 
Anatomical sub-location, n (%) 
Cervical esophagus 
Upper third esophagus 
Middle third esophagus 
Lower third esophagus 





















Differentiation grade, n (%) 
Grade 1 (good) 
Grade 2 (moderate) 
Grade 3 (poor) 








Distant metastasis at diagnosis (cM stage), n (%) 2,372 (26.2%) 





Chemotherapy + radiotherapy 
neoadjuvant chemotherapy + surgery  
Chemotherapy +radiotherapy + surgery 
Surgery + radiotherapy 















range. a other treatment combinations with either endoscopic or surgical resection 








The majority of ESCCs were located in the middle (36.4%) and lower third (38.7%) of the 
esophagus (Table 1). ESCC tumor stage was low in 26.3% and high in 55.7% of patients. 
Pathological assessment of ESCCs revealed good or moderate differentiation grade (G1/G2) 
in 33.5%, and poor or undifferentiated grade (G3/G4) in 28.7%. In total, 2,372 patients (26.2%) 
had distant metastasis at time of diagnosis (cM stage). In total, 2,163 patients (23.9%) were 
treated with radiotherapy for ESCC, 1,812 patients (20.0%) with chemo-radiotherapy, and 
1,288 (14.2%) patients received neoadjuvant therapy folowed by surgery.  
MPTs 
A total of 545 MPTs were registered in 476 (5.3%) patients. Of these 476 patients, 50 patients 
developed a third primary tumor, 16 patients a fourth primary tumor, and one patient 
developed another fifth, sixth and seventh primary tumor (Figure 1). Of al MPTs (545), 329 
(60.4%) were diagnosed synchronously and 216 (39.6%) metachronously (Table 2). The 
majority of both synchronous and metachronous MPTs were located in the head and neck 
���������������;���������������������������;��������� ��������������������������������������
in 39.6%, and high (stage III/IV) in 43.5% of the tumors, which was roughly the same for 
synchronous and metachronous MPTs. Of al MPTs, 160/545 (29.4%) were treated with 
radiotherapy and 170/545 MPTs (31.2%) did not receive any treatment. Squamous cel 
������������������;���������������� ������������������������� ������������������ 
SIRs 
In total, 545 MPTs were detected during the observation period. Patients with ESCC had a 
significantly increased risk of both synchronous (SIR 10.95, 99% CI 9.40-12.53) and 
metachronous MPTs (SIR 4.36, 99% CI 3.56-5.10) compared to the general population (Table 
3). Sub-analyses showed that patients with ESCC had the highest risk of developing 
synchronous (SIR 36.33, 99% CI 29.44-44.30) and metachronous (SIR 14.17, 99% CI 10.41-
17.52) MPTs in the head and neck region. Patients aged 41-60 years at ESCC diagnosis had 
a highest SIR of 32.07 (99% CI 24.71-40.77) for developing synchronous MPTs, and patients 
aged 18-40 years at ESCC diagnosis had a highest SIR of 70.87 (99% CI 2.72-329.97) for 
developing metachronous MPTs. In order to determine whether radiotherapy had influence on 
MPT development compared to other treatments, we stratified the MPT risk for different 
treatment groups. The MPT risk was high for al different treatment groups compared to the 
general population. We were unable to address any influence of previous radiotherapy on 
MPT �����������;������������������������������������������������������������������
diagnosis (n=15), only four patients received radiotherapy for ESCCs. For al sub-analyses, 
females had the highest SIR compared to males (Table 3). 
Metachronous SPT 
Of al patients who were alive 6 months after ESCC diagnosis (n=5,715), 191 patients 
developed metachronous MPTs. Of these patients, 16 had already developed a synchronous 
SPT. In total, 175 patients developed a metachronous SPT. Figure 2 shows the cumulative 
incidence of metachronous SPTs. Fifteen years after ESCC diagnosis, the cumulative 
incidence of metachronous SPTs was 19.7%. Cumulative incidences of different SPT sub-
locations is shown in the Supplementary Tables S1-S4, Figures S1 and S2. The median time 
between ESCC diagnosis and metachronous SPT diagnosis was 3.0 years (IQR 1.8 – 5.9). 
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The median time between ESCC and metachronous head and neck SPT diagnosis was 2.8 
years (IQR 2.2 – 3.4) and for lung SPT diagnosis 3.2 years (IQR 1.9 – 4.5). SPT stage was 
high (stage III/IV) in 57.4% of the patients with metachronous SPTs. These patients had a 
significantly worse two-year survival after SPT diagnosis than low stage SPTs (stage 0/ I/II) 
(15.1% vs 51.9%, p<0.01) (Figure 3).  
Cumulative incidence of MPTs in patients with low-stage ESCC 
Subgroup analysis was performed in patients with low-stage ESCC (n=2,381). The 15-year 
cumulative incidence for this subgroup was 21.7% (Supplementary Table S5 and Figure S3). 
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Chemo + surgery 
Chemo + radio + surgery 
Surgery + radio 
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Figure 2. Cumulative incidence of metachronous SPT after ESCC diagnosis 

















Figure 3. Survival after SPT diagnosis between low- and high-stage metachronous SPT 
SPT, second primary tumor, ������;�������������were excluded for this analysis as result of missing 
SPT tumor stages  
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Predictive factors for MPTs 
Multivariable Cox proportional hazard analysis showed that being male (HR 1.59, 95% CI 
1.29-1.97, p<0.001), age <70 years (HR 1.51, 95% CI 1.19-1.90, p=0.001), and having a low 
ESCC tumor stage (stage 0/I/II) at diagnosis (HR 1.50, 95% CI 1.19-1.89, p=0.001) were 
independent predictors for MPT development (Table 4). Analysis with age (HR 0.99, 95% CI 
0.98-0.10, p=0.022) and tumor stage (HR 0.73, 95% CI 0.64-0.82, p<0.001) as continues 
variables did not alter the outcomes. 
 
Table 4. Multivariable analysis for MPT development using  
Cox proportional hazards regression model 
 






































We determined the risk of developing MPTs in the UADT and stomach in patients with primary 
ESCC. Our study shows that a minimum of one out of 20 patients with primary ESCC develops 
an SPT, with a 15-year cumulative metachronous SPT incidence of 19.7%. Which means that 
approximately one in five ESCC patients who survive longer than 6 months wil develop an 
SPT within 15 years. The risk of developing synchronous (SIR 10.95) and metachronous 
MPTs (SIR 4.36) among patients with primary ESCC was increased compared to the general 
population, with the highest risk of developing MPTs in the head and neck region. Risk factors 
associated with MPT development are being male, age <70 years, and low ESCC tumor stage. 
In retrospective studies, the incidence of MPTs localized the UADT among patients with 
primary ESCC ranged between 1.9-19.3%.3, 10-13 Most studies are performed in the Asian 
population, where the MPT incidence is reported to be >10%.3, 11, 13, 23 Studies performed in a 
Western population reported lower MPT incidences (1.9-6.3%), which is in accordance with 
our findings.12, 24, 25 The difference in MPT incidence between Asian and non-Asian populations 
could possibly be explained by a difference in etiology. While the etiology of ESCC and MPTs 
in the UADT is clearly linked to smoking and alcohol intake in a Western population, the 
etiology in an Asian population is also linked to a poor nutritional status.26, 27 Another 
explanation might be the difference in genetic polymorphisms in alcohol metabolism between 





The increased MPT risk among patients with primary ESCC, as reported in our study, has also 
been reported in other studies.12, 15, 30, 31 Chuang et al. reported an increased risk of MPTs in 
the UADT, especialy in the head and neck region (SIR 6.68) and lungs (SIR 1.55), among 
ESCC patients in 13 different countries.15 Other studies also reported increased MPT risks.10, 
14, 24, 30, 32 As reported in our study, patients with ESCC diagnosis at a young age showed the 
highest SIR for developing both synchronous (SIR 32.07) and metachronous MPTs (SIR 
70.87). The same results were reported in a study by Chen et al., with a SIR of 36.56 for 
patients aged between 20-39 years at ESCC diagnosis.30 
We found the head and neck region to be the most common region for developing MPTs 
������������;������������ ������������������������� �����������������������������������������
15.83) and Western (SIR 6.68-8.64) studies.12, 14, 15, 30, 31 Studies from Japan and Korea 
reported the stomach as their most common MPT location.3, 4 This could be due to the high 
incidence of stomach cancer in Japan and Korea.2 Unfortunately, SIRs were not reported in 
these studies.3, 4 For synchronous MPTs, we found the stomach to be the second most 
common region for MPT development. Less patients had synchronous or metachronous 
esophageal MPT in our cohort. In case a synchronous esophageal SPT is detected, one could 
argue that these patients probably had mucosal dysplasia or neoplasia at time of primary 
ESCC diagnosis. Careful inspection of the esophagus with Lugol chromoendoscopy is 
therefore very important in cases of curative primary ESCC diagnosis, because early 
esophageal SPT might be easily overlooked during routine white light endoscopy.33 
Patients who develop metachronous SPT may potentialy benefit from screening programs. 
The median time between ESCC diagnosis and metachronous SPT detection was 3 years 
(IQR 1.8-5.9 years), with a cumulative 15-years incidence of 19.7%. Most metachronous 
SPTs, however, had a high tumor stage (57.4%), with a worse two-year survival compared to 
low-stage metachronous SPTs (15.1% versus 51.9%, p<0.01). Screening for metachronous 
SPTs could possibly help to increase survival in these patients by detecting these SPTs at an 
early stage. Patients with high-stage ESCC with poor prognosis wil possibly not benefit from 
screening programs since their prognosis is already determined by the ESCC. Diagnosing 
MPTs in these patients is probably not clinicaly relevant. The overal survival of our cohort 
was 9.9 months, the overal five-year survival was 15.9%. Prospective studies are necessary 
to investigate the yield of screening for MPTs, and especialy whether screening wil lead to 
survival benefit. One could argue that synchronous SPTs already existed at time of index 
tumor diagnosis but had not yet been detected at that time. The question arises whether 
routine screening of especialy the head and neck region should be performed in curative 
ESCC patients prior to ESCC treatment. 
Asian screening studies to detect head and neck SPTs have been performed in patients with 
primary ESCC. A systematic review about active screening for head and neck SPTs in patients 
with primary ESCC showed a pooled prevalence of 6.7% (range 3.0-29.6%).22 Active 
screening showed a low SPT tumor stage in most patients (85.7%), and a better survival 
compared to patients who were not screened.22, 34 These studies suggest that active screening 
contributes to an increase in SPT detection and overal survival.4 Nowadays, no screening 
studies in patients with ESCC have been performed in Western countries.  
Being male was a predictive factor for MPT development in our study, which is in accordance 
with previous studies.24, 30, 31 Our study revealed age <70 years as a significant predictive 
factor, which is also in line with a previous study.24 Chen et al., however, reported age ≥60 
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years as a predictive factor for MPT development.30 Although higher age is reported as a 
significant risk factor for cancer development in the UADT or stomach in general, one might 
hypothesize that when patients survive ESCC at a young age they are expected to live longer 
and might have an increased risk in MPT development. The same might be true for patients 
with low ESCC tumor stage, they have a more favorable course of their disease and are 
therefore expected to live longer. We reported low ESCC tumor stage as a predictive factor 
for MPT development, but this has to be interpreted with caution.  
Although this is the largest registry study in Europe with more than 9,000 patients, some 
limitations need to be acknowledged. First, this is a retrospective cohort study with limited 
patient information and a substantial amount of missing data. We could therefore not report 
on risk factors such as smoking or alcohol which are common risk factors for MPT 
development.30 This might have caused confounding in our risk factor analysis. In addition, 
cause of death was not reported in the NCR and this information could be relevant in this 
patient cohort with a large number of high-stage ESCC and a median survival of only 10 
months. Second, since this is a registry study, MPT incidence could be underestimated. 
Because of the retrospective design of this study, we did not know whether MPTs were 
diagnosed during regular folow-up or as a result of patients symptoms. As a consequence, 
no specific advice for time-interval for screening can be drawn from this study. 
A minimum of one out of 20 patients with primary ESCC develops an MPT in the UADT or 
stomach. The majority of these MPTs were detected synchronously, in the head and neck 
region and in young patients. Survival of patients with ESCC is low. Prospective screening 
studies are necessary to determine the true MPT incidence and to investigate the yield and 
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Table S1. Cumulative incidence for head and neck SPTs in ESCC patients who were alive 6 
months after ESCC diagnosis (n=5,715) 
Interval Begin total (n) SPT (n) death (n) SPT located in other region 
Cumulative 
incidence (95% CI) 
0-5 year 5,715 57 4,719 62 2.9% (2.2-3.9) 
5-10 year 877 15 549 26 5.3% (3.9-6.9) 
10-15 year 287 8 214 6 9.0% (6.3-12.4) 
15-16 year 59 0 58 1 9.0% (6.3-12.4) 
Table S2. Cumulative incidence for metachronous lung SPTs in ESCC patients who were alive 
6 months after ESCC diagnosis (n=5,715) 
Interval Begin total (n) SPT (n) death (n) SPT located in other region 
Cumulative 
incidence (95% CI) 
0-5 year 5,715 52 4,719 67 2.8% (2.1-3.8) 
5-10 year 877 23 549 18 7.2% (5.4-9.4) 
10-15 year 287 4 214 10 9.9% (6.6-14.1) 
15-16 year 59 1 58 0 13.6% (7.0-22.4) 
Table S3. Cumulative incidence for metachronous esophagus SPTs in ESCC patients who 
were alive 6 months after ESCC diagnosis (n=5,715) 
Interval Begin total (n) SPT (n) death (n) SPT located in other region 
Cumulative 
incidence (95% CI) 
0-5 year 5,715 6 4,719 113 0.4% (0.1-0.9) 
5-10 year 877 3 549 38 1.1% (0.4-2.3) 
10-15 year 287 1 214 13 1.5% (0.6-3.0) 
15-16 year 59 0 58 1 1.5% (0.6-3.0) 
Table S4. Cumulative incidence for metachronous stomach SPTs in ESCC patients who were 
alive 6 months after ESCC diagnosis (n=5,715) 
Interval Begin total (n) SPT (n) death (n) SPT located in other region 
Cumulative 
incidence (95% CI) 
0-5 year 5,715 4 4,719 115 0.2% (0.1-0.6) 
5-10 year 877 0 549 41 0.2% (0.1-0.6) 
10-15 year 287 1 214 13 0.6% (0.1-1.8) 
15-16 year 59 0 58 1 0.6% (0.1-1.8) 
49
RISK OF SPT IN PATIENTS WITH ESCC
2
Table S5. Cumulative incidence for all SPTs in patients with low-stage ESCC (n=2,381) 
Interval Begin total (n) SPT (n) Death (n) Cumulative incidence (95% CI) 
0-5 year 2,381 158 1,778 8.1% (6.4-10.0) 
5-10 year 445 21 262 15.0% (11.8-18.6) 
10-15 year 162 7 122 21.7% (15.6-28.6) 




















Figure S1. Cumulative incidence of metachronous head and neck SPT after ESCC diagnosis 
(n=5,715) HN SPT, head and neck second primary �����;������������������������;������������������
����������������������� 
 
Figure S2. Cumulative incidence of metachronous lung SPT after ESCC diagnosis (n=5,715) 
��������������� ���������;������������������������;��������������������������������carcinoma 
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Background: Esophageal squamous cel carcinomas (ESCCs) are often accompanied by 
head and neck second primary tumors (HNSPTs). The prognosis of patients with an additional 
HNSPT is worse compared to patients with only ESCC. Therefore, early detection of HNSPTs 
may improve the overal outcome of patients with ESCC. The purpose of this study was to 
investigate the yield of endoscopic screening for HNSPTs in patients with primary ESCC. 
 
Methods: We conducted a systematic literature search of al available databases. Studies 
were included if ESCC patients were endoscopicaly screened for HNSPT. The primary 
outcome was the pooled prevalence of HNSPTs.  
 
Results: Twelve studies, al performed in Japan, were included in this systematic review with 
a total of 6,483 patients. The pooled prevalence of HNSPTs was 6.7% (95% CI: 4.9-8.4). The 
overal heterogeneity was high across the studies (I2=89.0%, p<0.001). Most HNSPTs were 
low-stage (85.3%) and located in the hypopharynx (60.3%). The proportion of synchronous 
(48.2%) and metachronous (51.8%) HNSPTs was comparable. 
 
Conclusion: Based on our results, HNSPT screening could be considered in patients with 
primary ESCC. Al studies were performed in Japan, it is therefore not clear if this this 








Both esophageal and head and neck (HN) cancer are common malignancies worldwide.1, 2 
Esophageal squamous cel carcinoma (ESCC) is the most common histologic type in the 
esophagus.3 Patients with ESCC, frequently develop second primary tumors (SPTs) in the 
upper aerodigestive tract. Most often in the HN region, but also in the esophagus and lungs.4, 
5 The presence of SPTs can be explained by the “field cancerization” theory: Premalignant 
epithelial changes can occur because of chronic local exposure to common carcinogens, such 
as alcohol and tobacco, which contributes to the development of syn- and metachronous 
SPTs.6 An important risk factor in Western countries for the development of both ESCC and 
SPTs is alcohol.7, 8  
Head and neck second primary tumors (HNSPTs) in patients with primary ESCC are reported 
up to 7% in retrospective studies.4, 5 The prognosis and survival of patients with esophageal 
cancer (EC) is poor because most ECs are diagnosed in advanced stages, when definitive 
cure is most often not achievable.9 The long-term prognosis is even worse in patients with an 
additional HNSPT compared to ESCC alone (five-year survival rate of 9.2% vs. 21.0%).10 This 
poor prognosis makes early detection of HNSPTs vitaly important, especialy for ESCC 
patients with low-stage tumors that could be treated endoscopicaly, since they have a 
considerably higher five year survival rate.11  
Different endoscopic techniques for HN cancer screening have been studied. Although Lugol 
chromoendoscopy is often used in the esophagus to detect dysplastic mucosal lesions, it is 
known to cause side effects in the HN region such as chest pain and aspiration.12 Narrow-
band imaging (NBI) seems to be the best technique for the detection of HNSPTs in patients 
with primary ESCC.13 The HNSPT detection rate is significantly higher using NBI (sensitivity 
100%, specificity 97.5%) compared to only white light endoscopy (WLE).13 The sensitivity of 
fluorodeoxyglucose-positron-emission tomography / computed tomography (CT) for the 
detection of HNSPTs is 61.5%, more HNSPTs were detected by endoscopy.14  
The European Society for Medical Oncology Clinical Practice Guidelines for EC recommends 
endoscopic screening of the HN region and trachea-bronchoscopy to detect SPTs in the upper 
aerodigestive tract in al ESCC patients with chronic tobacco and alcohol consumption.15 
However, no Western screening studies have been published to date. The Japanese EC 
guideline recommend appropriate diagnostic measures of other organs (HN, stomach, large 
intestine) after treatment of ESCC because of the risk of developing SPTs.16 However, no 
specific screening recommendations (i.e. diagnostic method and the time of screening) are 
mentioned.16 
We have performed a systematic review and meta-analysis of studies that investigated the 
use of endoscopic screening for the detection of HNSPTs in patients with primary ESCC. Our 
primary objective was to investigate the yield of endoscopic screening for HNSPTs in patients 
with primary ESCC. Our secondary objectives were to investigate whether there is evidence 
to justify endoscopic HN screening in primary ESCC patients in the Western world, and to 









MATERIALS AND METHODS 
 
Literature search and selection criteria 
A systematic literature search was performed in colaboration with the medical library of the 
Erasmus University Rotterdam, the Netherlands, in February 2019 with no limit on publication 
date. The search was performed in PubMed, Embase, Medline, Cochrane Central, Google 
Scholar and Web of Science databases. The ful electronic search strategy for the Embase 
database is provided in Supplementary data. The search was limited to English studies 
performed on humans. After removing duplicate citations, the remaining articles were 
reviewed based on title and abstract by two independent reviewers (S.V. and O.B.). 
Subsequently, the ful text of the remaining articles was screened by the same authors and 
discrepancies were discussed mutualy. If there was no agreement, a third party was involved 
(A.K.). Studies were included if patients with primary ESCC were endoscopicaly screened for 
HNSPTs. Studies were excluded if patients with primary head and neck squamous cel 
carcinoma (HNSCC) were screened for esophageal SPTs, since we investigated the yield of 
HNSPT screening in patients with primary ESCC. Moreover, these studies are already 
included in a systematic review about screening for esophageal SPT in patients with primary 
HNSCC.17 Studies without ful text, case reports, reviews, and studies where only imaging 
techniques were used to detect HNSPTs were excluded. References of the retrieved studies 
were manualy screened to locate additional studies. 
Study quality 
The Methodological Index for Non Randomized Studies (MINORS) was used to test the risk 
of bias and the methodological quality of the selected studies.18 The study relevance was 
determined using a checklist. This checklist includes (1) impact factor of publishing journal 
(indication of the peer-review quality), (2) data of the HNSPT sub-location, and (3) text clarity 
(Table 1). The total quality score of the studies was the sum of the MINORS and relevance 
criteria score. The total scores were classified as low (≤ 10 points), medium (11-14 points) or 
high (≥ 15 points). Medium and high classified studies were included. 
 
Table 1. Relevance criteria 
Criteria Score 
 0 1 2 
Text clarity Low Medium High 
Sub-location No - Yes 
Impact factor < 2 2-3.9 ≥ 4 
 
Data extraction and outcome parameters 
Data from included studies were summarized as Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) checklist and flow chart.19 The primary outcome was 
the prevalence of diagnosed HNSPTs. An HNSPT was defined as a lesion in the HN region 
classified as carcinoma in situ or carcinoma. With NBI, these lesions can be described as wel-





increased intraepithelial papilary capilary loops.20 Secondary outcomes were recorded when 
possible: (1) HNSPT prevalence per sub-location (upper, middle and lower esophagus) and 
per tumor stage (0 to IV according to the Vienna classification of gastrointestinal epithelial 
neoplasia) of the primary ESCC, (2) synchronously (≤ 6 months after diagnosis of primary 
ESCC) or metachronously (> 6 months after diagnosis of primary ESCC) diagnosed HNSPTs, 
and (3) tumor stage and sub-location of HNSPTs.21 Other characteristics of the studies were 
also recorded: first author, publication year, study design, size and country of the study 
population.  
Statistical analysis 
For each study, the HNSPT prevalence was calculated (total number of HNSPTs divided by 
the total population that was screened). The standard error (SE) was calculated from the 
prevalence using the folowing formula: SE =  √(p ∙ (1 − p))/n, p = prevalence and n = total 
number of patients with ESCC that were screened. Estimation of the prevalence was carried 
out with the aid of a random-effects meta-analysis. Combined estimates and 95% confidence 
intervals (CIs) for the HNSPT prevalence rates were calculated. The heterogeneity among 
studies was measured by calculating the inconsistency index (I2), with values from 0% to 100% 
(maximum heterogeneity). Categories of low, moderate and high were assigned to I2 values 





Study selection and quality assessment 
The study selection process and eligibility assessment are outlined in Figure 1. Literature 
search identified 4,537 citations. After screening, 148 articles were examined by ful text 
review for their eligibility by two reviewers (S.V. and O.B.). Discrepancies were discussed 
mutualy without any final disagreements. One additional study was included after screening 
the references. Twelve studies were included in our systematic review.7, 10, 13, 20 ,23-30 Exclusion 
reasons are shown in Figure 1. Al twelve included studies were qualified as medium or high 
(Table 2). The relevance criteria score ranged between 0 and 5 points (maximum possible 
score is 6). The MINORS-criteria score ranged from 9 to 23 points (maximum possible score 



















     
     
     
     
     
     





     
     
     
















Figure 1. Study selection process  
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25, 27, 29 In only four studies, the entire HN region was screened.10, 20, 27, 28, 30 Screening was 
limited to the pharynx and larynx, sub-locations known to be at an increased risk, in most other 
studies. Eleven of the 12 studies only screened patients with ESCC.7, 10, 13, 20, 23-26, 28-30 One 
study screened both patients with ESCC (93%) and esophageal adenocarcinoma (7%).27 In 
total, 98% of the esophageal tumors were squamous cel carcinomas and 2% 
adenocarcinomas. Screening was performed by an otolaryngologist or head and neck surgeon 
in 5/12 included studies.7, 24, 25, 27, 28 Screening was performed by a gastroenterologist in 2/12 
studies.20, 29 In these two studies, only the oropharynx and hypopharynx were screened. In 
5/12 included studies, however, it was not clearly reported who performed the screening 
endoscopy of the head and neck region (otolaryngologist or gastroenterologist).10, 13, 23, 26, 30  
Pooled SPT prevalence 
The prevalence of HNSPTs in patients with ESCC is shown for each study in Figure 2. In total, 
353/6,483 patients were diagnosed with HNSPT. Meta-analysis with a random-effect model 
was used to calculate the pooled prevalence since the I2 was 89.0%. The pooled prevalence 
for HNSPTs of the 12 included studies was 6.7% (95% CI: 4.9-8.4%) (Figure 2).  
Figure 2. Forest plot of prevalence of head and neck second primary tumors in patients with 
esophageal squamous cell carcinoma  
HNSPT, head and neck second primary tumor 
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Sub-location of HNSPT and tumor stage 
The sub-location of the HNSPTs was reported in eight of the twelve studies, for a total of 288 
SPTs.10, 13, 23-26, 28, 30 In one study the sub-location was reported together for primary HN tumors 
and HNSPTs. Therefore, we excluded the study for this sub-analysis.10 A total of 234 HNSPTs 
remained. The combined data showed that 60% (141/234) of al HNSPTs were located in the 
hypopharynx, 18% (41/234) in the oropharynx, 11% (26/234) in the oral cavity, 9% (22/234) 
in the larynx and 2% (4/234) in other sub-locations. In total, 405 HNSPTs were detected in 
353 patients. Tumor stage of HNSPTs were reported in eight of the 12 studies.13, 20, 23, 24, 26-28, 
30 Morimoto et al. reported tumor characteristics of metachronous HNSPTs only.23 Combined 
data showed that tumor stage was available for 62% of the HNSPTs (251/405). Overal, 
HNSPTs were classified as low-stage (stage 0, I and II) in 85% (214/251) and high-stage 
(stage III and IV) in 15% (37/251).  
 
Time to diagnosis 
Eight studies performed both syn- and metachronous endoscopic screening of the HN 
region,10, 20, 23-25, 28-30 and six studies adequately reported the percentage of detected 
synchronous and metachronous HNSPTs (Table 3).10, 23-25, 28, 29 The median time to 
metachronous HNSPT diagnosis of these six studies ranged from 12 to 48 months. The time 
to SPT diagnosis in ESCC patients was reported for al SPTs together in Motoyama et al., not 
separately for HNSPTs.25 Two studies, only performed HN screening synchronously,26, 27 and 
two only metachronously.7, 13 The HNSPT prevalence in the study by Nonaka and coleagues13 
was 3.3% (14/424) with a median detection period of 27.6 months (range 7.1-143.5) in patients 
screened with NBI and 101.0 months (range 11.0-134.5) in patients screened with WLE.  
 
Table 3. Percentages synchronous and metachronous HNSPT 
Authors ref Total SPTs Synchronous HNSPTs (%) 
Metachronous 
HNSPTs (%) 
Median time to diagnosis 
(months) (range) 
Morimoto et al.23  67 14 (21%) 53 (79%) 31 (7-107) 
Shimizu et al.24  5 0 5 (100%) 37 (15-61) 
Motoyama et al.25  8 0 8 (100%) Not reported 
Watanabe et al.28 85 37 (44%) 48 (56%) 48 (12-103) 
Onochi et al.29 32 23 (72%) 9 (28%) Not reported 
Lo et al.10 54 47 (87%) 7 (13%) 12 (8-110) 
Total 251 121 (48%) 130 (52%)  
���������������� ����������;�HNSPTs, head and neck second primary tumor�;��������������� 
 
Primary ESCC tumor characteristics 
Only four studies reported the sub-location of the index esophageal tumor.10, 24, 25, 27 One study 
only included patients who underwent esophagectomy for thoracic ESCC.25 The prevalence 
of HNSPTs in this study was 4.0%. The average percentages of index upper, middle, and 
lower ESCC of the other three studies were 17.0%, 57.7%, and 25.3% respectively.10, 24, 27 
However, they did not report the prevalence of HNSPT per ESCC sub-location. The tumor 
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stage of the primary ESCC was reported in nine studies (75%).7, 10, 20, 23-25, 27, 29, 30 On average, 
most esophageal lesions were stage 1 (29.0%) and stage 3 (29.8%). Other tumor stages were 
0 (high grade dysplasia) (7.3%), 2 (20.2%), and stage 4 (13.6%). The HNSPT prevalence per 
tumor stage of the primary ESCC was reported in three studies, where only superficial ESCCs 




To our knowledge, this is the first systematic review on endoscopic screening for HNSPTs in 
patients with primary ESCC. Worldwide, the incidence of HN cancer is more than 550,000 
cases annualy.2 We found an HNSPT (pooled) prevalence of 6.7%. Most HNSPTs were 
located in the hypopharynx (60.3%), and classified as low stage (85.3%). The proportion of 
synchronous and metachronous HNSPTs was comparable. Although the worldwide incidence 
cannot be compared directly with the pooled prevalence from this meta-analysis, the concept 
of endoscopic screening in patients with ESCC bares promise. An increase in early detection 
of HNSPTs could potentialy improve the overal survival of ESCC patients. 
Screening in Western countries wil possibly show a different HNSPT prevalence because the 
etiology partly differs among these continents and ESCC and HNSCC have a higher 
prevalence in Asia.3, 31 The etiology of ESCC in Asia is, besides smoking and alcohol intake, 
clearly linked to a lowered fruit and vegetables intake.32 The overal incidence of HN cancer in 
Japan was increasing, whereas the incidence in the United States was decreasing.31, 33 Since 
the included studies were performed in Japan, it is unlikely that these results can be applied 
to the contemporary Western population. 
Non-screening Asian studies have reported HNSPT prevalence up to 7% in patients with 
primary ESCC.4, 5 This is lower than the prevalence of the included studies (3.0%-29.6%). This 
might indicate that active screening of ESCC patients increase the number of detected 
HNSPTs.23 Early diagnosis and treatment of both tumors can increase the survival rate.23, 24  
Eighty-five percent of the HNSPTs were classified as low-stage, which is higher than in the 
general HN cancer population.35 Morimoto et al. reported a higher percentage of low-stage 
HNSPTs in patients with primary ESCC who were actively screened, and 83% of these 
HNSPTs could be treated with ER.23 Furthermore, survival was better in ESCC patients with 
HNSPTs who were actively screened.23 ESCC patients could benefit from HN screening 
because this could result in an increased detection of superficial HN cancer, which can be 
treated with curative intent.  
There is lack of standardization in HN examination protocols among the included studies 
because different screening techniques are used (WLE, NBI and Lugol). Studies that 
compared NBI with WLE described a significantly higher detection rate of HNSPTs and a 
higher sensitivity and accuracy when using NBI.13, 20, 23, 26 It would therefore be useful to always 
perform HN screening with WLE and NBI. Lugol chromoendoscopy is not recommended in 
the HN region because this has to be performed under general anesthesia because of possible 
side effects.28 
The average percentage synchronous and metachronous HNSPTs of al studies together is 
comparable. This could indicate that HN screening in patients with ESCC should be performed 





from 12-101 months.10, 13, 23, 24, 28 However, the optimal moment for screening during folow-up 
has yet to be defined.  
Our systematic review showed that 78% of the HNSPTs were located in the pharynx, which 
suggest that the pharynx has the highest risk of developing SPTs. Moreover, patients with 
pharyngeal cancer also showed the highest prevalence of esophageal SPTs.17 The pharynx 
is the head and neck region that should definitely be screened in patients with primary ESCC. 
Although 10 of the 12 included studies performed screening of the pharynx, only four studies 
screened the whole HN region. We are aware of the fact that, of these four studies, only two 
studies reported the HNSPT sub-location.28, 30 It was not possible to state if there was a 
correlation between ESCC tumor stage and the occurrence of HNSPTs since this information 
was only reported in three studies.7, 29, 30 In these studies, only superficial ESCCs (stage 0 and 
I) were screened, which could underestimate the true HNSPT prevalence per ESCC tumor 
stage.  
Some potential limitations about the methodology of the included studies need to be 
���������;���������������������������������������� WLE, NBI, Lugol chromoendoscopy) were 
used. The combination of WLE and NBI has the highest HNSPT detection rate, potential 
HNSPTs could be missed when using only WLE;� ������� ������ ���������� ���������������
endoscopy and CT-scan.27 It was not clearly described which proportion of HNSPTs were 
detected by endoscopic screening. The proportion of HNSPTs detected by endoscopic 
���������� ������ ��� ������ ����� ��������;� ��� �� ���������� ����������� ��� ������������� ����
synchronous was used in three studies, whereby the comparison of the different studies was 
more difficult and the proportion of metachronous SPTs could be higher than reported 7, 27, 28;�
4) only four studies screened the whole HN region. Therefore, we could not easily determine 
which HN sub-���������������� ���������� �������������������������;���� ���������-analysis 
contained both prospective and retrospective data, a significant bias may be present. 
In conclusion, the pooled prevalence of HNSPTs in patients with primary ESCC is 6.7%. Most 
HNSPTs were classified as low-stage. Patients with low-stage HN tumors can be treated 
curatively with an excelent prognosis. Screening for HNSPTs could therefore be useful in 
ESCC patients. More screening studies are needed to investigate which type of ESCC (i.e., 
tumor stage and sub-location) increases the risk of HNSPTs and to report on risk factors 
associated with HNSPTs. More important, it is necessary to perform Western screening 
studies to assess the HNSPT prevalence since it is unclear whether the results of Asian 
studies can be extrapolated into the Western population. Head and Neck examination 
��������������������������������� ��������;������������������������������������������-up 
and folow-up with WLE in combination with NBI. The pharynx is the head and neck region 
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Background: Early detection of esophageal secondary primary tumors (SPT) in head and 
neck squamous cel carcinoma (HNSCC) patients could increase patient survival. The 
purpose of this study was to determine the diagnostic yield of esophageal SPTs using Lugol 
chromoendoscopy.  
 
Methods: A systematic review of al available databases was performed to find al Lugol 
chromoendoscopy screening studies.  
 
Results: Fifteen studies with a total of 3,386 patients were included. The average yield of 
esophageal SPTs in HNSCC patients was 15%. The prevalence was the highest for patients 
with an index hypopharyngeal (28%) or oropharyngeal (14%) tumor. The esophageal SPTs 
were classified as high-grade dysplasia in 49% of the cases and as invasive carcinomas in 
51%.  
 
Conclusion: Our results show that 15% of the HNSCC patients that underwent Lugol 
chromoendoscopy were diagnosed with an esophageal SPT. Based on these results there is 











Part of the mortality of patients treated for head and neck squamous cel carcinoma (HNSCC) 
is caused by the occurrence of second primary tumors (SPT).1 Risk factors for their 
development include alcohol and tobacco use, age, and the sub-location of the index tumor 
(e.g., hypopharynx).2 Most SPTs in patients with HNSCC occur in the head and neck region, 
esophagus, and lungs.1, 3-6 The risk of esophageal cancer after HNSCC treatment is an 8-fold 
to 22-fold greater than in the general population.7-9 These SPTs are often diagnosed in 
advanced stages, which lead to a very low five year survival rate for affected patients.6, 10-12 
The prevalence of esophageal SPTs in patients with HNSCC is estimated to range from 0-
22%.13 
The occurrence of esophageal SPTs in patients with HNSCC is often explained by field 
cancerization of the entire upper aerodigestive tract.14, 15 The theory of field cancerization 
states that the mucosal field around the index tumor possesses subtle histologic and genetic 
changes that increase the risk of synchronous and metachronous malignancies. These subtle 
tissue changes are thought to be the effect of exposure to accumulating carcinogens (e.g., 
alcohol and tobacco).10  
Early diagnosis and treatment of an esophageal SPT may improve the overal outcome of 
patients with HNSCC.5, 10, 16 It has even been suggested that its treatment wil affect patient 
survival more than the index HNSCC tumor.5 Esophageal carcinomas can remain 
asymptomatic for a long time during development. A result of this is that many patients’ SPTs 
only seek medical attention when the tumor is in advanced stages development.17 Routine 
screening of the esophagus in the work-up and folow-up of patients with HNSCC could 
potentialy detect more early stage esophageal SPTs.18-20  
The diagnosis of esophageal SPTs may impact the management of both tumors.13 Early stage 
esophageal SPTs may benefit from less invasive endoscopic resection, which can be 
performed without compromising the treatment of the HNSCC.21 However, advanced 
esophageal SPTs are often diagnosed metachronously and wil typicaly be managed by 
chemoradiotherapy and surgery.22 The treatment of the index HNSCC could also hinder that 
of the esophageal cancer due to treatment sequelae or restrictions to therapeutic options. 
When possible, personalized treatment should be focused on both tumors.22, 23  
Endoscopic techniques to screen the esophagus have undergone major improvements over 
the last decades.10 White light endoscopy is deemed to be insufficient for the detection of 
superficial cancerous lesions in asymptomatic patients.9, 10 However, studies with image-
enhanced endoscopy, which includes Lugol’s stain, have shown very promising results. 
Lugol’s stain isolates abnormal “mucosal islands” within otherwise normal esophageal tissue, 
enabling targeted biopsy.9 Lugol chromoendoscopy has a high diagnostic accuracy. When 
combined with narrow band imaging (NBI), it is reported to have a sensitivity of 94.7% and a 
specificity of 90.4% to detect early stage esophageal lesions.24, 25 
Based on these results many clinics in Asia implemented esophageal SPT screening in 
patients with HNSCC.10 Recently, the French Society of Otorhinolaryngology recommended 
routine flexible white-light esophageal endoscopy in the workup of patients with oropharyngeal 
and hypopharyngeal HNSCC or chronic alcohol use.13 The addition of Lugol’s stain was 
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recommended. They also suggested to perform routine screening for metachronous 
esophageal SPTs in the folow-up of HNSCC patients.9 
Esophageal Lugol chromoendoscopy is not widely used in the management of patients with 
HNSCC in the Western world. We performed a systematic review on studies that used Lugol 
chromoendoscopy to detect esophageal SPTs in patients with HNSCC. Our main objective 
was to investigate the yield of Lugol chromoendoscopy for head and neck cancer patients in 
general, but also for specific head and neck sub-locations. A second aim was to investigate 
whether current data from non-Asian patient populations provide enough evidence to justify 
Lugol chromoendoscopy screening for esophageal SPTs in patients with HNSCC in the 
Western world. 
 
MATERIALS AND METHODS 
 
Literature search and selection criteria 
We searched the Embase, Medline (including PubMed), Web of Science, Cochrane, and 
Google Scholar databases for relevant studies. The search was performed in April 2017 
without a limit on publication date. The folowing keywords were used for the search: “second/ 
multiple primary tumor”, “esophageal cancer”, and “head and neck cancer”. We limited our 
search to studies written in English and on humans. Duplicate studies were removed. The 
remaining citations were reviewed (by O.B.) bases on title and abstract and in second stage 
on ful text. We included studies that investigated the use of Lugol chromoendoscopy to detect 
esophageal second primary tumors in HNSCC patients. We excluded studies primarily 
designed as case reports or reviews. The next paragraph presents our ful electronic search 
strategy for the Embase database (see Supplementary file for the search strategy).  
(“second cancer”/exp OR “multiple cancer”/de OR (((Metachronous OR Synchronous OR 
Second* OR Multiple OR double OR triple OR quadruple OR quintuple OR subsequen* OR 
Simultan*) NEAR/6 ( tumo* OR primary OR malignan* OR carcin* OR neoplas* OR 
cancer*))):ab,ti) AND (“esophagus tumor”/exp OR “esophagus”/exp OR “esophagus 
examination”/exp OR (esophag* OR oesophag* OR (upper NEXT/3 (aerodigest* OR 
digest*))):ab,ti) AND (“head and neck tumor”/exp OR “larynx tumor”/exp OR ((“head”exp OR 
neck/exp) AND “primary tumor”/de) OR (((lip OR mouth OR oral OR nose OR nasal OR tongue 
OR tonsil OR nasopharyn* OR oropharyn* OR hypopharyn* OR pharyn* OR laryn* OR head 
OR neck ) NEAR/10 (tumo* OR primary OR malignan* OR carcin* OR neoplas* OR cancer* 
OR primar*))):ab,ti) AND [english]/lim NOT ([animals]/lim NOT [humans]/lim).   
Assessment of study quality  
The methodological quality and risk of bias of the selected Lugol chromoendoscopy screening 
studies was tested (by O.B.) with the Methodological Index for Non-Randomized Studies 
(MINORS).26 Its relevance to the current topic was determined using a three-criterion checklist, 
including (1) impact factor of publishing journal and thus an indication of quality of peer-review, 
(2) data on the prevalence of esophageal SPT per head and neck sub-location, and (3) clarity 
of the text (Table 1). The total score of both the MINORS scale and relevance criteria was 
used as a quality score. Based on this score, the quality was classified as low (total score ≤ 





medium and high quality were included for further analysis and low-quality studies were 
excluded. 
 
Table 1. Relevance criteria 
Criteria Score 
 0 1 2 
Impact factor < 2 2-3.9 ≥ 4 
Sub-location No - Yes 
Text clarity Low Medium High 
 
Data extraction 
Data from al included studies were extracted onto record forms (by O.B.) and results were 
summarized as a Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) check list and flow chart.27 The total prevalence of diagnosed esophageal SPTs 
were recorded as primary outcome. An esophageal SPT was defined as an esophageal lesion 
classified as category 4 and 5: high-grade dysplasia (HGD) or carcinoma. When possible three 
secondary outcomes were recorded : (1) n the SPT prevalence per sub-location of the index 
head and neck tumor (oral cavity, oropharynx, hypopharynx, larynx, nasopharynx and other) 
���� ���� ������ ������ ��� ��� ��� ��� ���� ������ �����;� �2) whether the SPTs were diagnosed 
synchronously (≤ 6 months after diagnosis of index tumor, in some cases simultaneously) or 
metachronously (> 6 months after d��������� ��� ������ ������;� ���� ��) in which stage of 
development the SPTs were according to the Vienna classification of gastrointestinal epithelial 
neoplasia.28 Finaly, first author, country of study population, year of publication, study design, 
and population size were also recorded.  
Statistical analysis  
Data were reported as counts and percentages. The SPT prevalence was calculated for each 
study as the total number of detected SPTs divided by the total population that was screening 
in the particular study. In studies where the Standard Error (SE) was not reported, we 
calculated it from the prevalence using the following formula: SE=√(p (1-p)/ n);������������
�������������������������������������������������������������������������������������������
SPTs. Review Manager software (version 5.3) was used for meta-analysis. Random effects 
model was used to calculate the pooled prevalence. I2 was used to evaluate the level of 
heterogeneity between studies. Subgroup analyses were performed for specific head and 




Study selection, quality assessment, and characteristics  
Results of our search query for eligible qualitative Lugol chromoendoscopy screening studies 
are presented in Figure 1. The search identified 4,077 citations. After removing duplicates 
2,241 citations were reviewed. Based on review of title and abstract, 1,859 citations were 
excluded. The remaining 382 studies were reviewed for their eligibility by reviewing the ful 
text. This revealed 96 studies that screened a population of patients with HNSCC for 
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esophageal SPTs. Reasons for exclusion of other studies are mentioned in Figure 1. Review 
of the 96 screening studies resulted in the selection of 23 Lugol chromoendoscopy screening 
studies (Table 2).21, 22, 25, 29-48 Most other screening studies were performed with only white-
light endoscopy (e.g., ‘triple-endoscopy) or with the use of PET/CT. 
The combined quality score of the MINORS and relevance-criteria qualified 15 studies as 
medium or high quality and these were included in the present review.21, 22, 25, 29-40 The 
remaining studies of low quality were excluded. The methodological quality assessment using 
MINORS resulted in scores ranging from 6 to 11 points, (median 8 and maximal possible score 
16). The relevance criteria score ranged from between 0 to 5 points (median 3 and maximal 
possible score 6). Twelve of the studies included (80%) were performed in Asia (Korea, Japan, 
and Taiwan) and the remaining three in Switzerland, France, and Brazil. Nine studies were 
performed within the last decade and al studies within the last two decades. Most studies 
colected data prospectively (13, 87%). The study populations ranged from 40 to 676 patients 
(median 171) and the total number of patients was 3,386. Al studies used similar methods by 
applying 10-40 mL of 0.8-3.0% Lugol’s solution on the esophageal mucosa.  
Prevalence  
The average prevalence of esophageal SPTs in HNSCC patients of the 15 included studies 
was 15.2% (413 of 3,386, 95% CI: 11.4-19.0) (Figure 2). The three studies with the highest 
prevalence included only or mostly patients with a hypopharyngeal index tumor.21, 22, 33 Two 
Japanese studies only included patients with oral cavity tumors.30, 39 The average esophageal 
SPT prevalence of the 12 Asian studies was 17.7% (358/2627, 95% CI: 12.7-22.7). This was 
higher than the average of the three non-Asian studies: 6.0% (55/759, 95% CI: 2.3-9.7). 
Prevalence per sub-location 
Nine Asian studies reported data of esophageal SPTs per sub-location of the index HNSCC 
(Figure 3).21, 22, 29-32, 38-40 The prevalence of esophageal SPTs was the highest in patients with 
hypopharyngeal index tumors, folowed by patients with oropharyngeal, oral cavity, laryngeal 
and nasopharyngeal tumors. The average prevalence of esophageal lesions in patients with 
hypopharyngeal tumors of seven studies was 28.0% (161 of 574, 95% CI: 22.5-33.5)). Five 
studies reported an average of 14.0% (35 of 308, 95% CI: 5.4-22.5) esophageal SPTs in 
patients with oropharyngeal tumors. The diagnostic yield of Lugol chromoendoscopy in 
patients with oral cavity tumors was 7.2% (47 of 637, 95% CI: 3.2-11.2). For patients with 
laryngeal index tumors the rate of esophageal SPTs was 3.4% (19 of 474, 95% CI: 1.8-5.4). 
Four studies reported only two esophageal SPTs in 109 patients with nasopharyngeal tumors 
and none were found in patients with other index tumors (e.g., glandular tumors).  
Time to diagnosis  
Most studies only performed endoscopic screening of the esophagus in the work-up of the 
index HNSCC tumor and thus only diagnosed synchronous, or even simultaneous, 
esophageal SPTs. Four studies performed both synchronous and metachronous esophageal 
endoscopies.21, 32, 33, 35 Morimoto et al. performed at diagnosis of the HNSCC and annualy 
during folow-up.21 Eighteen (69.2%) of al SPTs were diagnosed synchronously and 8 (30.8%) 
metachronously. Fukuhura et al. found a similar distribution between synchronously 





[32.1%]).32 The two other studies also metachronous endoscopies, but did not separately 
mention the syn- or metachronous diagnostic yield of Lugol chromoendoscopy.33, 35  
 
                                                           







n                                                     
 
     4,077 record identified                                
     database screening*                                 
                             1,836 excluded             
                            duplicats                   
                                                       






                                                     
     2,241 record screened                                
     after duplicates removed                             
                             1,859 excluded     
                            title/ abstract screening     
                                                       







                                                     
     382 ful-text articles                                 
     assesed for eligibility                                 
                            288 excluded               
                             113 incidence              
                            42 outcome/ survival        
                            39 predictive factors        
                            22 review/ guidelines        
                            19 conference abstracts     
                            16 no SPT                
                            15 no HN group            
                            9 descriptive               
                            8 case report              
                            2 letters to the editor        
                            2 no new patients          
                            1 no esophageal SPT         
     94 eligible endoscopic                                
     screening studies                                   
                            71 excluded               
                             38 WLE          
                            25 PET and CT            
                            7 others                  
                            1 WLE + NBI       
                                                       





                                                     
     23 Lugol screening studies 
                            
     assessed for quality                                 
                            8 excluded                 
                             MINORS and study criteria     
                                                       





                                                      
     15 Lugol screening studies 
                            
     included                                           
                                                         
                                                           
Figure 1. Study selection process 
* ����������������� �������������������������������������������;������������������������;�����
�������������;����������������������������������;������������������� �����;���������������� ����
�����;�WLE, white light endoscopy;���������������������������������������������������������  
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Authors Country Year Design N 
Score 
Quality 
 MINORS Relevance Total 
Included studies         
 Gong et al.29 Korea 2016 Pro 458 10 5 15 High 
 Wang, CH et al.25 Taiwan 2014 Pro 294 11 3 14 Medium 
 Wang, Wang, et al.22 Taiwan 2013 Pro 180 9 5 14 Medium 
 Ikawa et al.30 Japan 2012 Pro 171 8 4 12 Medium 
 Wang, Lee, et al.31  Taiwan 2011 Pro 315 11 5 16 High 
 Morimoto et al.21 Japan 2010 Pro 64 7 4 11 Medium 
 Fukuhara et al.32 Japan 2010 Pro 157 8 4 12 Medium 
 Lee et al.33 Taiwan 2009 Pro 44 11 4 15 High 
 Boler et al.34 Switzerland 2009 Pro 40 11 3 14 Medium 
 Dubuc et al.35 France 2006 Pro 393 10 3 13 Medium 
 Hashimoto et al.36 Brazil 2005 Pro 326 10 4 14 Medium 
 Muto, Nakane, et al.37 Japan 2002 Pro 78 9 4 13 Medium 
 Tanabe et al.38 Japan 2001 Retro 134 8 3 11 Medium 
 Fukuzawa et al.39 Japan 1999 Pro 56 7 4 11 Medium 
 Horiuchi et al.40 Japan 1998 Retro 676 7 4 11 Medium 
          
Excluded studies         
 Laohawiriyakamol et al.41 Thailand 2014 Pro 89 10 0 10 Low 
 Komínek et al.42 Czech R. 2013 Pro 132 9 0 9 Low 
 Chow et al.43 China 2009 Retro 118 7 2 9 Low 
 Muto, Hironaka, et al.44 Japan 2002 Retro 389 6 1 7 Low 
 Tincani et al.45 Brazil 2000 Pro 60 7 0 7 Low 
 Ina et al.46 Japan 1994 Pro 127 7 2 9 Low 
 Chisholm et al.47 China 1992 Pro 37 7 0 7 Low 
 Shiozaki et al.48 Japan 1990 Pro 178 7 2 9 Low 
 



























Figure 2. Overview of prevalence of esophageal SPTs of 15 Lugol chromoendoscopy screening 
studies 
Hypo, �������������������������������������������������������;�����, study included only patients with 
����� ������� ������;� ���, second ��� ���� �����;� �, both synchronous ����������������� ���������;� 
†, transnasal Lugol chromoendoscopy. Error bars represent 95% confidence intervals  
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Figure 3. Overview of prevalence of esophageal SPTs per sub-location of index head and neck 
squamous cell carcinoma (A) hypopharynx, (B) oropharynx, (C) oral cavity, and (D) larynx. Nine Asian 
studies with sub-location specific data. Fukuhara et al. and Morimoto et al. screened both syn- and 
metachronously. Error bars represent 95% confidence intervals. 
 
Vienna classification 
Eight studies differentiated between esophageal SPTs classified as category 4 (HGD) or 5 
(carcinoma).21, 25, 29, 31, 33-36 The remaining studies either did not mention the category or only 
mentioned category 5. Almost half of al esophageal SPTs found in these eight studies (48.6%, 
range 22.2-100.0) were category 4 lesions, HGD. That was approximately the same for Asian 
(43.3%, n = 5) and non-Asian (57.4%, n = 3) studies. Three of these seven studies also 
differentiated the esophageal carcinoma’s in low- (stage I and II) and high-stage (stage III and 
IV) esophageal tumors.21, 29, 31 Their combined data shows that 53.9% (41/76) of al 
esophageal carcinoma’s were classified as low-stage and 46.1% (35/76) as high-stage.  
Prevalence per index tumor stage  
Three Asian studies also reported the prevalence of esophageal SPTs in HNSCC patients per 
tumor stage of the index tumor.21, 29, 39 There were a total of five (3.1%, 95% CI: 0.3-5.8) 
esophageal SPTs in 150 patients with stage I HNSCC, 28.8% (95% CI: -5.7-63.3) esophageal 
SPTs in patients with stage II HNSCC, 5.34% (95% CI: 1.1-9.6) esophageal SPTs in stage III 







To the best of our knowledge, this is the first systematic review on the diagnostic yield of Lugol 
chromoendoscopy for esophageal second primary tumors in patients with HNSCC. Our main 
findings show that on average, 15% of the primary HNSCC patients that underwent Lugol 
chromoendoscopy were diagnosed with an esophageal SPT. We found that the prevalence 
was the highest for patients with hypopharyngeal index tumors. 
There is a large discrepancy between the prevalence of esophageal SPTs in HNSCC patients 
found with Lugol chromoendoscopy screening (15%, 95% CI: 11-19) and the prevalence of 
retrospective non-screening studies (1-6%).6, 7, 49-53 This was also noted by Wang, Lee, et al.31 
This discrepancy could indicate that without an active screening programme esophageal SPTs 
are underdiagnosed in patients with HNSCC.7 Multiple studies state that the occurrence of 
esophageal SPTs negatively influences patient survival, especialy in patients with advanced 
esophageal SPTs.23, 54-56 Some researchers even claim that SPTs are the leading cause of 
treatment failure and death in HNSCC patients.31 
The hypopharynx, and in particular involvement of the piriform sinus, is a wel-known risk factor 
for the development of esophageal SPTs.57-60 The results from the present review also SPTs 
underlined this. Wang, WL et al. compared two hypopharyngeal HNSCC cohorts: before and 
after implementing pretreatment Lugol chromoendoscopy esophagus screening.22 Active 
esophageal screening tripled the amount of diagnosed esophageal SPTs (5.3% vs. 15.3%). 
The present study also found esophageal SPTs in 11% of oropharyngeal cancer patients, 
which is also a known sub-location to be at risk factor for the development of an esophageal 
SPT.60, 61 However, the two largest studies in this review with specific oropharynx data by 
Horiuchi et al. and Gong et al. found relatively low prevalence of esophageal SPTs (7.2% and 
2.8%) in this sub-group of patients. 
The finding that up to a third of al esophageal SPTs found in the studies by Morimoto et al. 
and Fukuhara et al. were diagnosed metachronously during folow-up could indicate that the 
results of the other synchronous studies underestimate the true prevalence of esophageal 
SPTs.21, 32 It is also an indication that esophageal screening of HNSCC patients should also 
be performed in the folow-up of the index tumor. However, the optimal esophageal screening 
schedule has yet to be defined. 
Approximately 50% of the esophageal lesions found in this review were classified as HGD. Of 
the remaining lesions classified as invasive carcinoma, about half were early-stage. This is 
similar to findings from other researchers.22, 29, 38 Wang, WL et al. showed that an active 
screening protocol diagnosed more HGD lesions and early-stage carcinomas, which 
significantly reduced the mortality rate of affected patients.22 This is possibly the result of 
adjustments of the treatment strategy aimed at treating two instead of one tumor and less 
invasive endoscopic treatment of the esophageal lesions. Multiple studies claim that treatment 
of the esophageal SPT increases the survival, especialy in patients with early-stage tumors.23, 
54-56 
Five of the included studies in this review used NBI in addition to Lugol chromoendoscopy.22, 
25, 29, 31, 33 Wang, CH et al. concluded that this combination of both techniques has the highest 
diagnostic accuracy to detect esophageal lesions: a sensitivity of 95%, a specificity of 90%, 
and an accuracy of 91% (95% CI 88-94).25 Several other researchers have investigated the 
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use of ful-body 18F-FDG-PET/CT. They reported a considerably lower diagnostic esophageal 
SPT yield that ranged from 0.43% to 4.85%.62-66 As Kondo et al. also mentioned that PET/CT 
seems to be an inferior technique for detection of esophageal SPTs because it is not sensitive 
for early tumors.62  
Two of the studies included in this review performed transnasal Lugol chromoendoscopy.25, 33 
Tumor-related airway obstruction or post-radiation trismus sometimes make the 
oropharyngeal passage difficult to reach with conventional endoscopes. The transnasal route 
bypasses this problem. Transnasal Lugol chromoendoscopy has the additional advantage that 
it can be performed in unsedated patients and that it even has a higher completion rate than 
conventional endoscopy.67 
The prevalence of SPTs after HNSCC in the existing literature varies greatly geographicaly. 
In Asia, second primary gastrointestinal tract malignancies are more common after index 
HNSCC than in the Western world.2 It is thought that Asians have a higher exposure to risk 
factors such as smoking and alcohol use. Other risk factor such as hot beverage drinking and 
betel quid chewing and genetic susceptibility have also been suggested to play a part.68 As a 
result, the literature on this topic, including the studies of this review, are mostly from Asian 
countries. In the present review only three studies were non-Asian. This prohibits us to draw 
bold conclusions and extrapolate results on the usefulness of Lugol chromoendoscopy in a 
non-Asian patient population, as also stated by Morimoto et al.21 
Another limitation is the quality of the included studies. Since the quality of a review greatly 
relies on the quality of the included data, we excluded studies of low quality. Although the 
remaining 15 studies were al similar in methodology and research question, there was some 
heterogeneity among the studies in the sub-sites of the index HNSCC tumors that were 
included. This might have had an influence on the average prevalence of al studies. However, 
the four largest studies (n = 326-676) with the highest weight on the average fortunately 
included al sub-locations. A final potential limitation is that the study selection and quality 
assessment was performed by one reviewer. The overal study quality could have benefited 
from an assessment by two independent reviewers. 
In conclusion, this review has shown that the prevalence of esophageal second primary 
tumors in head and neck cancer patients is high, especialy for patients with a hypo- and 
oropharyngeal index tumor. A large percentage of esophageal lesions were found in early 
stage of development. Literature shows that this group of patients could significantly benefit 
from dual tumor treatment, resulting in an increased five year survival rate. Based on our 
results there appears to be strong evidence to perform Lugol chromoendoscopy screening in 
an Asian patient population. More screening studies are needed to confirm the same for the 
Western world and Lugol chromoendoscopy holds the potential to increase the overal survival 
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Background: Patients with head and neck squamous cel carcinoma (HNSCC) have an 
increased risk of developing esophageal second primary tumors (ESPTs). We aimed to 
determine the incidence, stage and outcome of synchronous ESPTs in patients with HNSCC 
in a Western population. 
 
Methods: We performed a prospective, observational, cohort study. Patients diagnosed with 
HNSCC in the oropharynx, hypopharynx, any other sub-location in combination with alcohol 
abuse, or patients with two synchronous HNSCCs, between February 2019 and February 
2020 underwent screening esophagogastroduodenoscopy (EGD). ESPT was defined as 
presence of esophageal squamous cel carcinoma (ESCC) or high grade dysplasia (HGD). 
 
Results: Eighty-five patients were included. A lesion suspected for ESPT was detected in 14 
of 85 patients, which was pathologicaly confirmed in 5 patients (1 ESCC and 4 HGD). The 
radiotherapy field was extended to the esophagus in two of five patients, HGD was treated 
with endoscopic resection in three of five patients. None of the ESPTs were detected on MRI 
and/or CT-scan prior to EGD. Of the remaining nine patients, three had low grade dysplasia 
on histology whereas the other six patients had benign lesions. 
 
Conclusions: Incidence of synchronous ESPT was 5.9% in our cohort of HNSCC patients. 
Al ESPTs were diagnosed at an early stage and treated with curative intent. We recommend 










Patients with head and neck squamous cel carcinoma (HNSCC) are at increased risk of 
developing second primary tumors (SPTs).1 The development of SPTs might be explained by 
the field cancerization theory: premalignant changes of the epithelium around the primary 
tumor caused by exposure to common carcinogens such as alcohol and tobacco.2 The 
esophagus in particular is at increased risk of developing SPTs.3  
Esophageal cancer is often diagnosed in an advanced stage because these tumors remain 
asymptomatic for a long period.4 In general, these patients have to be treated with invasive 
surgery, associated with high morbidity.5 If esophageal cancer is detected in an early stage, 
patients can be treated with minimal invasive endoscopic resection (ER). Therefore, early 
diagnosis of esophageal second primary tumor (ESPT) in HNSCC patients is crucial to 
improve survival with minimum morbidity.6, 7 Screening of the esophagus with 
esophagogastroduodenoscopy (EGD) has the potential to detect ESPTs at an early stage.8 In 
addition, endoscopic screening is reported to be superior to Positron emission tomography 
(PET).9 
ESPT is often defined as esophageal squamous cel carcinoma (ESCC) or high grade 
dysplasia (HGD) of squamous epithelium.8 Low grade dysplasia (LGD) is a precursor of 
ESCC, and requires careful folow-up or ER.10, 11 Therefore, LGD is often included in studies 
on ESPT.6, 12 
ESPTs are characterized by flat lesions, which are easily overlooked with white light high 
resolution endoscopy (WLE).13 Narrow-band imaging (NBI) improves the identification of these 
lesions due to the visibility of intraepithelial papilary capilary loop patterns.14 Stil, the gold 
standard for ESPT detection is Lugol chromoendoscopy (LCE).8, 15 Lugol iodine binds to 
glycogen, which is absent or diminished in dysplastic and neoplastic tissue, and therefore 
highlights ESPT.16 However, LCE is associated with a high rate of false positive lesions.17 
Combining LCE with NBI improves ESPT detection, with a reported accuracy of 91%.18  
There are multiple reports on endoscopic screening for ESPTs in HNSCC patients.8 A recent 
systematic review with meta-analysis by our research group showed a pooled prevalence of 
15.2% (95% confidence interval [CI] 11.4-19.0).8 However, 12 of 15 included studies were 
performed in the Asian population.8 Only very few wel-defined screening studies in the 
Western population exist. The aim of this study was to establish the incidence, stage and 
outcome of synchronous ESPTs in a selected group of Western patients with HNSCC. 
 
MATERIALS AND METHODS 
 
Study design 
We performed a prospective, observational cohort study in a tertiary referral center in the 
Netherlands. This study was approved by the Medical Ethical Review Committee of the 
Erasmus MC in Rotterdam, the Netherlands (MEC-2018-1243) and is registered in the 
Netherlands Trial Register (NL7299). Patients diagnosed with HNSCC between February 
2019 and February 2020 were eligible for inclusion. To be included in the study, patients had 
to have an increased risk of ESPT development: HNSCC located in the oropharynx, 
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hypopharynx, any other head and neck sub-location in combination with alcohol abuse, or the 
presence of two HNSCCs regardless of location.8 Alcohol abuse was defined according to the 
classification for ‘risky alcohol use’ of The National Institute on Alcohol Abuse and 
Alcoholism.19 Patients with history of ESCC, oropharynx carcinoma associated with human 
papilomavirus infection,20 or incurable HNSCC at time of diagnosis were excluded. In every 
patient with oropharynx carcinoma, high-risk human papilomavirus testing was performed 
with immunohistochemistry for a surrogate p16 marker. 
EGD was performed within six months after HNSCC diagnosis. In general, EGD was 
performed within two weeks after HNSCC diagnosis. Al patients underwent routine clinical 
workup with imaging techniques for HNSCC (i.e., MRI-scan and/or CT-scan). Treatment 
strategy for HNSCC and ESPT was discussed in a multidisciplinary tumor board meeting 
consisting of a head and neck surgeon, gastroenterologist, gastrointestinal surgeon, 
radiotherapist, medical oncologist, and radiologist. If it was deemed impossible to perform 
EGD during the workup for HNSCC, HNSCC treatment was started and EGD was performed 
thereafter. 
Screening esophagogastroduodenoscopy 
EGD was performed with WLE, NBI and LCE, by an experienced interventional endoscopist 
���;���;���;���;�and AD). Al endoscopists participated in dedicated upper gastrointestinal 
cancer screening programs and had extensive experience with al three screening techniques. 
EGD was performed as folows: at first, the duodenum, stomach and esophagus were 
observed with WLE. Then, the esophagus was observed with NBI for aberrant intraepithelial 
papilary capilary loop patterns. After observation with NBI, the filter was switched to white 
light again and LCE was performed. For LCE, the esophagus was stained with 20-30 mL Lugol 
iodine (1.2%). Incidental findings such as reflux-esophagitis, Barrett’s esophagus or erosive 
gastritis, not related to this study were treated as per standard clinical practice. 
Synchronous ESPT was defined as ESCC (category 5) or HGD of squamous epithelium 
(category 4) according to the Vienna classification, detected within six months after HNSCC 
diagnosis.21 A lesion was considered a possible ESPT or LGD if it was suspect on at least one 
of the three endoscopic detection techniques and had a diameter of at least 5mm. Al 
suspected lesions in the esophagus were systematicaly assessed for size, location (distance 
from the incisors), macroscopic appearance according to the Paris Classification, and whether 
the lesion could be removed by ER.22 ER was preferably performed for proximal lesions in the 
esophagus rather than being included in the radiotherapy field for HNSCC because (1) ER 
provides a more precise histopathological staging of early ESCC, (2) curative ER is superior 
to radiotherapy alone for ESCC, and (3) extending the radiotherapy field is considered a 
second best because a larger field might lead to more side effects such as stricture 
development. If ER was deemed possible, a biopsy was preferably avoided to prevent 
submucosal fibrosis, which might make ER more difficult. Al resected specimens and biopsies 
were reviewed by an expert gastrointestinal pathologist (Supplementary File 1).22, 23 Al ER 
specimens were assessed whether they fulfiled the pathological criteria for a curative 







The primary endpoint of this study was the incidence of ESPT. Secondary endpoints were: (1) 
histology and tumor stage of ESPT, (2) the incidence of LGD, (3) treatment and outcome of 
ESPT and LGD, (4) the number of ESPTs that were not detected with routine imaging 
techniques for HNSCC workup, and (5) detection rate of ESPT and LGD with WLE, NBI, and 
LCE. 
Statistical analysis 
Continuous data were expressed as mean (± standard deviation) for normaly distributed data 
and as median (interquartile range [IQR]) for skewed data. Categorical data were presented 
with frequencies and percentages. Folow-up data were retrieved until July 2020. Analyses 





Out of 129 eligible patients, 92 patients underwent a screening EGD (Figure 1). Seven patients 
with oropharynx carcinoma who underwent EGD were positive for human papilomavirus 
infection (no ESPT was detected) and were excluded from further analyses. The remaining 
85 patients were included in the final analysis. Baseline and HNSCC characteristics are 
presented in Table 1. Most HNSCCs were located in the hypopharynx (33%) or oropharynx 
(29%). Six out of 85 patients died within one year after HNSCC diagnosis.  
 













Table 1. Baseline characteristics of patients with HNSCC (n=85) 
 
Patient characteristics 
Male sex, n (%) 67 (79%) 
Median age, years (IQR) 65 (59-70) 








Present alcohol use, n (%)  
Yes 67 (79%) 
Median units alcohol/week (IQR) 21 (19-42) 
No 18 (21%) 
Alcohol use in the past, n 9 
Median units alcohol/week (IQR) 35 (23-77) 
Current tobacco use, n (%)  
Yes 46 (54%) 
Median pack years (IQR) 40 (29-55) 
No 39 (46%) 
Smoking in the past, n 31 
Median pack years (IQR) 40 (40-50) 
HNSCC characteristics 





























14 (15%) / 2 (2%) 
N stage, n (%) a 
N0 
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3 (3%) / 2 (2%) / 14 (15%) / 8 (9%) 
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Esophageal second primary tumors 
The median time between HNSCC diagnosis and EGD was 9 days (IQR: 6-20). No adverse 
events occurred during EGD. A total of 15 suspected lesions were detected in 14 patients 
(16.5%).  
Confirmed ESPT 
ESPT was histopathological���������������������������������������������������;�����������-5). 
This was an ESCC in one patient (patient 1) and HGD in four patients (patients 2-5). Al ESPTs 
were ≥20 mm (range 20-80). The radiotherapy field for HNSCC was extended to the 
esophagus because of the presence HGD (T2 lesion on PET-scan) in one patient (patient 2) 
and the presence of LVI after ER for T1a ESCC in another patient (patient 1). The remaining 
three patients with HGD were treated with ER only (patients 3-5). 
Low grade dysplasia 
LG��������������������������������������������;����������-8). Two patients underwent ER and 
one patient died due to HNSCC before ER was performed.  
No dysplasia 
In 5 out of 14 patients, ESPT or LGD could not be confirmed on histopathological analysis. 
These patients are presented in Supplementary Table 2. The median size of these non-
dysplastic lesions was 6 mm (IQR: 5-9). One out of 14 patients had a suspected lesion but 
histopathology was not obtained because of refusal of further treatment by the patient. 
Overal, an ESPT was detected and histopathologicaly confirmed in 5 out of 85 patients (5.9%, 
95% CI 1.9-13.2). LGD was detected in 3 out of 85 patients (3.5%, 95% CI 0.7-10.0). These 
(pre)malignant lesions were al found in an early stage and could be treated with curative 
intent. None of the ESPTs and LGD lesions were identified by MRI and/or CT-scan. 
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Figure 2. Esophageal second primary tumor visible with narrow band imaging and Lugol 
chromoendoscopy ������������������������������������������������������������� �������� ��������������������
�������������������������������������������������������������������
 ID Treatment Follow-up 
ESPT 





� ����������������������������� ������������� 
� ����������������������������� ������������� 
� ����������������������������� ������������� 
LGD 
6 ����������������������������� ������������� 
� ����������������������������� ������������� 
8 ������������������������������� ������������ 
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We performed a prospective endoscopic screening study in patients with HNSCC and found 
an ESPT incidence of 5.9%. ESPT or LGD was found in approximately one in 10 patients. Al 
esophageal lesions were diagnosed at an early stage and could be treated with curative intent 
with either ER or radiotherapy. Since none of the ESPTs were identified by other imaging 
techniques, our findings suggest that screening for ESPT by EGD is of added value for a 
selected group of HNSCC patients. 
Previous screening studies reported prevalences of ESPT between 4.1 and 40.9%.8 A recent 
meta-analysis by our research group, which included more than 3,000 patients, found a pooled 
prevalence of 15.2% (95% CI 11.4-19.0).8 This is much higher compared with our current 
findings, which may be explained by the fact that metachronous ESPTs were also included in 
the meta-analysis.8 Another possible explanation is that the majority of previously published 
screening studies were performed in Asia. The prevalence of synchronous ESPTs is higher in 
the Asian population compared with the Western population.8 This difference might be due to 
a higher exposure of risk factors (e.g. alcohol and tobacco) in the Asian population and a 
difference in genetic polymorphisms of alcohol metabolism between these two populations.25 
However, the majority of patients in our cohort were exposed to these risk factors. Western 
gastroenterologists might have a relative lack of experience in screening for early ESCC 
compared with Asian gastroenterologists, which might contribute to the difference in ESPT 
prevalence. 
The only two screening studies in Western population reported incidences of 6.9% and 10.0%, 
which is more in line with our results.12, 26 The French study by Dubuc et al., included 393 
patients with a history of head and neck (n=384) or tracheobronchial squamous cel carcinoma 
(n=9). ESPT was detected in 27 of 393 patients (6.9%).12 However, the time between HNSCC 
and ESPT diagnosis was not reported. The proportion of synchronous ESPTs is probably 
lower than 6.9%. Boler et al. included 40 patients with HNSCC, ESPT was detected in four 
patients (10.0%).26 The mean time since HNSCC diagnosis was 5.0 years, it is therefore most 
likely that no synchronous ESPTs are detected in this study.26 
Al patients with an ESPT in our study had an oropharynx or hypopharynx carcinoma. Several 
studies have shown that patients with an HNSCC in these sub-locations have a higher risk of 
developing ESPT.27 An endoscopic screening study by Gong et al. showed that the ESPT 
prevalence was highest in patients with hypopharynx carcinoma (21%).27 Wang et al., reported 
an ESPT prevalence of 36% in patients with an oropharynx carcinoma and 29% in patients 
with a hypopharynx carcinoma, in contrast to an ESPT prevalence of only 9% in patients with 
laryngeal cancer.28 According to a pooled analysis, the ESPT incidences are 14% and 28% 
for patients with an HNSCC in the oropharynx and hypopharynx, respectively.8 This suggests 
that endoscopic screening for ESPT is most effective in these patients. 
It is wel established that esophageal lesion size is associated with malignancy with 20mm as 
the most common cut-off value.26, 29 In an endoscopic screening study by Boler et al., none of 
the Lugol voiding lesions (LVL) <20mm showed dysplasia on histopathological assessment, 
whereas dysplasia was found in 80% of lesions ≥20mm.26 In another endoscopic screening 
study, 37% of the LVL >10mm showed dysplasia or neoplasia compared with only 5% of the 
LVL between 5 and 10mm.17 In our study, all ESPTs were ≥20mm, whereas the six non-
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dysplastic lesions had a median diameter of only 6mm. Therefore, we would suggest folow-
up with repeat EGD or biopsy instead of ER in esophageal lesions smaler than 20mm. 
Although LCE is considered the gold standard for ESPT detection by many, its application is 
subject to debate because of its side effects and prolonged procedure time.12 In addition, the 
specificity of LCE is low, since non-dysplastic lesions can also be unstained.13 An endoscopic 
screening study by Shao et al. found that 74% of the LVL showed no dysplasia on 
histopathological assessment.17 Another endoscopic screening study in patients with HNSCC 
showed that 82% of the LVL were non dysplastic.26 A high false positive detection rate is also 
reflected by our results: 46% of lesions that were suspicious on LCE were false positive, 
compared with 14% in NBI. 
Although our endoscopists have extensive experience in assessing esophageal lesions, the 
relatively high number of false positive lesions detected by LCE might indicate that LVL were 
easily misinterpreted by the endoscopists. However, our study was not designed to calculate 
the accuracy rates of endoscopic detection techniques. As reported in a systematic review 
and meta-analysis by Morita et al., NBI was superior to LCE in differentiating ESPTs from 
other esophageal mucosa alterations, but the sensitivity rates of these techniques to detect 
ESPTs were comparable.30 LCE is helpful to highlight suspected lesions but endoscopist’ 
experience is stil key in the characterization and detection of suspected ESPT.31 
Our study is subject to certain limitations. First, we included relatively few patients. This made 
it impossible to perform risk factor analysis. Second, a large number of patients were excluded 
and these patients could potentialy have had a synchronous ESPT. This might lead to a 
chance of bias skewing the incidence of ESPTs. Third, several patients had an incurable 
HNSCC, which came to light after they had underwent endoscopic screening. Since these 
patients would not have benefitted from endoscopic screening it would have been better if 
screening was performed after workup for HNSCC was completed. If endoscopic screening is 
implemented in daily practice, patients with incurable HNSCC wil most likely not be included. 
Fourth, patient burden was not taken into account. Screening EGD is an invasive examination 
for patients. Patient burden is an important parameter for the decision whether screening 
should be performed. 
The major strength of our study is its prospective design. Al eligible patients were asked to 
participate, which prevented selection bias. This design also ensured that we had no missing 
data. Another strength is that screening EGD was performed in a systematic manner with 
three different endoscopic techniques. This presumably lead to a high detection rate with only 
minimal missed lesions. 
We believe that screening for synchronous ESPTs in patients with HNSCC is promising. 
Screening should be first considered in high-risk patients (e.g. HNSCC located in the 
oropharynx and hypopharynx, patients with alcohol abuse). The combination of WLE and NBI 
is probably the most sensitive method. Although LCE can be performed, extra awareness is 
indicated in case of lesions <20mm because of the high rate of false positive lesions. 
However, more research is necessary before screening for ESPT can be implemented. More 
studies with a larger patient cohort are necessary, preferably in a multicenter setting. This 







who would benefit most from screening. Future studies should also take patient burden, 
survival benefit and cost-effectiveness of screening into account. 
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Supplementary file 1 
Histopathologic evaluation of resected specimens for: 
- Tumor depth invasion 1 
- Tumor differentiation (classified as good [G1], moderate [G2], poor/undifferentiated 
[G3/G4]) 2 
- The presence of lymphovascular invasion 2 
- Involvement of resection margins (R1) 2 
1 according to the Paris classification 20  



























































































































































































































































































































































































































































































































































































































































































































































SCREENING FOR SYNCHRONOUS ESOPHAGEAL SPT
5

S.E.M. van de Ven 
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When is Lugol still necessary in 2020? 








Detection of early esophageal squamous cel carcinoma (ESCC) is very important, because 
these cancers can be treated with minimaly invasive endoscopic resection instead of surgery. 
Early ESCC is characterized by subtle flat lesions, which are easily overlooked during routine 
white light endoscopy.1 To improve ESCC detection, the addition of Lugol iodine was 
introduced.2 Today, Lugol dye chromoendoscopy (LCE) is considered by many the gold 
standard for the detection of early ESCC.3, 4  
Lugol iodine was first used in the esophagus to screen for ESCC in 1966.2 In the esophagus, 
Lugol iodine binds to glycogen.5 Glycogen is diminished or absent in dysplastic or neoplastic 
tissue and abundant in normal squamous epithelium.5 As a result, areas with dysplasia or 
neoplasia have reduced or even absent iodine staining, whereas normal squamous epithelium 
is intensely stained by Lugol iodine.5 Although these unstained areas, so-caled lugol voiding 
lesions, make it more easy to detect dysplasia or neoplasia, non-dysplastic lesions such as 
inflammation can also appear unstained.1 As a consequence, LCE is highly sensitive but not 
very specific in the detection of ESCC.1  
In addition, several side effects of LCE have been described such as chest discomfort, 
heartburn, nausea, pulmonary aspiration, and alergic reaction.6, 7 Another disadvantage for 
both the patient and endoscopist is the extended procedure time.7 Different concentrations of 
iodine solution (1% to 3%) have been used in studies, and patient discomfort seems to depend 
on the iodine concentration used.8, 9 A recent randomized controled trial showed that the use 
of 1% iodine solution resulted in less heartburn and retrosternal pain compared to 2% iodine 
solution (p=0.02).8 In both groups, the color of the stained esophageal images were similar.8 
LCE with 1% iodine solution, therefore, is recommended.8 
Early ESCC can also be identified by narrow-band imaging (NBI) as brown, wel-demarcated 
lesions.6 This is a real-time optical chromoendoscopy technique that was first described in 
2004.10 It visualizes the mucosa and intraepithelial papilary capilary loop (IPCL) patterns.11 
Although NBI is easy to use by pressing a button on the endoscope, the device is expensive 
and expertise is required.6 For example, for inexperienced endoscopists, it might be difficult 
to distinguish inflammation from dysplastic lesions using NBI. 
Because endoscopic imaging techniques have drasticaly improved over time and Lugol has 
several side effects, the questions arises whether and when Lugol is stil necessary. Before 
we completely abandon the use of Lugol based on current knowledge and the evidence 
presented by Costa-Santos et al., we have to consider different phases in the endoscopic 
treatment of ESCC. There are three important phases that finaly lead to endoscopic 
treatment. First, lesions have to be detected. A second important step is characterization and 
if deemed amendable for endoscopic resection, the final important step is delineation. Al three 
steps can be done using either Lugol or NBI. The question arises whether NBI is superior to 
Lugol in al these three steps or there are distinct advantages for each technique in the 
separate steps.  
1. Lesion detection 
Several studies have compared accuracy of LCE with NBI in the detection of early ESCC. 
Wang et al. reported that the combination of NBI and LCE in detection of ESCC showed the 
highest sensitivity (94.7%), compared to LCE (93.0%) and NBI (84.2%) alone.9 A recent 
systematic review and meta-analysis, including 12 studies, showed that the sensitivity of NBI 
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and LCE were comparable (88% vs. 92%) and the specificity was superior with NBI (88% vs. 
82%, p<0.001).12 However, al endoscopies were performed by expert endoscopists.9, 12 
Therefore, accuracy rates may be lower when performed by a general endoscopist. 
2. Lesion characterization 
Esophageal lesions suspected of being dysplastic or neoplastic are highlighted by LCE as 
Lugol voiding lesions. Lugol voiding lesions are present or not, but no further characterization 
of these lesions can be made besides gross morphology. As a consequence, it might be 
difficult to distinguish inflammation from dysplasia or neoplasia or deeper invasion outside 
criteria for endoscopic treatment. In contrast to LCE, IPCLs visible with NBI can further 
characterize esophageal lesions. For example, variety in IPCL shapes, tortuous IPCL, 
presence of a demarcation line, lesions with brownish dots or brownish epithelium al were 
associated with mucosal high-grade neoplasia according to Ishihara et al.13 Based on the 
presence of brownish dots or brownish epithelium, the sensitivity for detecting neoplasia was 
100%.13 
3. Lesion delineation 
In the current issue of this journal, Costa-Santos et al. compared the effectiveness of NBI and 
LCE in defining lateral resection margins before endoscopic resection of ESCC and 
dysplasia.14 Studies on this important step in endoscopic treatment have not been previously 
reported. In their study two groups of patients with ESCC or dysplasia who underwent en-bloc 
resection were defined: (1) ins���������������������; and (2) inspection with LCE (with or 
without NBI). Of 132 included lesions, 68 (52%) were inspected with LCE and 64 (48%) with 
NBI only. The complete lateral resection rate for invasive carcinoma did not differ between the 
����������;�������������������� as 90% in the LCE group and 94% in the NBI group (p=0.715). 
Also, the lateral resection rate for dysplasia did not differ between the LCE (65%) and NBI 
(67%) groups (p=0.813). Costa-Santos et al. concluded that mucosal inspection with LCE 
before endoscopic resection of ESCC and dysplasia was not associated with an increased 
complete lateral resection rate compared to inspection with NBI alone.14  
The results of this study are very interesting and add to our knowledge about minimal invasive 
endoscopic treatment of early cancer. This study supports use of NBI for delineation but it 
does not show superiority of NBI versus Lugol. NBI was used in a recent cohort in which 
modern endoscopes were used, in contrast to the historical LCE cohort in which older 
endoscopes were used. NBI was combined with a white light imaging technique that has 
dramaticaly improved over the years, with improved magnification and image resolution. 
Results with the combination cannot be separated form use of NBI “alone”. In contrast, older 
endoscopes used in the LCE cohort did not display these superior features. Therefore, the 
technology in these two different cohorts with different endoscopes might have influenced the 
results of Costa-Santos et al. A fair comparison would be using both techniques with the same 
superior endoscopes. In addition, the authors did not clearly report on how many lesions in 
the LCE group were also inspected with NBI. Inspection with NBI before Lugol iodine staining 
may influence on the definition of lateral resection margins before endoscopic resection.  
For both NBI and LCE, adequate expertise and experience on the part of the endoscopist is 
key in the detection, characterization, and delineation of esophageal lesions. Although NBI 







depends on the experience of the endoscopist. Recognition of specific IPCL patterns is crucial 
in NBI, while detection of Lugol voiding lesion by LCE might be easier for an endoscopist with 
less experience. Future developments might very wel include artificial inteligence. Computer 
algorithms can ‘red flag’ or even characterize suspicious areas. They are already part of video 
capsule endoscopy and their use is increasing in colonoscopy screening.15, 16 In al likelihood, 
computer algorithms wil make use of these superior imaging techniques and the role of Lugol 
wil be pushed more to the background. Until that new era arrives, Lugol can stil be very useful 
“red flag” in detection of early squamous neoplasia.  
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Favorable effect of endoscopic reassessment 
of clinically staged T2 esophageal 
adenocarcinoma: 








Background: Clinical tumor stage of esophageal adenocarcinoma (EAC) is determined by 
endoscopic ultrasound and/or computed tomography scan, which have low accuracy for 
stages T1 and T2, potentialy leading to overtreatment. We aimed to assess the proportion of 
cT2 EACs downstaged to cT1 after endoscopic reassessment (ERA) by an experienced 
interventional endoscopist. 
 
Methods: We performed a prospective multicenter cohort study. Patients with cT2N0M0 EAC 
were included and underwent ERA. The primary outcome was proportion of cT2 EACs 
downstaged to cT1 after ERA. 
 
Results: 15/25 included patients (60%) were downstaged from cT2 to cT1 EAC after ERA and 
underwent attempted endoscopic resection. Endoscopic resection was aborted in 3/15 
��������� �������� ��� ������ ��������� ����� ����������� �����;� ���� ������ ���������� �����������
surgical resection. Endoscopic resection was successful in 12/15 patients (80%), al of whom 
had pT1 tumors. Overal, 10/25 (40%) were treated with endoscopic resection alone. 
 
Conclusion: ERA downstaged about half of the cT2 tumors to cT1, rendering them suitable 
for endoscopic resection. ERA had substantial clinical impact on therapeutic management, 










Patients with early stage (T1) esophageal adenocarcinoma (EAC) in the absence of poor 
prognostic criteria, have a good prognosis and can be treated with minimaly invasive 
endoscopic resection.1 Additional surgery is recommended when poor histological 
characteristics are present, such as those associated with increased risk of lymph node 
metastasis (LNM).2 
Endoscopic ultrasound (EUS) is often used for clinical tumor staging because it is superior to 
computed tomography (CT) and positron emission tomography (PET).3 Although EUS is 
accurate in staging T3 and T4 EAC, it is less accurate in differentiating between T2 and T1 
EAC (sensitivity 43%–55%, specificity 80%–85%).4, 5 This results in a substantial number of 
patients with pT1 stage who are overstaged as cT2 EAC. As a result, these patients 
unnecessarily undergo neoadjuvant chemoradiotherapy (nCRT) and surgery, which are 
associated with increased risks and morbidity.6-8 Treatment strategies for cT2N0M0 (clinical 
Tumor-Node-Metastasis stage) EAC are therefore subject to debate, and accurate tumor 
staging is crucial.6, 9 
It has been observed that endoscopic tumor staging, based on macroscopic tumor 
characteristics, is superior to tumor staging by EUS in cT2 EAC.6, 10 Besides endoscopic 
staging, the endoscopist can also assess whether endoscopic resection is possible.6 Idealy, 
this assessment should be performed by an endoscopist with experience in assessing the 
endoscopic resectability of tumors.6, 10 The aim of this study was to assess the proportion of 





We conducted a multicenter, prospective observational cohort study in five hospitals 
specializing in endoscopic resection of early EAC (two academic, three nonacademic). The 
study was approved by the Medical Ethical Review Committee of the Erasmus Medical Centre 
in Rotterdam (MEC-2018–1061). Al consecutive patients with cT2N0M0 EAC between April 
2018 and April 2020 were asked to participate and informed consent was obtained. EAC 
diagnosis was established by routine clinical work-up, consisting of a standard endoscopy with 
EUS, CT scan, and/or PET scan. EUS was performed by an experienced endosonographer 
in the referral or expert center with high-resolution endosonography. EUS-guided fine-needle 
aspiration was performed in cases of suspected LNM. Al staging examinations were 
systematicaly reviewed at multidisciplinary tumor board meetings by an expert 
gastrointestinal (GI) radiologist. If EAC staging had been performed at the referring center, 
cross-sectional imaging was reassessed by a GI radiologist in the expert center. Exclusion 
criteria were presence of metastasis, cytology-proven LNM, and esophageal stenosis. 
Endoscopic reassessment and endoscopic resection 
Al included patients underwent ERA using the latest series endoscopes, with white-light high-
resolution endoscopy and narrow-band imaging, to determine clinical tumor stage. ERA for 
invasive features was performed by endoscopists with experience in endoscopic resection of 
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early EAC. Most endoscopists merely detect lesions and define upper and lower limits, 
whereas an endoscopist who actualy carries out endoscopic resection looks for the precise 
borders and assesses the lesion for subtle signs of deep invasion that makes a lesion 
amenable to endoscopic resection or not. Invasive features included presence of a stricture, 
deep ulceration, nonprotruding depressed or excavated lesions, and a tumor that was not 
moving freely with peristalsis. If these features were absent, the tumor was staged cT1 and 
endoscopic resection was attempted. The type of resection technique was left to the discretion 
of the endoscopist. Endoscopic submucosal dissection (ESD) was recommended over 
endoscopic mucosal resection (EMR) for EACs >15mm, if the tumor was depressed, or when 
submucosal infiltration was suspected.11 
Histological evaluation 
Al resection specimens were reviewed by a GI pathologist for tumor differentiation, presence 
of lymphovascular invasion, tumor depth infiltration (mucosal tumors m1–�;� �����������
tumors sm1 [≤500 μm] and sm2/3 [>500 μm]), and tumor involvement of vertical resection 
margins (R0/R1).12 Al resection specimens were assessed for whether they fulfiled the criteria 
for a curative resection.13 If endoscopic resection was outside curative criteria, additional 
treatment was discussed in a multidisciplinary tumor board meeting. When EAC tumor stage 
was estimated as cT2 after ERA, patients underwent subsequent nCRT folowed by 
esophagectomy.8 In these patients, tumor stage after nCRT based on residual disease (ypTN), 
and pre-treatment pathological tumor stage (prepTstage) and N-stage (prepN-stage) were 
assessed in surgical resection specimens.14 
Follow-up 
Patients were folowed according to the European Society of Gastrointestinal Endoscopy 
guidelines if endoscopic resection had been performed 11, and according to the National 
Comprehensive Cancer Network guidelines if esophagectomy had been performed.15 In 
general, this consisted of upper endoscopy every 3–6 months and then annualy for curative 
endoscopic resection.11 Folow-up was indicated every 3 months in the first year after 
esophagectomy.15 
Study end points 
The primary end point was the proportion of cT2 EACs downstaged to cT1 after ERA. 
Secondary end points were: 1) proportion of tumors that were successfuly treated with 
����������� ���������� ���������;� ��� ����������� ��� ������������������ ����������������� ����
�����������������������������������������������������;���������-stage, prepN-stage, and ypTN-
stage in patients treated with nCRT and esophagectomy, and final pathology TN-stage (pTN) 
�������������������������������������������;����������������������������������������������������
of invasive features during ERA in differentiating T1 from T2 EAC. 
Statistical analysis  
Baseline characteristics were presented using descriptive statistics. The 95% confidence 
intervals (CIs) were calculated for proportions, sensitivity, and specificity, and performed with 
the epiR package in R, version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria. 
http://www.R-project.org). For sensitivity and specificity analyses, patients were only included 







2020. Analyses were carried out using IBM SPSS Statistics version 25 (IBM Corp., Armonk, 




Baseline and tumor characteristics 
�����������������������������������������������������;�������������������������������������
and tumor characteristics are presented in Table 1. Tumor stage was determined by EUS in 
24/25 patients and by CT scan in 1/25 patients. The median folow-up time was 16.4 months 
(interquartile range [IQR] 11.0–23.5). 
Endoscopic reassessment 
Information about ERA, subsequent management, and tumor stage is presented in Figure 1 
and Table 2. The median time between cT2 EAC diagnosis and ERA was 26 days (IQR 0–
35). ERA resulted in downstaging from cT2 to cT1 EAC in 15/25 patients (60%, 95%CI 39%–
79%), who al underwent attempted endoscopic resection. The median time between ERA and 
endoscopic resection was 26 days (IQR 15–32). Successful endoscopic resection was 
performed in 12/15 patients (80%), al of whom had pT1 tumors. Five of these 12 patients 
(Table 2, patients 1–5) were within the accepted criteria for curative endoscopic resection, 5 
patients (Table 2, patients 8–12) preferred a wait-and-see strategy, and 2 patients (Table 2, 
patients 6 and 7) received adjuvant treatment. ESD was aborted in 3/15 patients because of 
tumor invasion into the muscle layer (Table 2, patients 13–����������������������������������
a cT2 EAC that was downstaged to cT1 during ERA. In the remaining 10/25 patients (40%, 
95% CI 21%–61%), ERA confirmed cT2 tumor stage based on the presence of invasive 
features (Table 2, patients 16–25). Seven of the 10 patients were treated with nCRT folowed 
by surgery, without proven LNM in surgical resection specimens. Of the remaining three 
patients, one was treated with chemoradiotherapy folowed by active surveilance within a 
research protocol, one received radiotherapy alone owing to poor condition, and the remaining 
patient renounced further treatment. Figure 3 shows a cT2 EAC that was confirmed as cT2 
during ERA. Overal, 15/25 (60%, 95% CI 39%–79%) cT2 EACs turned out to be histologicaly 
proven pT1 or prepT1 EAC. A total of 12 of these 15 cT2 EACs were downstaged to cT1 EAC 
and therapeutic management changed for al 12 patients. Ten of 25 patients (40%, 95% CI 
21%–61%) were treated with endoscopic resection only. In 13/25 patients (52%, 95% CI 31%–
72%), the interventional endoscopist assessed EAC tumor stage as at least T2 during 
reassessment endoscopy (n=10) or attempted ESD (n=3). Ten of these 13 patients were 
treated with nCRT and surgery. PrepT-stage was at least T2 in 7/10 patients (70%). 
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Table 1. Baseline and tumor characteristics 
 
 
Parameter Total cohort (n = 25) 
Patient characteristics 
Sex, n (%)  
  Male 22 (88) 
  Female 3 (12) 
Age at diagnosis, median (IQR), years 69 (57–74) 
BMI, median (IQR), kg/m2 29 (25–31) 
ASA classification, n (%)  
  I 4 (16) 
  II 14 (56) 
  III 7 (28) 
Endoscopic tumor characteristics 
Barrett’s present, n (%) 23 (92) 
Tumor location, n (%)  
  Lower limit of the esophagus 23 (92) 
  Gastroesophageal junction 2 (8) 
Tumor diameter, median (IQR), mm 30 (20–45) 
Morphology1  
  0-I (protruded pedunculated) 2 (8) 
  0-Is (protruded sessile) 6 (24) 
  0-IIa (slightly elevated) 2 (8) 
  0-IIc (slightly depressed) 1 (4) 
  0-Is-IIa 6 (24) 
  0-Is-III 1 (4) 
  0-Is+IIa+IIc 3 (12) 
  Not reported 4 (16) 
Tumor differentiation grade (biopsy)  
  G1/2 10 (40) 
  G2/3 3 (12) 
  G3 1 (4) 
  Not reported in pathology report 11 (44) 
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Figure 2. cT2N0M0 esophageal adenocarcinoma that was 
assessed as T1 during endoscopic reassessment and later 














Figure 3. cT2N0M0 esophageal adenocarcinoma assessed 
as T2 during endoscopic reassessment. The tumor had a 
depressed center and did not move freely with the peristalsis. 
Pathology after neoadjuvant chemoradiotherapy and 
surgery: ypT2N0 (prepT3N0). 
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Sensitivity and specificity of invasive features during ERA 
At least one invasive feature was present during ERA in 12/25 patients (Table 2). In 2/12 
patients (Table 2, patients 13 and 14), the lesion moved freely with peristalsis and therefore 
the benefit of the doubt was given and these lesions were classified as cT1 EAC. The 
sensitivity of the presence of invasive features during endoscopy in detecting T2 EAC was 
86% (95% CI 42%–100%) and the specificity was 80% (95% CI 52%–96%) (Table 3). 
 
Table 3. Presence and absence of invasive features during endoscopy and final pathologic 
tumor stage of esophageal adenocarcinoma  
 ≥T2 EAC T1 EAC Total1 
Invasive features present 6 3 9 
Invasive features absent 12 12 13 
Total 7 15 22 
������������������������������;�����confidence interval. 
Diagnostic characteristics of the presence of invasive features in detecting T2 EAC: sensitivity 86% 
(95% CI 42–100), specificity 80% (95% CI 52–96), positive predictive value 67% (95% CI 30–93), and 
negative predictive value 92% (95% CI 64–100).  
1 ��������������������������;������������������������������������������������������������������������





interventional endoscopist downstaged about half of the cases to a cT1 EAC that was suitable 
for endoscopic resection. ERA prevented unnecessary adjuvant treatment in 40% of patients 
and therefore had a substantial clinical impact on the management of cT2 EAC. The presence 
of invasive tumor features during ERA for the detection of T2 EAC had a sensitivity of 86% 
(95 %CI 42%–100%) and a specificity of 80% (95%CI 52%–96%). We would suggest 
standardizing endoscopy reports for these invasive features. We advocate that al cT2-staged 
����� ������� ��� ����������� ���� ���� ��� ��� ������������ ����� ����������� ��� �����������
resection of early EAC. 
Retrospective studies have shown that up to 63% of pT1 EACs are overstaged as cT2 by 
EUS.4–6, 9, 16 Tumor downstaging by ERA may avoid the substantial risk of treatment-related 
morbidity and mortality of esophagectomy, with or without nCRT, in patients with cT2N0M0 
EAC, while maintaining equal curative outcomes when endoscopic resection is performed.7, 17  
In accordance with this study, previous studies have demonstrated that a substantial number 
of cT2 EACs can be treated with endoscopic resection and are in fact pT1 EACs.6, 18 Nelson 
et al. investigated whether patients with cT2N0 EAC benefit from attempted EMR to identify 
overstaged patients.18 EMR effectively eradicated pT1 EAC in 56.7%.18 However, only smal 
��������������������������������������������������������������������������������18, and this 
may have resulted in an overestimation of the number of overstaged cT2 EACs. The median 







treated with endoscopic resection. One might hypothesize that more cT2 EACs could be 
classified as pT1 EAC when ESD is performed. Our results reflect those of Gotink et al. who 
found that 85% of cT2N0 EACs were downstaged to cT1 EACs after ERA.6 Although this 
percentage is higher than in our study, there was a selection bias �������������������;������
patients with cT2 EAC that were considered “promising” underwent ERA.6 This may have 
resulted in an overestimation of the number of downstaged cT2 EACs. 
It could be argued that ERA should be the first step in determining clinical EAC tumor stage 
rather than EUS, especialy when low EAC tumor stage is expected. May et al. compared the 
sensitivity and accuracy of endoscopic tumor staging by an experienced interventional 
endoscopist with tumor staging performed by EUS for early esophageal cancer.10 Although 
not statisticaly significant, the sensitivity and accuracy of endoscopic tumor staging (82.9% 
and 83.4%) were slightly superior to those of EUS (79.8% and 79.6%).10  
To our knowledge, this is the first prospective, multicenter, cohort study of ERA for cT2 EAC, 
which is a major strength of our study. Furthermore, there was no selection bias because no 
patients were excluded based on tumor characteristics. A major limitation of the present study 
is the smal sample size, with only 25 patients included over 2 years. On the one hand, this 
might be explained by the relative low prevalence of cT2 EAC.6 On the other hand, we may 
have only included the tip of the iceberg because many patients with cT2 EAC do not undergo 
ERA. The participating centers were al expert centers that usualy treat patients who have 
been referred by other hospitals. Most endoscopists in nonexpert centers are not trained to 
assess whether cT2 EAC is suitable for endoscopic resection.10 As a consequence, these 
patients are not referred to an expert center for an attempt at endoscopic resection. Although 
one could argue that the smal sample size wil limit the generalizability of our results, our 
results confirmed the low accuracy of EUS in staging early EAC and showed that ERA 
downstaged 60% of cT2 EACs, of which 80% were pT1 EACs.  
We recommend ERA by an experienced interventional endoscopist for al cT2N0M0-staged 
EAC patients. ERA had a substantial clinical impact on therapeutic management, downstaging 
about half of the cases to T1 EAC in the current study. Although ERA prevented invasive 
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Propofol sedation without endotracheal 
intubation is safe for endoscopic submucosal 








Background: Endoscopic submucosal dissection (ESD) for early esophageal and stomach 
cancer is usualy performed under general anesthesia. However, propofol sedation without 
endotracheal intubation has been suggested as a viable alternative. The objective of this study 
was to evaluate the safety of propofol sedation without endotracheal intubation during ESD in 
the upper gastrointestinal tract. 
 
Methods: We performed a retrospective cohort study of patients who underwent ESD for 
upper gastrointestinal tumors with propofol-remifentanil analgosedation in a tertiary referral 
center in the Netherlands between October 2013 and February 2018. Primary endpoints were 
the rates of intraprocedural endoscopy- and anesthesia-related complications. Secondary 
endpoints were the postprocedural complication rates within 30 days and endotracheal 
intubation conversion rates. 
 
Results: Of 88 patients, intra-procedural ESD-related complications occurred in three patients 
(3.4%). Intra-procedural anesthesia-related complications occurred in two patients (2.3%), 
one of whom required conversion to endotracheal intubation. Post-procedural ESD-related 
complications occurred in 14 patients (15.9%), and minor postprocedural complications 
occurred in two patients (2.3%). Eighty-two (93.2%) patients were discharged within one day 
after ESD. No patient was readmitted for anesthesia-related complications. 
 
Conclusion: Propofol-based sedation without endotracheal intubation is safe for ESD 
procedures in the esophagus and stomach with low anesthesia-related complication rates and 










Endoscopic submucosal dissection (ESD) is a widely used endoscopic resection method for 
early gastric and esophageal neoplasms that cannot be removed by endoscopic mucosal 
resection (EMR) or when submucosal invasion is suspected.1, 2 ESD enables en bloc resection 
of the lesion and has a higher curative resection rate than EMR.3-5 However, ESD is difficult 
and time-consuming and can result in pain and discomfort for the patient during the 
procedure.3, 6 Minimal patient movement is preferred, as ESD involves complex and precise 
maneuvers.7 Therefore, appropriate sedation and analgesia are required to limit 
complications, such as bleeding or perforation.7-9  
Several types of (analgo) sedation have been used during ESD, ranging from conscious 
sedation using midazolam or propofol to general anesthesia.10-12 The advantages of propofol 
over midazolam as a sedative agent are clearly established: fewer movements of the patient 
during ESD and faster recovery after the procedure because of the short half-life of propofol.10, 
13-17 Propofol provides stable sedation, and as a result, patients do not experience any 
restlessness.8, 10, 13-15, 18 Combining remifentanil with propofol as analgosedation improves 
intraoperative hemodynamic control during painful procedures compared with fentanyl, which 
is mostly used in combination with midazolam.19 Nowadays, most ESDs are performed under 
general anesthesia with endotracheal intubation.12, 20-22 Aspiration in the course of long-lasting 
procedures or due to intraprocedural bleeding is a feared complication. The benefit of general 
anesthesia is continuous airway protection, which may lead to fewer respiratory problems and 
interruptions during the procedure and therefore fewer endoscopy- and anesthesia-related 
complications.7, 12, 23 The downsides of general anesthesia are a prolonged post-procedural 
hospital stay, the need for an anesthesiologist, additional logistic chalenges and higher 
procedural costs.7, 12  
Currently, there are no guideline recommendations regarding the preferred sedation method 
during ESD in the esophagus and stomach. We have used propofol-remifentanil 
analgosedation without endotracheal intubation for ESD in our center since October 2013. In 
general, in the Netherlands, propofol sedation can be performed by a sedation practitioner 
(SP) specialized in procedural sedation without the need for an anesthesiologist.24  
We hypothesize that ESD can be safely performed with analgosedation using propofol and 
remifentanil without endotracheal intubation with low endoscopy- and anesthesia-related 
complication rates. The aim of this study was to report on endoscopy- and anesthesia-related 
complications of ESDs in the upper gastrointestinal tract to determine the safety of propofol 
sedation without endotracheal intubation. 
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MATERIALS AND METHODS 
 
We retrospectively reviewed the medical records of al consecutive patients who were treated 
with ESD for upper gastro-intestinal tumors using propofol-remifentanil analgosedation in a 
tertiary referral center between October 2013 and February 2018. The study was approved by 
the Medical Ethical Review Committee (MEC-2018-1060). 
Anesthesia management 
Analgosedation was administered before and during ESD by an SP specialized in procedural 
sedation (L.L.). The SP is a registered anesthesia nurse having folowed an additional 
theoretical and practical, specialist-supervised training. The SP is responsible for the sedation 
of the patient and is trained to manage potential medical complications of sedation such as 
airway and cardiovascular changes. The SP is competent in advanced life-support skils and 
airway management and understands the pharmacology of the drugs used. The SP is 
supervised by an anesthesiologist, who is not present in the endoscopy room but on cal if 
necessary. Patients were continuously sedated with intravenous injection of 1%–2% propofol 
emulsion at a dose of 1–7 mg/kg/hour to achieve a Ramsay Sedation Scale (RSS) score 4 
(Table 1). Analgesia was obtained with intravenous injection of remifentanil, starting at a dose 
of 2–9 mg/kg/minute. Additional medications that could be administered during the procedure 
were glycopyrronium (reduction of mucus secretion), scopolamine butyl (reduction of spasms 
of the gastrointestinal tract), esketamine (anesthetic), granisetron (antiemetic), 
dexamethasone (antiemetic and analgesic) and piritramide (analgesic). Supplemental oxygen 
was administered via nasal cannula with CO2 monitoring. Heart activity (including five- or six-
lead electrocardiography), respiratory rate and RSS were continuously monitored. Blood 
pressure was monitored every five minutes. Ephedrine or low-dose norepinephrine was 
administered in case of low blood pressure and atropine in case of bradycardia. Oxygen flow 
was increased if desaturation occurred until saturation level >95% was achieved. 
Sedation parameters were colected from the anesthesiology patient data management 
system, including anesthesia duration, medications used, and complications. Anesthesia 
duration was defined as the time between the start of propofol sedation until patient’s 
awakening (RSS of 2).  
 
Table 1. Ramsey Sedation Scale 
1 Patient is anxious and agitated or restless, or both   
2 Patient is cooperative, oriented, and tranquil   
3 Patient responds to command only   
4 A brisk response to a light glabela tap or loud a auditory 
stimulus   
5 A sluggish response to a light glabela tap or loud a auditory stimulus   









Endoscopic submucosal dissection 
Al ESDs were performed by a single endoscopist (A.K.), an interventional endoscopist 
specializing in ESDs. ESD involved marking of the lesion, circumferential mucosal incision 
and submucosal dissection with simultaneous hemostasis. After circumferential marking of 
the lesion, a saline solution containing epinephrine (0.01 mg/ml) and indigo carmine was 
injected into the submucosal layer underneath the lesion to elevate the lesion from the 
muscular layer. A circumferential incision was made in the mucosa using a HybridKnife® 
(ERBE Elektromedizin GmbH, Tuebingen, Germany) and the submucosal layer was dissected 
until the lesion was completely resected. Al specimens were reviewed by an expert 
gastrointestinal pathologist and classified according to the Vienna classification of 
gastrointestinal neoplasia.25  
Data extraction 
Patient characteristics such as age, gender, use of anticoagulation, American Society of 
Anesthesiologists classification and clinical folow-up were colected from patient medical 
charts. Endoscopy characteristics such as location of the lesion, Paris classification, lesion 
size, accomplishment of en bloc resection (defined as a macroscopic complete resection of 
the lesion in a single specimen), intra-procedural ESD-related complications, and duration of 
the procedure (defined as the time between the introduction and removal of the endoscope) 
were colected from endoscopy reports. 
Complications 
Intra-procedural anesthesia-related complications were defined as oxygen desaturation 
(SpO2 <90%), hypotension (systolic blood pressure <80 mmHg), bradycardia (heart rate <50 
bpm), apnea or coughing during the procedure that caused an interruption of the procedure 
or conversion to endotracheal intubation. Intra-procedural ESD-related complications were 
defined as adverse events (e.g. bleeding or perforation) that caused a change of procedure 
management, such as discontinuation of ESD. Post-procedural complications comprised of al 
adverse events that resulted in prolonged hospital stay, hospital readmission or additional 
medical interventions within 30 days. 
Statistical analysis 
Categorical data are presented with frequencies and percentages. Continuous data are 
presented with mean (range) and median (interquartile range (IQR)) for normaly distributed 




A total of 97 ESDs were performed in 96 patients between October 2013 and February 2018 
(Figure 1). Three patients received general anesthesia during ESD. In two patients, the 
procedure was combined with other surgical procedures. In the other patient, the lesion was 
located near the upper esophageal sphincter, necessitating endotracheal intubation. In three 
patients midazolam was used as a sedative because procedural time and anticipated technical 
chalenges in relation to smal lesion size were estimated to be minimal. Anesthesia reports 
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were missing in three patients. These nine patients were excluded from further analysis. A 
total of 88 ESDs in 87 patients were included in the final analysis. 
�����������������������������������������;�����������������������;���������������������






discontinued and no histology was obtained (��������������������������������������������������
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Figure 1. flow chart of study inclusion  














Total included ESD  











Table 2. Baseline characteristics of 87 patients 










BMI (kg/m3)  26.3 (22.9-28.7) 
















Type of anticoagulant therapy   
Antiplatelet drugs 






ASA, American So��������������������������;���������������������;� 




Table 3. Tumor characteristics (n=80) 
 N (%) Median (IQR) 
Histology 
Adenocarcinoma 
Squamous cel carcinoma 
Neuro endocrine tumor 
Gastrointestinal stromacel tumor 
High grade dysplasia  




















Tumor size, diameter (mm)  30 (20-40) 
IQR, interquartile range 
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The complication rate was calculated for 88 ESD procedures (Table 4). Intra-procedural 
�����������������������������������������������������;����������������������������������������
���������������������������������������������������������������������������. In the other 
������������������������������������������������������������������������������ ���������
��������� ����������� ������������������ ��������������������������������������� ��������������
������� ���� ��������� �������� ��� ���������� ������������� �� �������cedural ESD-related 
complication occurred in 14 patients (15.9%). Six patients developed retrosternal pain for 
�������������������������������������������������������������������������������������������
�������� ������������������������������ ���������������������������������������� ���-����������
��������������������������������������������������������-���������������������������������
��������������������������������������������������������������������������������������������





����� ��� ���������������� ��������� ������ ���� ������������� ������� ���� ����������� ���������
���������������������������������������������������������������������-procedural ESD-related 
����������������������������� �two ���������� ��-������������������������� dilatation) and 
����������������� �������������������������������������������intervention). 
Anesthesia-related complications 
��� ���������������� ����������-�������� ������������� ��������� ��� ���� ��������� �������� ����
�������������������������������������������������� �������������������������������������������
placement. The other patie�������������������������������������������������������������������
����� �������������������������������� ������������������������ ���������������������������
������������� ������������ ���� ���� ����������� ���������� ���� ���������� �������������� ���






��� ����� ����������� ������� �������������� ����� ��������� ����� ����������� ���� ���� ������ ����
procedure. 













Table 4.  Complications (n=88) 









































In this retrospective, observational cohort study, we found that ESD for gastrointestinal tumors 
in the esophagus and stomach could be safely performed with propofol-remifentanil 
analgosedation without endotracheal intubation. There was no mortality as a result of 
complications. Conversion to endotracheal intubation took place in one patient only. Coughing 
was observed in another patient, which brings the intraprocedural anesthesia-related 
complication rate to 2.3%. Two other minor postprocedural complications were observed that 
were not obviously anesthesia or ESD related, without additional consequences for the 
patient. No post-procedural anesthesia-related complications were observed. The intra-
procedural ESD-related complication rate was 3.4% and post-procedural ESD-related 
complication rate was 15.9%. A total of 93.2% of the patients were discharged the same day 
or the day after the procedure. 
Endoscopy-related complication rates in gastric ESDs range from 1.2% to 5.2% for perforation 
and 0% to 15.6% for delayed bleeding.26 In ESDs performed in the esophagus, perforation 
ranges from 0% to 6.9% and delayed bleeding range from 0% to 5.2%.27 Although no 
perforations occurred in our study, the overal postprocedural ESD-related complication rate 
was stil 15.9%, which seems high compared with other studies. However, in our series pain 
was also considered a complication if this resulted in a longer hospital stay, even one day after 
the procedure. When taking only perforation and delayed bleeding into consideration, in line 
with what is reported in most studies, the ESD-related complication rate is 9.1% (8/88). This 
includes only bleeding in the stomach, which corresponds with the reported range of 0% to 
15.6% in literature.26 Studies in which the sedation method was taken into account reported 
low ESD-related complication rates during ESD when general anesthesia was used. Song et 
al. reported a lower perforation rate in esophageal ESDs in patients receiving general 
anesthesia compared with those who received propofol sedation (1.2% vs. 14.0%).12 This 
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reported perforation rate of 14.0% when using propofol sedation seems exceedingly high. No 
perforations were reported in our study. Another study, using general anesthesia, reported no 
ESD-related complications during esophageal ESD and low complication rates in gastric ESD 
(bleeding: 1.6% and perforation: 1.7%).7 
To judge the safety of ESD in relation to the sedation method used, it would be appropriate to 
focus on anesthesia-related complications. Several studies reported fewer anesthesia-related 
complications in patients receiving general anesthesia during ESD. In a study by Yurtlu et al., 
cough was observed more frequently during ESD in patients receiving propofol compared with 
general anesthesia (50% vs. 5.4%).23 Likewise, desaturation occurred more often in the 
propofol sedation group (18.5% vs. 2.7%).23 In contrast, we observed cough in only one patient 
(1.1%). This was likewise for desaturation (1.1%). Other studies in which general anesthesia 
was used during ESD in the esophagus and stomach reported no hypotension, desaturation 
or aspiration.7, 28 We encountered no hypotension or aspiration either.  
The published literature to date indicates that, compared with propofol sedation, the risk-
benefit balance is in favor of general anesthesia. It is difficult, however, to discern to what 
extent the training and experience of the SP plays a decisive role in this equation. In our 
setting, propofol sedation is managed by an SP, a member of the anesthesiology department 
who is supervised by the anesthesiologist. Under these conditions, the results of propofol 
sedation were excelent and only one case required conversion to general anesthesia with 
endotracheal intubation. Moreover, our anesthesia-related complication rates are lower 
compared with other studies in which hemodynamic events and respiratory events during 
propofol sedation were reported to be 37.3% and 14.1%, respectively.29  
Another reported advantage of general anesthesia is a shorter procedure time due to fewer 
interruptions during ESD.28 In that particular study, however, the time between insertion and 
withdrawal of the endoscope was considered the ESD procedure time without including the 
time the patient was in operation room.28 Therefore, the total procedure time including 
preparation for general anesthesia might be much longer. The median ESD procedure time in 
the study of Rong et al., in which general anesthesia was used was 42.5 minutes compared 
with 100 minutes in our study.28 This is a huge difference. Rong and coleagues, however, 
excluded lesions >20 mm in contrast to a median lesion size of 30mm in our study, which 
explains this difference. In the same study less body movement and more comfort for the 
patient were reported as other advantages of general anesthesia.28 In our anesthesia reports, 
interruptions and body movements were not reported, which precludes further quantitative 
analysis in our series. According to the SP (L.L.) and the endoscopist (A.K.) who performed 
al the procedures, no procedure was interrupted because of patient movements. In this 
retrospective study we could not report on patient satisfaction after the procedure. 
This study demonstrates the feasibility and safety of propofol sedation for ESD. This was 
accomplished with limited hospital admission time with 48.9% of the patients being discharged 
the day of the procedure and another 44.3% being discharged the day after the procedure. In 
contrast, other studies in which general anesthesia was used for ESD reported a mean 
hospital stay of more than four days.7, 12, 23  
Compared with propofol sedation, general anesthesia requires additional facilities, more 
expertise, and an anesthesiologist.28 Furthermore, most patients cannot be discharged the 







hospital stay.7, 12, 23 Therefore, general anesthesia in al likelihood results in higher costs, 
although formal cost-effectiveness studies are needed to quantify potential savings in a 
specific local setting.28  
The main strength of this study is that al ESDs were performed by the same endoscopist 
(A.K.) and by the same SP (L.L.), both with extensive experience in this procedure. This limits 
confounding factors such as experience and technical skils. However, we are aware of the 
fact that such a dedicated team is quite unique in the clinical routine. In particular, an SP is 
not very common since an anesthesiologist is required in most countries when propofol 
sedation is used.30 A second strength is that we included al consecutive ESDs in the upper 
digestive tract between October 2013 and February 2018 performed with propofol sedation 
regardless of location or size of the lesion.  
Some limitations need to be discussed. This is a retrospective, observational, single center 
study, which potentialy limits the generalizability of our results. There was no comparator 
group in our study, which could be seen as a limitation. A randomized controled trial in which 
propofol sedation (performed by an SP) is compared with general anesthesia (performed by 
an anesthesiologist) during ESD is needed to definitively prove the safety of propofol sedation 
performed by an SP. Owing to the retrospective nature of this study, we did not know the exact 
number of interruptions during ESD caused by restlessness of the patient. Patient satisfaction 
could also not be assessed. 
In conclusion, in this retrospective, observational proof-of-concept cohort study, propofol-
remifentanil analgosedation without endotracheal intubation proved to be a feasible and safe 
sedation method for ESD in esophagus and stomach. Patients could be discharged shortly 
after the procedure without readmission for anesthesia-related complications. In line with 
these observations and logistical and financial ramifications, propofol-remifentanil 
analgosedation without endotracheal intubation for ESD should be considered over general 
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preventing esophageal strictures after 








Background and study aims: A disadvantage of endoscopic resection (ER) of early 
esophageal cancer (EC) is the high stricture rate after resection. A risk factor for stricture 
development is a mucosal defect after ER of ≥75% of the esophageal circumference. Stricture 
rates up to 94% have been reported in these patients. The aim of this study was to investigate 
the effectiveness of oral treatment with topical budesonide for stricture prevention after ER of 
early EC. gastrointestinal tract. 
 
Patients and methods: We performed a retrospective analysis of a prospective cohort study 
of patients who received topical budesonide after ER of EC between March 2015 and April 
2020. The primary endpoint was the esophageal stricture rate after ER. Stricture rates of our 
cohort were compared with stricture rates of control groups in the literature. 
 
Results: In total, 42 patients were treated with ER and topical budesonide. A total of 18 of 42 
patients (44.9%) developed a stricture. The pooled stricture rate of control groups in the 
literature was 75.3% (95% CI 68.8%-81.9%). Control groups consisted of patients with 
esophageal squamous cell carcinoma with a mucosal defect after ER of ≥75% of the 
esophageal circumference. Comparable patients of our cohort had a lower stricture rate 
(47.8% vs. 75.3%, p=0.007). 
 
Conclusions: Topical budesonide therapy after ER for EC seems to be a safe and effective 
method in preventing strictures. The stricture rate after budesonide treatment is lower 
compared to the stricture rate of patients who did not receive a preventive treatment after ER 










Over the past few decades, the incidence of esophageal cancer (EC) has increased.1 The 
most common histological type of EC is esophageal squamous cel carcinoma (ESCC).2 The 
overal survival of patients with EC has improved due to better treatment options such as 
neoadjuvant chemoradiotherapy, and the treatment shift from esophagectomy to endoscopic 
resection (ER) for early EC.3-5  
Compared to surgery, ER has a lower morbidity and mortality for early EC while maintaining 
equal curative outcomes.5 Endoscopic mucosal resection (EMR) and endoscopic submucosal 
dissection (ESD) are established treatment options when EC is limited to the superficial 
layers.6 ESD is recommended over EMR for a selected number of adenocarcinomas larger 
than 15mm with suspected submucosal invasion, and for al superficial ESCCs except if 
submucosal invasion is suspected.7 Moreover, ESD provides en bloc resection and it reduces 
the number of recurrences compared to EMR.8, 9  
A major disadvantage of ER of large esophageal tumors, however, is the high stricture rate 
after resection.10, 11 Stricture formation after ER of early EC with a mucosal defect ≥75% of the 
esophageal circumference is reported up to 94.1% in the literature.10 Esophageal strictures 
develop as a result of inflammation in the wound healing process of the mucosal defect 
folowing ER.12 Previous studies have shown that a mucosal defect of ≥75% of the esophageal 
circumference was associated with esophageal stricture rates of 70% to 94% and it is reported 
as a significant risk factor for stricture development.10, 13-15 Patients with strictures might suffer 
from dysphagia with the need for endoscopic dilations, and patients quality of life might 
substantialy decrease.16 In addition, endoscopic dilations are associated with an increased 
perforation risk.17  
In an effort to reduce the stricture rate after ER of esophageal tumors, preventive strategies 
have been investigated.18 For example, treatment with triamcinolone injections, the use of 
polyglycolic acid sheet (PGA) with fibrin glue, preventive endoscopic baloon dilation (EBD), 
and treatment with oral prednisolone.16, 19-24 Although these studies have shown promising 
results in preventing strictures after ESD, limited patients were included and the optimal dose 
and duration of steroids has not yet defined.16, 19-24 The use of triamcinolone injections in the 
esophagus has raised several concerns about the safety and effectiveness.18 Moreover, 
systemic therapy with oral steroids is wel-known to have several side effects.25  
The question arises whether the use of topical steroids is effective in stricture prevention after 
ER of esophageal tumors, due to its effect in the suppression of the inflammatory process 
after ER.12 Topical steroids have shown to be beneficial for eosinophilic esophagitis treatment 
and have resulted in stricture reduction after EMR of short Barrett’s segment.12, 26  
The aim of this study was to investigate the effectiveness of oral treatment with topical 
budesonide for the prevention of strictures after ER of EC (ESCC or esophageal 
adenocarcinoma (EAC)). We hypothesized a lower esophageal stricture rate when using 
topical budesonide compared to the stricture rate in patients who did not receive a preventive 
treatment after ER, reported in the literature. The secondary aim of this study was to 
investigate whether the use of topical budesonide after ER affects esophageal stricture 
treatment. We hypothesized that less dilations were required in patients treated with topical 
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budesonide who developed a stricture after ER compared to patients who did not receive 





We performed a single-center, retrospective analysis of data that has been prospectively 
colected in our ongoing registry of ER of the esophagus at the Department of 
Gastroenterology and Hepatology at the Erasmus MC, University Medical Center. Patients 
treated with ER (EMR or ESD) for superficial ESCC or EAC between March 2015 and April 
2020 were retrospectively included in this study. Al patients that were deemed to have a high 
chance of stricture development (i.e. patients with a mucosal defect size after ER >50% of the 
esophageal circumference) were treated with topical budesonide after ER in order to prevent 
stricture development.15 This was decided directly after ER by the treating endoscopist [A.K.]. 
Patients were excluded if they had known intolerance to budesonide, candida esophagitis, or 
immunocompromised conditions. Additionaly, patients were excluded from final analysis if 
they were treated with prior ESD, EMR, radiotherapy, radiofrequency ablation, or endoscopic 
dilation in the area where the current ER was performed. These prior treatments could be of 
influence on stricture development. This study was approved by the Medical Ethical Review 
Committee of the Erasmus University MC in Rotterdam, the Netherlands [MEC-2019-0819].  
Data colection 
Patient and tumor characteristics were colected from medical charts and endoscopy and 
pathology reports. An overview of colected characteristics can be found in Supplementary file 
1. If a patient developed a second (metachronous) tumor, the first tumor was included for final 
analysis to avoid bias.  
ER was performed with either EMR or ESD which was up to the discretion of the endoscopist 
or dictated by the tumor type. ESCC was always removed by ESD. EAC was only removed 
by ESD when submucosal invasion was expected. EMR was performed using the multiband 
mucosectomy method.27 ESD was carried out with a HybridKnife® (ERBE Elektromedizin 
GmbH, Tuebingen, Germany), lifting fluid contained saline with indigo carmine and 
epinephrine.28 Al EMRs and ESDs were performed by a single endoscopist [A.K.].  
Treatment with budesonide after endoscopic resection 
The standard dose for topical budesonide was 2.3 mg once a day, 2.3 mg twice a day or 1 mg 
twice a day, for a duration of 6 weeks from the first day after ER. In general, if adjuvant therapy 
(e.g. surgery or chemo-radiotherapy) was needed, budesonide was stil given for 6 weeks 
because strictures can develop shortly after ER. For every patient, this was discussed in a 
multidisciplinary team. Only if adjuvant therapy started within this 6-week period, budesonide 
treatment discontinued earlier. The budesonide dose depended on the availability of topical 
budesonide in the pharmacy. In 2015, 2.3mg budesonide once a day was given, and 2.3mg 
budesonide twice a day was given beginning in 2016. In the last 6 months of inclusion, 
orodispersible topical budesonide tablets of 1mg became available for eosinophilic 
esophagitis (EoE) treatment wherefore this dose was chosen. Because no orodispersible 







budesonide enema was used for oral intake. Patients were instructed to let the tablet dissolve 
on the tongue and swalow the dispersed budesonide. This is a common off-label use of 
budesonide in the treatment of EoE. Recently, a budesonide orodispersible tablet has become 
available for the treatment of EoE.29, 30  
Endoscopic dilation 
Endoscopic dilation was only performed when the patient had dysphagia in combination with 
esophageal stenosis. Prophylactic dilation was not performed. The type and interval of 
endoscopic dilation was up to the discretion of the endoscopist. In general, two dilation 
techniques were used: bougie and baloon dilation.31 Dilations were usualy done with a weekly 
repetition if necessary. 
Study end points 
The primary end point was the esophageal stricture rate in patients who received topical 
budesonide therapy after ER of early EC. A stricture was defined as the inability to swalow 
solid food and/or the inability to pass a standard diagnostic endoscope (diameter: 9.9mm, GIF-
H190 and GIF-H180J, Olympus) which resulted in the need for dilation. We only included 
strictures that developed before adjuvant treatment (e.g. radiotherapy, radiofrequency 
ablation, EMR, chemotherapy) started. Stricture development after adjuvant treatment could 
also be attributed to the adjuvant treatment. Therefore, the date of adjuvant therapy was 
considered as the last moment of folow-up in these patients and strictures after that date we 
not included. Stricture rates in our cohort were compared with stricture rates of comparable 
control groups in the literature. Secondary endpoints included identification of risk factors for 
stricture development, number of endoscopic dilations per patient, type of dilation 
(baloon/bougie), time to dilation after ER (days), number of patients with dysphagia, number 
of patients who experienced budesonide side effects, and the number of patients with adverse 
events (AEs) after dilation, including the type of AE. To investigate whether topical budesonide 
affects esophageal stricture treatment, the number of endoscopic dilations performed in 
patients who developed a stricture in our cohort was compared with the number of endoscopic 
dilations performed in patients who developed a stricture in control groups from the literature. 
Statistical analyses 
Continuous variables were presented with mean (range) and median (interquartile range 
(IQR)) for normaly distributed and skewed data, respectively. Patients who developed a 
stricture were compared with patients who did not develop a stricture after ER to determine 
potential risk factors for stricture development. These two groups were compared with 
univariable analysis, performed by the independent Student’s T-test for normaly distributed 
continuous data and the Chi-square test for categorical data.  
For the comparison of stricture rates and the number of dilations of patients in our cohort with 
patients who did not receive a preventive treatment after ER of EC, control groups of several 
studies were used in which other methods were investigated to prevent stricture development. 
For the selection of these control groups, a systematic literature search was performed in 
Pubmed and Medline by two independent reviewer (S.V. and M.S.). The search strategy and 
selection of relevant literature is outlined in Supplementary file 2. Stricture rates in the control 
groups were calculated for each study as the total number of patients who developed a 
stricture in the control group divided by the total number of patients in the control group. We 
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calculated the standard error (SE) for each study using the folowing formula: SE =
 √(s ∙ (1 − s) / n);� ��������������������������������������������������������������������������������
A fixed-effects meta-��������� ���� ���������� ��� ���� ���� ���� ���������� ����� ��� ���� ��������
studies������������������������������������������������������������������������������I2) was 
�����������32 ���������������������������������������������������������������������������������
rate of our cohort using the Z-��������������������������������������������������������������















Table 1. Baseline characteristics of 42 patients and univariable analysis of the stricture group 
(n=18) versus the non-stricture group (n=24) 
Characteristics Total (n=42) Stricture (n=18) No stricture (n=24) 
p-
value 














Median age, years (IQR) ����������-����� ����������-����� ����������-����� ���� 
























































































Tumor and treatment characteristics 
Tumor and treatment characteristics are presented in Table 2 for 42 cases. Most tumors were 
located in the mid esophagus ������;� ������� ���� ������ ���������� ������;� �������� ����
�����������������������;�������� �������������������������������-locations or were located 
in the upper thoracic esophagus. The median circumferential range of the mucosal defect after 
�����������������������-��������������������������������������� ����������������������������
������������������������������������������������������������� ������������������������������
����� ��������������2 ���������-��������������������������������������������������������2 
��������������������������������������������������������������������������������������;�
������������������������������������������������������������������������������ of 42 tumors 
��������������������������������������������������������������������������eported with a 
������������������������������-��������� 
������������������ ��������������������������������������� ��� ��������������������The 
d���� ��� ����� ����������� ���� ����� ����������� ������ �� ���� ������� ������]��� ���mg 
�����������������������������14.���� or 1m���������������������������������������������
patient discontinued budesonide treatment before the 6-week period was completed (reason 
�����������������������������������������������������������������������������������������
���������������������������e effects of topical budesonide were reported. 
Adjuvant treatment 
��������������������������������������������� ����������������������������� �������� ����������
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Table 2. Univariable analyses of tumor characteristics (42 tumors) and treatment characteristics 
between the stricture group (n=18) and non- stricture group (n=24)





Tumor location, n (%) 
Upper thoracic esophagus 
Mid thoracic esophagus 















Median circumferential range of the mucosal defect 
after ER (%) (IQR) 80 (75-100) 100 (75-100) 75 (75-88) 0.01 










Morphology (Paris classification), n (%) 
Protruded lesions 
Overlapping protruded/flat elevated lesions 
Flat elevated lesions 
Overlapping flat elevated/flat lesions 
















































































Median length of the resected specimen, cm (IQR) 4.5 (3.5-5.4) 4.5 (3.8-5.3) 4.4 (3.3-5.7) 0.95 


































Dose of budesonide, n (%) 
2,3 mg 2dd budesonide 
2,3 mg 1dd budesonide 












���������;� ���, ��������������� ��������;� ���, ����������� �������� ���������;� ���, endoscopic 
submucosal dissection. 1 ������������������������������������������splasia (n=3) or low grade dysplasia 
(n=1). 2 Not reported for patients with high grade dysplasia (n=3) or low grade dysplasia (n=1). 










Figure 1. Adjuvant treatment after endoscopic resection of early esophageal cancer  
CRT, �����������������;����������������������������������;������ ��������������� ��������;����, 
��������������� ���������� ����������� ����� ��� ����� ���� ���������� ������� ��� ���� �������;� ��tive 




�������� of 42 patients (44.9%) developed a stricture during folow-up. Patients with a 
mucosal defect of ≥75% of the esophageal circumference had a stricture rate of 43.6% (17/39) 




in control groups from these studies al ����������������������� ������� �������������� ��
circumference ≥75%. All studies were performed in Asia (five in Japan and three in China and 
�������������������otal, 104 of ���������������������������������������������������������������
developed a stricture. The stricture rate for �������������������������������������� to �������
����-analysis with fixed-effect model was used to calculate the pooled stricture rate since I2 
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was 44% (low heterogeneity). The pooled stricture rate was 75.3% (95% CI 68.6%-81.9%) 
(Figure 2). The stricture rate in our cohort of patients with ESCC and a mucosal defect after 
ER with a circumference ≥75% was 47.8% and was significantly lower compared with the 
control groups (47.8% vs. 75.3%, p=0.007).  
Potential risk factors for stricture development 
Patients who developed a stricture were compared with patients who did not develop a 
stricture. The stricture group consisted of 18 of 42 patients (44.9%) whereas the non-stricture 
group consisted of 24 of 42 patients (57.1%). There was no significant difference in sex, age, 
smoking status, alcohol consumption or American Society of Anesthesiologists classification 
between the two groups (Table 1). The median circumferential range of the mucosal defect in 
the stricture group was 100.0% compared to 75.0% in the non-stricture group (p=0.02) (Table 
2).  
Figure 2. Forest plot of the stricture rate of patients who did not receive a preventive treatment 
after endoscopic resection of esophageal carcinoma  







Stricture development and dilations 
The median folow up time of patients who developed a stricture (n=18) was 53.4 (IQR: 17.7-
79.5) weeks. Dysphagia was reported in 17 of 18 patients (94.4%). In total, 147 dilations were 
performed. The median number of endoscopic dilations per patient was 6.0 (IQR: 4.0-14.0). 
The median number of dilations in patients with ESCC and a mucosal defect after ER with a 
circumference ≥75% was also 6.0 (IQR 2-�����������������������������������������������������;�
78.9%) was more often used compared with �����������;������������� �������� ��������������
����������������������������-44.5) days. Two patients developed an AE after dilation. One 
patient had a poor healing ulcer after dilation, which was successfuly treated with 
pantoprazole. Another patient developed a perforation, which was treated with stent 
placement. The patient was hospitalized for two days for observation without further events. 
The stent was removed after four weeks and the perforation had healed.  
The median number of dilations in patients who developed a stricture in control groups was 
reported in t������������;�������������-�����������������-������������������-15).���������� Other 
��������������������� �����������������������;�����������������-17.9) in Takahashi et al., 6.6 
(range 0-������������ �����������������������-������� ����������������������3.5 (range 0-����




ER of EC is an excelent minimaly invasive treatment method to cure patients from early EC. 
A major disadvantage, however, is the development of esophageal strictures after the 
procedure.10 Most strictures have been observed when the mucosal defect after the procedure 
extends beyond 75% of the esophageal circumference.10, 13, 14 We performed a retrospective 
analysis of a prospectively colected cohort of patients who received topical budesonide after 
ER of early EC, to investigate whether the use of topical budesonide prevents esophageal 
strictures after ER.  
We found an overal stricture rate of 44.9% in patients who received a 6-week treatment of 
topical budesonide after ER of early EC (both ESCC and EAC), compared with a pooled 
stricture rate of 75.3% when no preventive measures are taken as reported in the literature.19, 
��-��, 33-36 No side effects of budesonide were reported. Al patients had an esophageal mucosal 
defect after ER with a circumference ≥60%. The median circumference of the mucosal defect 
was higher in patients who developed a stricture compared to patients who did not develop a 
������������������������������;�p=0.02). Al patients who developed a stricture were treated 
���������������������������������� �������� ������������������������������������-44.5) and the 
median number of dilation was 6.0 (IQR 4.0-14.0). There was only one perforation after 
dilation, successfuly treated with stent placement.  
The stricture rate of patients in our study with ESCC and a mucosal defect ≥75% of the 
esophageal circumference was 47.8%, which is lower than the pooled stricture rate in patients 
���� ���� ���� �������� ����������� ����� ���� ������ ��� ������;� p=0.007). Topical budesonide 
therapy seems to be effective on stricture prevention after ER of early EC. The median number 
of dilations performed in patients who developed a stricture in our cohort (6.0) is in line with 
�������������������������������� �������� �������� to 8.1, performed in patients who did not 
receive preventive treatment after ER.���������� ����������������������������������������� ������
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number of dilations without a standard deviation or IQR. We could therefore not compare our 
results with control groups from the literature using meta-analysis. As a consequence, we 
could not investigate whether use of topical budesonide after ER affects esophageal stricture 
treatment. 
Several studies have investigated different methods of preventing esophageal strictures after 
ER, such as preventive EBD, oral prednisolone, triamcinolone injections and treatment with 
viscous budesonide slurry.12, 19, 21-24 Patients in these studies had an esophageal mucosal 
defect with a circumference ≥75%, comparable to our study. Although most of these studies 
reported a lower stricture rate in the treatment group compared to the stricture rate in our 
cohort, several limitations of these preventive methods are reported and al studies had smal 
sample sizes with only 13 to 29 patients included in the treatment group.12, 19, 21-24 The stricture 
rate in patients with ESCC who were treated with preventive EBD after ER was 59% compared 
to 92% in the control group (p=0.04).21 There was no significant difference in the number of 
dilations after stricture development in the treatment group compared to the control group (2.0 
�������;�p=0.05).21 Patients in the treatment group received preventive EBD every week until 
complete healing of the mucosal defect was observed, which could be associated with patient 
burden and additional costs.21 Treatment with oral prednisolone in ESCC patients was 
reported in two studies and resulted in a significantly lower stricture rate of 17.7% to 23.1% 
compared to 68.8% to 80.0% in the control groups.22, 23 In both studies, the number of required 
dilations was significantly higher in the control group compared to patients receiving oral 
prednisolone.22, 23 A disadvantage of systematic therapy with oral steroids are several side 
�������� ����� ���� ������ ����� ��;� � ����� ������������� ������������ �������� ������� ����
psychiatric disturbance.25 Use of triamcinolone injections after ER in patients with ESCC 
resulted in a significantly lower stricture rate of 19.0% to 62.5% compared with 75.0% to 87.5% 
in control groups.19, 24 In both studies, fewer dilations were required in the treatment groups. A 
limitation of this invasive method are the extra required endoscopic procedures, causing 
additional costs and potential patient burden. Moreover, there is a risk of developing 
perforations after these injections.19 Bahin et al. reported the effect of an oral treatment with 
viscous budesonide slurry (a mix of budesonide with sucralose) in patients with an EAC and 
a significant stricture reduction after EMR was observed compared to a control group (13.8% 
vs 37.3%, p<0.01).12 This treatment was only given to patients with an EAC, and patients with 
a Barrett segment larger than C3M5 were excluded.12  
This is the first study to investigate the effect of topical budesonide on stricture prevention 
after ER of early esophageal neoplasia. Our study suggest that the use of topical budesonide 
is safe and effective for stricture prevention after ER. Topical budesonide is a noninvasive 
treatment, which is a major strength of this study, and no side effects were reported. However, 
our results have to be interpreted with caution due to several limitations. The first limitation is 
the retrospective design of our study, performed in a single center. We had several missing 
data, which may have influenced our results and could have resulted in information bias. The 
second limitation is the smal sample size of 42 patients, of whom 18 patients developed a 
stricture. Therefore, we could not perform multivariable risk factor analysis to adjust for 
confounders. The third limitation is the non-randomized study design without the availability of 
a control group. Because there was no control group, it is impossible to know whether use of 
topical budesonide was the main reason for the lower stricture rate. Another limitation is the 
potential for selection bias. The endoscopist decided whether patients received budesonide 







reported taking the medication correctly during folow-up, we did not have a formal procedure 
in place to confirm that. Because no topical budesonide tablets were available during the 
largest part of the study period, we prescribed the dispersible budesonide tablets from a 
budesonide enema. This off-label use could result in incorrect use of budesonide. Moreover, 
different doses of budesonide were used during the study period. It seems likely that an 
orodispersible tablet designed for this indication could yield an even higher effect in prevention 
of strictures. To address these limitations, a prospective, randomized controled trial (RCT) is 
necessary to investigate the efficacy and tolerability of budesonide orodispersible tablets.  
In conclusion, based on comparisons with historical published data, topical budesonide after 
ER for EC seems to be an effective method for preventing stricture development. The stricture 
rate was lower compared with the rates of patients who did not receive a preventive method 
after ER. However, a prospective RCT is required to investigate whether topical budesonide 
is safe and effective for prevention of strictures after ER in patients with early stage EC, and 
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Supplementary file 1. Patient and tumor characteristics colected from medical charts, 
endoscopy reports and pathology reports. 
Baseline characteristics: sex, age at time of endoscopic resection, smoking status (pack 
years), alcohol consumption (units per week) and ASA-classification.  
Treatment characteristics: type of endoscopy resection (endoscopic mucosal resection or 
endoscopic submucosal dissection), dose of topical budesonide, treatment duration (weeks) 
and reported budesonide side effects.  
Tumor characteristics: ������ ��������� ������� ���������;� ��-24 cm from the incisors, mid 
���������;���-������������������������� ���������������;���-40 cm from the incisors, and 
overlapping location between two parts of the esophagus), circumference of the mucosal 
defect after endoscopic resection estimated by the endoscopist, tumor morphology (Paris 
classification: protruded lesion [0-Ip, 0-Is, 0-lps], overlapping protruded/flat elevated lesions 
[0-ls + 0-IIa], flat elevated lesions [0-IIa, 0-IIa + 0-IIc], overlapping flat elevated/flat lesion [0-
IIa + 0-IIb], and flat lesions [0-IIb, 0-IIc, 0-IIc + 0-IIa]), histology (ESCC or EAC), invasion depth 
��������� ������� ��� �� ����������� �������������� ��������;� ���������� ��� ���� ������
classification), the presence of lymphovascular invasion, tumor differentiation (wel/moderate 
�������;������������������������������������������������ �����������������������������������������
and surface of the resected specimen (in cm2). Surface of the resected specimen was 
calculated with measurements from pathology reports, since the diameter of the tumor and 
resected fragment were missing in a large number of endoscopy reports. In case of a 
piecemeal endoscopic mucosal resection, the surface of the resected fragment could not be 
reliably calculated.  
Folow-up information: presence of a clinicaly important esophageal stricture resulting in 
dysphagia, and the total folow-up time (defined as the time from endoscopic resection to the 
last hospital visit in weeks). In case of stricture formation, the folowing information was 
���������;��������������������������������������������������� �����������������������������������
time to dilation after endoscopic resection (days), dysphagia (yes/no) and the occurrence of 
adverse events after dilation.  
Supplementary file 2. Systematic literature search strategy 
��������������������������������������������� ��������������������������-07-2020, with no 
limit on publication date. Only English studies were selected. Title and abstract of the articles 
were reviewed by two reviewers (S.V. and M.S.). The ful text of the selected articles was 
reviewed thereafter. Discrepancies were discussed mutualy.  
Literature search (Pubmed and Medline):  
������������� �������� ���������� � ������ ��� ������������ ����������� ������������
��������������������� ����������������������������������� ��������������������� ��������������
����������� ����������� ������������������ ��� (Submucosal Dissection, Endoscopic 
������������������ ��� ������������ ������������� ������������� ���� ������������� ���������







[Title/Abstract]) OR (Cancer of the Esophagus [Title/Abstract]) OR (Esophagus Cancer* 
[Title/Abstract]) OR (Esophageal Cancer* [Title/Abstract]) OR (Esophagus Neoplasms [Mesh]) 
OR (Esophagus [Mesh]) OR (Adenocarcinoma [Mesh]) OR (Adenocarcinomas 
[Title/Abstract]) OR (Esophageal Squamous Cel Carcinoma [Mesh])) AND ((Esophageal 
Stenosis [Mesh]) OR (Esophageal Stenos* [Title/Abstract]) OR (Esophageal Stricture* 
[Title/Abstract]))  
Selection criteria for included articles: 
• The primary outcome of the study was the stricture rate after endoscopic resection 
• The presence of a control group, including their stricture rate. 
• Circumferential defect ≥75% after endoscopic resection of esophageal cancer  
























• 16 narrative review 
• 26 animal study 
• 2 circumferential defect not reported 
• 3 no esophageal cancer 
• 43 no control group 
• 4 editorial 
• 3 letter to the editor 
• 18 case report 
• 2 systematic review 
• 107 not about stricture prevention 
• 1 stricture rate not separately mentioned for mucosal defect >75%  
• 1 protocol publication 
9 studies included 
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Individual risk calculator to predict lymph node 
metastases in patients with submucosal (T1b) 
esophageal adenocarcinoma: 








Background: Lymph node metastasis (LNM) is possible after endoscopic resection of early 
esophageal adenocarcinoma (EAC). This study aimed to develop and internaly validate a 
prediction model that estimates the individual risk of metastasis in patients with pT1b EAC. 
early EC. 
 
Patients and methods: A nationwide, retrospective, multicenter cohort study was conducted 
in patients with pT1b EAC treated with endoscopic resection and/or surgery between 1989 
and 2016. The primary end point was presence of LNM in surgical resection specimens or 
detection of metastasis during folow-up. Al resection specimens were histologicaly 
reassessed by specialist gastrointestinal pathologists. Subdistribution hazard regression 
analysis was used to develop the prediction model. The discriminative ability of this model was 
assessed using the c-statistic. 
 
Results: 248 patients with pT1b EAC were included. Metastases were seen in 78 patients, 
and the 5-year cumulative incidence was 30.9% (95% confidence interval [CI] 25.1%–36.8%). 
The risk of metastasis increased with submucosal invasion depth (subdistribution hazard ratio 
[SHR] 1.08, 95%CI 1.02–1.14, for every increase of 500 μm), lymphovascular invasion (SHR 
2.95, 95%CI 1.95–4.45), and for larger tumors (SHR 1.23, 95%CI 1.10–1.37, for every 
increase of 10 mm). The model demonstrated good discriminative ability (c-statistic 0.81, 
95%CI 0.75–0.86). 
 
Conclusions: A third of patients with pT1b EAC experienced metastasis within 5 years. The 
probability of developing post-resection metastasis was estimated with a personalized 
predicted risk score incorporating tumor invasion depth, tumor size, and lymphovascular 






Esophageal adenocarcinoma (EAC) is an aggressive cancer, carrying a 5-year survival rate 
of 19%.1 The most important prognostic factor for survival is the presence of lymph node 
metastasis (LNM).2 Radical esophagectomy with lymphadenectomy has long been the 
standard treatment for EAC, including early cancer. Endoscopic resection is a safe and 
effective treatment and is indicated for the curative management of early EAC.3 Additional 
surgery after endoscopic resection is advocated when the risk of LNM outweighs the risk of 
mortality associated with esophagectomy.4
Histopathological characteristics, such as lymphovascular invasion (LVI), poor tumor 
differentiation, and invasion into the submucosa of more than 500 μm, are associated with a 
risk of LNM.5–7 When EAC is limited to the esophageal mucosa (T1a), the risk of LNM is only 
1%–2% and radical endoscopic resection of the lesion suffices.4, 8–11 When EAC invades the 
submucosa (T1b), guidelines recommend additional surgical resection of the esophagus and 
locoregional lymph nodes.4, 9 The prevalence of LNM in esophagectomy specimens varies 
between 0 and 78% for T1b EACs and depends on the extent of invasion into the submucosa.7, 
12–15 Superficial submucosal invasion (sm1: ≤500 μm) was associated with variable LNM risk 
in previous studies (0–22%), while deep submucosal invasion was associated with higher LNM 
risk, ranging from 26%–36% (sm2: 501–1000 μm) to 50%–78% (sm3: >1000 μm).12, 15–17 
In the chalenging clinical scenario when LNM is not seen on imaging, management depends 
on metastasis risk assessment. Not every patient with pT1b EAC develops LNM, while surgery 
is associated with morbidity, mortality, and decreased quality of life.18, 19 Endoscopic resection 
might be a good alternative for selected patients with pT1sm1 EAC in combination with “low 
risk” histopathological characteristics, such as well-to-moderate differentiation (G1/G2) and 
absent LVI.20 Only 1.9% of these patients developed LNM.20 Other studies also reported LNM 
risk of <2% in patients with pT1sm1 EAC with “low risk” histopathological characteristics.21–23 
In contrast, the LNM risk is reported to be higher (up to 9%) in patients with pT1sm1 EAC with 
at least one “high risk” histopathological characteristic, such as poor tumor differentiation or 
LVI.24 The European Society of Gastrointestinal Endoscopy guidelines state that R0 resection 
of pT1bsm1,G1-2,LVI– is potentialy curative and the decision about whether or not to perform 
additional treatment should be individualized in these patients in terms of morbidity and 
mortality risk vs LNM risk.25  
Although many studies have described separate histopathological risk factors associated with 
LNM, no appropriate clinical tool is available that incorporates al accepted prognostic 
histopathological parameters to accurately predict the LNM risk on an individual basis. Little 
is known about how the individual risk increases with the accumulation of more than one 
histopathological feature. The aim of this study was to develop and internaly validate a 
prediction model based on histopathological variables that estimates the risk of LNM or distant 
metastasis in individual patients with pT1b EAC. 
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We performed a nationwide, retrospective, multicenter cohort study in colaboration with the 
Netherlands Cancer Registry (NCR). Since 1989, al patients diagnosed with pT1b EAC in the 
Netherlands have been included in the NCR. Patients diagnosed with pT1b EAC between 
1989 and 2016 were selected for the current study. Eight hospitals participated in the study 
and were expert centers in EAC treatment. Patients with pT1b EAC were included if they were 
treated with primary surgery or endoscopic resection (with or without adjuvant surgery). 
Patients were excluded if they were treated with chemoradiotherapy prior to surgery, as we 
could not reliably assess whether LNM developed. We also excluded patients with no 
histopathology data available for review, when histological parameters could not be 
reassessed, or when no patient data were available in medical charts. The study was 
approved by the Medical Ethical Review Committee of the Erasmus Medical Center in 
Rotterdam, the Netherlands (MEC-2016-050) and by al local Medical Ethical Review 
Committees at the participating centers. Clinical data were colected from medical records, 
pathology reports, and endoscopy reports (Supplementary File 1). 
Histopathological reassessment 
Owing to renewed pathology insights and different classification systems over the years, al 
resection specimens were histologicaly reassessed for the folowing parameters: submucosal 
��������� ������ ������ ���������������� ������� ���� ����� ��������� �������������� ���������� ���
three specialist gastrointestinal pathologists (F.tK., M.D., K.B.) for 84 patients, as explained in 
detail in our previous study.26 The interobserver agreement was good for differentiation grade 
(к = 0.77), excellent for LVI (к = 0.88), and moderate for submucosal invasion depth 
(к = 0.60).26 For al other patients (n=164), histopathological reassessment for differentiation 
�������������� ��������������������pathologist (F.tK.) because the interobserver agreement 
was good and excelent, respectively, for these histopathological variables.26 Submucosal 
invasion was assessed in a consensus meeting by two pathologists (K.B., M.D.) in the 
remaining 164 patients because the interobserver agreement was moderate for submucosal 
invasion depth.26 The reassessment is explained in supplementary File 2.27, 28  
After histopathological reassessment, patients were excluded if the tumor was located in the 
cardia or when tumor location was not known. Patients with vertical R1 or Rx endoscopic 
resection with residual tumor in biopsy or with residual EAC in surgical resection specimen 
����� ����� ���������� ��� ������ ������� ��� ������ ���� ��������� ������� ��������� ������ ��� �����
Patients with vertical R1 or Rx after endoscopic resection were included if no residual tumor 
was found during surgery. 
End points 
The primary end point was the presence of LNM in surgically resected specimens (≥12 
resected lymph nodes), or the development of metastasis during folow-up. Owing to the use 
of different surgical resection techniques over time, with less extensive lymphadenectomy in 
the past, the development of metastasis during folow-up was used as a surrogate end point 
����������������� ���������������������������������������������������������������������������
prior to surgical resection, the tumor was found in the endoscopic resection specimen and 
lymph node status in the surgical resection specimen. When no additional surgery was 







used as a surrogate end point, and patients were excluded if biopsy-proven residual tumor 
was found after endoscopic resection.  
Folow-up 
Patient folow-up data were retrieved until November 2019. A minimum folow-up period of 
2 years was required in cases with <12 lymph nodes resected during surgery or when no 
surgery was performed. Patients who died within 2 years after primary treatment with an 
unknown cause of death were excluded because it was not clear whether these patients died 
as a result of metastasis. Only when the cause of death was known in these patients they 
were included because it was clear whether metastasis had developed or not. 
Sample size calculation 
The prevalence of LNM in T1b EAC varies between 0 and 78% in previous studies.5–7, 12–15 In 
these studies, LNM was found in 110/456 patients (24%, 95% confidence interval [CI] 20%–
28%) who underwent esophagectomy. At least 10 events were needed per predictor in our 
model. We predefined that we would incorporate al four histopathological predictors: 
differentiation grade, submucosal invasion, LVI, and tumor size. A minimum of 40 patients with 
LNM were needed in our calculator. Using the lower CI for the prevalence of LNM in T1b EAC 
(20%), a sample size of at least 200 patients was needed for the study. 
Statistical analyses 
Baseline characteristics are described using standard descriptive statistics. Continuous data 
are presented as mean (range) for normaly distributed data and median (interquartile range 
[IQR]) for skewed data. Categorical data are presented with frequencies and percentages. 
Univariable and multivariable analysis 
Different folow-up periods and the competing risk of al-cause/non-EAC mortality were taken 
into account using the Fine and Gray model. In the Fine and Gray model, subdistribution 
hazard ratios (SHRs) are estimated, describing the effect of covariates on the subdistribution 
hazard. SHRs and associated 95% CIs were calculated for candidate predictors. The 95% CIs 
were calculated through bootstrapping. 
Based on previous literature about prediction model development, al variables with a P value 
of <0.2 at univariable analysis were incorporated into multivariable analysis.29 The folowing 
variables were included in univariable analysis: sex, LVI, tumor differentiation grade, 
submucosal invasion depth, and tumor size. Microscopic or macroscopic tumor size was used 
for analysis. 
Information about tumor size was missing in 38 of 248 patients (15.3%). We assumed these 
data were missing at random and used multiple imputation to impute the missing values 10 
times. Separate analyses were performed on the 10 imputed datasets and results were 
subsequently pooled using Rubin rules.  
Statistical analyses were performed in R version 3.6.3., the mice package was used for 
multiple imputation, and the riskRegression package was used to fit the Fine and Gray 
method. 
Prediction model and discriminative ability 
Only variables that were statisticaly significant (p <0.05) after multivariable analysis were 
included in the final prediction model. For completeness, nonsignificant variables were also 
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incorporated into the prediction model to check whether they altered the predicted scores. 
Submucosal depth invasion was incorporated as a continuous variable (absolute depth 
invasi���������������������������� ����������������������������������������������������������������
score chart. Tumor size was also incorporated as a continuous variable in the prediction model 
and divided into <20 mm and ≥20 ���������������������;��������������alue was chosen based 
on previous studies.5, 24  
The discriminative ability of the model was assessed using the Harrell’s concordance statistic 
(c-�����������������������������������������������������������������������������������������
model was internaly validated using bootstrapping to calculate the Harrell’s concordance 
����������������� �� ��� �����������������������.29 �������������������������������������������������












90 patients were excluded (���ure ���������������������������������������������������������
���������� ���� ���� �������������� ��������� �������� ���������� ���� ���� ������� ���������
(n = ������� ���� �������������� �������� ��� �������������� ���������������� ���������� ��������
���������� ��������� ����� ���� ���� ����� ��������� ������ ���� �������� ��� ��������� �����
excluded (���ure ���������������������������������������������������������������� 
Patient and tumor characteristics 
��������� ���������������� ���� ���������� ��� ������ ��� ���� ������� ���� ��� ���� ������� ����
65.6 ���������������–�������������������������������������������������������������� ����
����������������;�������;����������������������������������������������������������������





�������������� ������������� ��������� ���������� ������������� ���������� ��� ���������������
����������������������������� 
���������������������������������������������������������������������������������������������
���� ���������� ����������� ����������� ����������� ��������� ���������� ���� ���������� ��� ����
�������������������������������������������������������������������� ���� 









  NCR search [524 patients] 
Period: 1989 - 2016 
Exclusion  [90 patients] 
• Pathology material not available for revision [42] 
• Too little pathology material available [6] 
• No patient data available [36] 
• Chemo-radiotherapy prior to surgery [6] 
pT1b EAC [319 patients] 
Exclusion [115 patients] 
• pT1a EAC [66] 
• pT2 EAC [7] 
• No malignancy [3] 
• Tumor located in the cardia or missing tumor 
location [39] 
Exclusion [71 patients] 
• Missing folow-up information or inadequate 
folow-up [27] 
• ����������;��������������������� ����������
(esophagus or colon) [1] 
• pT1b R1 or Rx (vertical) ER, with residual EAC 
in biopsy or in surgical resection specimen [43] 
LNM or distant metastases 
during surgery or folow-up 
[78] 
Inclusion [248 patients] 
No LNM or distant 
metastases [170] 
Distant metastases [6] 
• Detected during follow-up [6] 
 
LNM [49] 
• Detected during follow-up [2] 
• Detected during surgery [47] 
•  
LNM and distant metastases [23] 
• Both detected during follow-up [4] 
• LNM detected during surgery,  
distant metastases detected 
during follow-up [19] 
T1b EAC [434 patients] 
Pathology re-assessment 










Table 1. Clinicopathological features of the study cohort (n = 248) 






Age, median (IQR), years 65.6 (57.8–72.5) 


















 Laparoscopic transhiatal 
 Transthoracic 

























Median (IQR), mm 


















��������������������� ��������������� 1300 (590–2495) 
















����� �������������� �����; ����� ����������� �������� ���������;� ����� ����������� �����������
����������;� ���� ����������;� ����� ��������������� ��������;� ����� ������ ����� metastasis. 




The median folow-up time was 5.5 years (IQR 4.9–7.7) in patients treated with endoscopic 
resection only and when <12 lymph nodes were present in surgical resection specimens. The 
median folow-up time was 3.3 years (IQR 1.8–5.3) in patients treated with primary surgery 
with ≥12 lymph node dissections during surgery. The 5-year cumulative incidence of 
metastasis was 30.9% (95% CI 25.1%–36.8%) (Figure 2). In total, 78 patients developed 
metastasis. In 6/78 patients, only distant metastasis developed. Al had undergone surgery 
(without LNM) for primary pT1b EAC. In only 2/6 patients were >12 lymph nodes (range 14–
30)resected during surgery.
The majority of patients only developed LNM (49/78) and al these patients were treated with 
�������;����� �������������������������������������s. LNM was found during folow-up in only 
����� ��������;� ��� ���� ��� ������ ��tients, adequate lymph nodes (n=18) had been resected 
during surgery. 
Both LNM and distant metastasis were found in 23/78 patients. One patient was treated with 
endoscopic resection only (due to comorbidity), and both LNM and distant metastasis were 
detected during folow-up. A total of 22 patients were treated with surgery. LNM was found in 
the surgical resection specimen in 19/22 patients and during folow-�������������������;��������
patients, >12 lymph nodes had been resected during surgery. Al distant metastasis were 
detected during folow-up. 
Of al detected LNMs (n=72), the majority were found in the surgical resection specimen 
������;����������������������������������������metastasis (LNM or distant metastasis) during 
folow-up (n=31), the median time to detection was 1.9 years (IQR 1.2–4.9). The disease-
specific 5-year survival rate after primary treatment was 87.5% (Supplementary file Figure 4). 
Prediction model 
In multivariable analysis, the risk of developing metastases was higher for LVI positive tumors 
(SHR 2.95, 95% CI 1.95–4.45), for tumors with deeper submucosal invasion (SHR 1.08, 95% 
CI 1.02–1.14), and for larger tumors (SHR 1.23, 95% CI 1.10–1.37) (Table 2). For every 
increase in invasion depth of 500 ��������������������������������������������������������
���������������������������� ��������� ������������������� ���������������������������ard of 
developing metastases increased by 1.2. These variables were al incorporated into the 
prediction model. Incorporating differentiation grade into the prediction model did not alter the 
outcomes and therefore this variable was not incorporated into the score chart (Table 3). 
The risk of developing metastases for different combinations of histological variables is 
presented in the score chart (Table 3). The 5-year risk of developing metastases ranged from 
5.9% (95% CI 2.3–11.2) for patients with pT1,sm1,LVI- tumors <20 mm to 70.1% (95% 
CI 60.5–78.7) for patients with pT1,sm3,LVI+ tumors ≥20 mm. After internal validation using 
bootstrapping, the prediction model demonstrated good discriminative ability with a c-statistic 
of 0.81 (95% CI 0.75–0.86).  
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Interval Begin total (n) Metastases (n) Death or lost to follow-up (censored cases) (n) 
Cumulative 
Incidence (95% CI) 
0-1 year 248 68 10 27.5% (22.1-33.2) 
1-2 year 170 5 9 29.7% (24.1-35.5) 
2-3 year 156 1 19 30.3% (24.6-36.1) 
3-4 year 136 0 19 30.3% (24.6-36.1) 
4-5 year 117 1 25 30.9% (25.1-36.8) 
5-6 year 91 2 32 32.9% (26.6-39.2) 
6-7 year 57 1 12 34.1% (27.5-40.7) 
Figure 2. Cumulative incidence of developing metastases, with death (not related to esophageal 




Table 2. Univariable and multivariable subdistributional hazard regression analysis of risk 
factors associated with metastases (no metastases n = 170, metastases n = 78) 
Variable Univariable subdistributional 
hazard regression analysis 
Multivariable subdistributional 
hazard regression analysis 
SHR (95%CI) p value SHR (95%CI) p value 
Sex, n (%) – – 
 Female Reference 
 Male 1.51 (0.74–3.10) 0.26 
Differentiation grade 
 G1/2 (good/moderate) Reference Reference 
 G3/4 (poor/undifferentiated) 1.78 (1.20–2.65) <0.01 1.01 (0.66–1.55) 0.96 
Submucosal invasion (per 500 ��� 1.13 (1.08–1.18) <0.01 1.08 (1.02–1.14)1 <0.01 
LVI 
 No Reference Reference 
 Yes 3.58 (2.45–5.22) <0.01 2.95 (1.95–4.45) <0.01 
Tumor size (per 10 mm) 1.39 (1.25–1.53) <0.01 1.23 (1.10–1.37)2 <0.01 
���������������������������������;������������������������;������������������������������ 
1For every 500 ����������������������������������;�2For every 10 mm increase in tumor size 
Table 3. Score chart for 5-year metastases risk (both lymph node metastases and distant 
metastases) for different combinations of histopathological variables in patients with pT1b 
esophageal adenocarcinoma 
LVI-, % (95%CI) LVI+, % (95%CI) Tumor size 
sm1 5.9 (2.3–11.2) 15.7 (6.0–29.3) 
sm2 7.3 (2.6–13.8) 19.3 (6.3–36.8) <20 mm 
sm3 14.1 (7.9–21.9) 34.7 (19.7–50.8) 
sm1 16.1 (6.2–29.2) 38.8 (17.0–61.4) 
sm2 19.4 (8.6–32.2) 45.6 (20.8–67.9) ≥20 mm 
sm3 35.2 (25.8–44.7) 70.1 (60.5–78.7) 
LVI, �����������������������;������������������������;�������������� 
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DISCUSSION 
The selection of patients who need additional treatment due to the risk of LNM after 
endoscopic resection of pT1b EAC can be chalenging. Not al T1b EACs are alike when it 
come�� �������������� ����;� ��������� ��������� ������������ ����� ������������������������ ���
���������������������������������������������������������������������������������������������
�������������������������������� ������� ������������������������������ �������� ��terrelate or 
����������������������� ���� ���������� �����������������������������������������������������
���������������������������������������������������������������������������������������.5-7 We 
established a prediction model that includes histopathological tumor characteristics and 
���� ����������������������������������������������������������������������������������������
������������������� ���������������������������������������������������� ���������� ��� �����
������������������������������� 
����������������������������������������������������������������������������������������
������� ��������������������������������������������������������������������� ����������� ���
������ ���� �� ���������� ����� ������ ���������� ����� ����� �������� ����� ����������� ���������
�������������������������������������������������������������������������������������������
������������������������� ���������� ���������������������������������������������������������
with endos������ ���������� ����������� �������������������� ������-up time was 5.5 ������ ���
��������������������������������������������������������������������������������������������
resection specimens. Because of this long folow-������������������������������������ both 
groups as a single cohort is acceptable.  
���������������������� �������������������������������� ���������������������������������������
��������������������������������������������������������������������������������������
������������������������������������������������ ����������������������������������-statistic of 
��������������������������� �������� ����� �������� ������������������������������ ���������
����������� ��������������������� ������������������������������������������������������
combination������������������������������������������� ��������������������������������������
is the direct result of the combination of al poor histopathological parameters. This risk can 
������������������������������������������������������������������������������t present with 
LVI.30
The 5-����� ����������� ���������� ��� ����������� ����������� ���� ������ ���� CI �����–
�����������������������������������������������������������������–����.�� 12–��� ��� ��� 32 ���������
������������������������������������������������������������������������������������������������
�������������������������� �������.�� �� ��� 32 �������������������������������������������������
���������������������������������������������������������� ����������������������������������������
��������������������������������������������������������������� 
�������� ����� ���������� �� ��������� ��� ��������� ����� ����� ���� ��� ������ �������������
���������� ������ ����������� �������������� ��� ����.�� ��� ��� 32 Graham et al. suggested that 
��������� ����� ����������������-���� ���� ���� ��� �������� ����� ����������� ����������alone 
���������������������������������������������������������������-up.32 ������������������������
���������� ������������� ���������� ������ �������pic resection of pT1bsm1 EACs with one 
high-����� ������������� �������� �������� ���� ��� ���� ��������������� �������� ����-risk tumors 
���������������������������-up.32 ������������������������������������������������������� ���
too smal to make recommendations.32 Another study reported LNM in only 2% of “low-risk” 
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CHAPTER 10.1
����� �����������;���������������������� ���������������������������������������������� ����
����������������.24 ������������� ����������������������������������� 
�������� ������������������������������� ����������������������������������������������
�����������������������������������������������������������������������������������������
���� ������ ����� �� �-���������� ��� ����� ���� �� ����–�����.13 ����� ������ ���������� �����
��������������������������������������������������������������������������������������������




��������������� ��� ���� ����� ����� ���� ���������� ��� ���������� ���������� ��������
����������������������������������������������������������������������������������������������
������ ���������������� ����� ���������� ������� �������� �������� ������ ��������� ��������� �����
���������������������������������������������� ��������� �����������������������-����������
���� ����������� ��� ��������� �������� ����� ����������� ���������� ���� ��� ��������� ����� ����
�����������������������������������������������������������������������������������������������
�������������������� �������� ����������������������������������������� 
������������������������������������������������������������������������������ ����������������
����������������������������������������������������������������������������������������������
������ �������� ��������� ����� ��������� �������� ����������� ������ ��� ���������� ������ ���� ���
�������������������-������� ���� �������������������������������������������������������������
�� ������ ��� ����� ���������� ��� �� ������������ ������� ��� ���� ����� �� ������� �� �������� ����
����������������������������������������������������������������������������������������������
sp��� ����� ���������� ����� ��� ���������� ���������� ���� ����������� ��� ����������� ����
������������������������ ������ �������� ������������������������������������������ ������
����������������������������������������� �������������������������������������������������������
����������������������� ���� ��������������������������� �����������������������������������
�������������������������������������������������������������������������������������������
���� ��������� ����������� ��� �������������� ��������� ��� ���������� ����� ���� ������������ ���
������������������������-��������������������������������������������������������� ����������������
��� ����������� � ������������������ ��������� ���� ���������� ���� ���� ����������� ��� �����
�������� ��������-������ ��������-��������� ������ ������� ����� ���� �������� ���������� ��� ����
������������ ������������������������������������������������������������������������������
���� � ������ ��������������������.33 ���� ������ �� �������� ��� ���������������������������������
�������������� ������������������������������������������������������������������������� ���
����������������������������������������������������������������������������������������������
��������������������������� ����������������������������������������� ����������������� ����
�������������������������������������������������������������������������������������������������
������� ������ ������������� ��������� ���������� ��� ����������� ���������� ����� ���� ��� ����
������������������������������������������������������������������������������������������
��������� ���������� ������ ���� ������ ��� ��� ��������� �������� ��� ���� ��������� �������� �����
����������� ���������� ���� ���� ���� ����� �������� ����� ����������� ��������� ����� ����������� ���
���������������������������������������������������� ������������������������������������������
�������� ���������� ���������������������� ����� ��� ��� ���� ������ ������ ����� �����������������;�
���������� ����������������������������������������� 
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In conclusion, one third of patients with pT1b EAC developed metastases. A personalized risk 
could be predicted based on the presence or absence of each histopathological characteristic, 
with good discriminative ability. Deep submucosal tumor invasion, the presence of LVI, and 
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Supplementary file 1. Patient and tumor characteristics colected from medical charts, 
endoscopy reports and pathology reports.  
Patient characteristics: sex and age. 
Tumor characteristics: ������ ��������� ����� ���������;� ��-����� ����� ���� ���������� �������
���������;� ��-����� ����� ���� ���������� ������-����������� ��������;� ��������� �������� ����
��������������������������������� ���������������������� ���������������������������������
tumor size (m���� ���������������� ������� ����������� ��������� ������ ������ ���� ��������� ���
��������������� ��������� ������� ����������� ��� ��������� ���������� �������� ������ endoscopic 
resection, and the presence of Barrett’s esophagus after endoscopic resection.  
Treatment characteristics: primary treatment (endoscopic resection ��������������������������
������� �������������������� ���������� ������� ����������� ����������� ����������� �������
transhiatal, laparoscopic transhiatal, transthoracic, thoraco-laparoscopic esophagus 
resect��������������������������� 
������-up data: ������������������������� �������������������������� ��������������������
������-���� ����� ����� ��� ������-���� ������ ��������� ���� ����� ���� ������ ��� ������ ��� ����� ���
mortality. 




���� ����� ���������������� ���� ����������� ���������������� ���� ������� ��������������� ���� ����
undifferentiated, according to the World Health Organization classification for tumor grading.�� 
���� ����������������������������������������������������������������������������������
�������� ��� �������� ���� ������������������ ������������� ��� ����������� ��������� ������ ���
�������������������������������������� �����������������������������������������������������tK.] 
��� �������� ����������� ���������� ���� ���� ������ ���� �������������� ����� ������ ����� ����
���������������������������������� ����������������������������������������������������� ����
����� ���� ������������ ��������������� ���� ��������������� ������������ ��������� ���� ��������
�������������� ������������������������������������������������������������ ����������� ����
����������� ��������������� �������������������������� ���������������������������� �����
���������� �������� ��� ���� ������������� ������� ������� �������������� ������� ����� ���� ���
invasion depth ≤500����������������������;������������������������-�������������������
��������� ������ �������� ��� ���� ���������� ��� ���� ������ ����������������� ��� ��������� ����
���������� ����������� �������� ������ endoscopic resection�� ����� ���������� ����� ����
(endoscopy and surge��������� ���������������� ��������� ���������� ������ ��� ���� ���������
��������������� ������������������������������������������������� 
Supplementary file 3. 










Supplementary file 4. Disease specific survival after primary treatment of esophageal 
adenocarcinoma. 
 
Figure S4: Disease specific survival after primary treatment of esophageal adenocarcinoma 
Interval (years) Number at risk* (n)  EAC related death (n) 
Non EAC related death or lost to 
follow-up (censored cases) (n) 
0 – 1 248 5 22 
1 – 2   221 7 13 
2 – 3   201 9 25 
3 – 4  167 2 21 
4 – 5  144 2 27 
5 – 6   115 0 36 
6 – 7  79 3 13 
7 – 8   63 0 15 
8 – 9   48 0 11 
9 – 10 37 0 6 
10 – 15  31 0 25 
15 – 20  6 0 4 
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Quantification of lymphovascular invasion is 
useful to predict lymph node metastases in 









Aim: To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients 
with pT1b esophageal adenocarcinoma (EAC). 
 
Methods: In this nationwide, retrospective cohort study, patients were included if they were 
treated with surgery or endoscopic resection for pT1b EAC. Primary endpoint was the 
presence of metastases (lymph node metastases or distant metastases) in surgical resection 
specimens or during folow-up. A prediction model to identify risk factors for metastases was 
developed and internaly validated. 
 
Results: �������������������������������������������������������������������������;���������
�����������������;���������-3 LVI foci (n=21; 8.5%), and ≥4 LVI foci (n=15; 6.0%). Seventy-
eight patients had metastases. The risk of metastases was increased for tumors with 2-3 LVI 
����������������������������������������������������������-5.47) and ≥4 LVI foci (SHR 3.81, 
���� ������-���������������������� ������������������������������� ����ive ability (c-statistic 
������ 
 
Conclusion: The risk of metastases is higher when more LVI foci are present. Quantification 
of LVI could be useful for a more precise risk estimation of metastases. This model needs to 





The presence of lymph node metastases (LNM) is an important prognostic factor in 
submucosal esophageal adenocarcinoma (pT1b EAC).1 Various risk factors for LNM have 
been identified including depth of infiltration, grade of differentiation and lymphovascular 
invasion (LVI ).2-6 
We recently developed a prediction model based on histopathological risk factors to estimate 
the risk for metastases in patients with pT1b EAC.6 We showed that LVI was the strongest 
predictor for metastases with an estimated 5-year risk of developing metastases ranging 
between 15.7%-70.1% for pT1b EAC with LVI as compared to 5.9%-35.2% for those without 
LVI.6 Other studies reported a worse 5-year survival in patients with pT1b EAC with LVI
compared to pT1b EAC without LVI (27% vs. 77%, p<0.01).7, 8
������������������������������������������������;��������������������������6-14 Intuitively, there 
may be a differential metastatic risk in case of only a single LVI focus versus a case with 
extensive LVI. This is supported by a study on gastric cancer in which a higher number of 
lymphatic tumor emboli was an independent predictor for LNM.15 We hypothesized that the 
number of LVI foci in pT1b EAC is of influence on patient outcome. Quantification of LVI may 
possibly further classify these patients into low- and high-risk for the development of 
metastases.  
The aim of this study was to quantify LVI and to assess the prognostic value in patients with 
pT1b EAC. 
MATERIALS AND METHODS 
This was a nationwide retrospective cohort study. Patients diagnosed with pT1b EAC between 
1989 and 2016 were included. This study was approved by al Medical Ethical Review 
Committees in the participating centers [MEC-2016-050]. A detailed description of in- and 
exclusion criteria, data colection, patient selection, reassessment of histopathological 
variables and the statistical analyses can be found in our previous study, as the present study 
is an extension to our previous study.6 Histopathology reassessment was performed by three 
gastrointestinal pathologist for 84 patients to calculate the inter-observer agreement as 
explained in our previous study.16 For the other 164 patients, histopathological reassessment 
was performed by one pathologist for LVI (к = 0.88) and differentiation grade (к = 0.77) 
because of the good and excelent interobserver agreement.16  
A model was developed to predict the risk of metastases in patients with pT1b EAC.6 In the 
prediction model of the present study, quantification of LVI on a four tier assessment scale is 
incorporated instead of interpreting LVI as a dichotomous parameter. The same patient cohort 
is used and the same statistical analyses are performed as in our previous study.6 The added 
value of LVI quantification to the model was assessed using the likelihood ratio test and 
quantified by the increase in Harrell’s concordance index (c-statistic).  
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Histopathological reassessment of LVI and LVI quantification  
Whole case hematoxylin and eosin stained (H&E) slide sets were used for LVI reassessment. 
Immunohistochemical staining was not performed because formalin-fixed paraffin embedded 
tissue blocks were not available. Initialy, LVI was defined as being present or absent as in 
standard clinical practice. Al slides were assessed with high power up to and including the 
submucosa. When LVI was present, al LVI foci were counted in every H&E slide that was 
available. In general, resection specimens of 2mm thickness were assessed when endoscopic 
resection was performed in contrast to 5mm thickness when surgical resection was performed. 
Figure 1 shows an example of an H&E slide with three LVI foci. The LVI focus number was 
the sum of al counted LVI foci in al H&E slides from one patient. In patients in whom LVI was 
analyzed by three pathologists, the highest LVI focus number was included for analysis. 
Patients were categorized into four groups based on the ������������������;���-LVI, 1 LVI 
focus, 2-3 LVI foci or ≥4 LVI foci. This 4-tier assessment scale was used to create different 




example of three foci of LVI which may very wel al be located in the same lymph vessel. 
 
Endpoints 
The primary endpoint was the presence metastases defined as LNM in surgical resection 
specimens or the development of metastases (LNM or distant metastases) during folow-up. 
In case surgical resection was performed, at least 12 lymph nodes were required for adequate 
assessment of LNM.16 The development of metastases during folow-up was used as a 
surrogate endpoint in case no surgery was performed after endoscopic resection (ER), or if 
surgical resection specimen contained <12 lymph nodes without LNM. In these cases, a 
minimum folow-up period of two years was required. If patients died within these two years, 




In total, 248 patients with pT1b EAC were included. Patient characteristics are presented in 
Table 1. Primary endoscopic resection was performed in 82 of 248 (33.1%) patients and 
primary surgery was performed in 166 of 248 (66.9%) patients. Of patients who were treated 
with endoscopic resection, additional surgery was performed in 49/82 (59.8%) patients. Local 
recurrence was detected during folow-up in 12 of 248 (4.8%) patients, of whom 11 also 
developed metastasis.  
Table 1. Patient characteristics and number of LVI foci (n=248) 
������������������������;�����������������������������;���������������������������;�
Quantification of LVI 
�������������������������������������������������������������������������������������������
������������������������������������������������������������������������������������������������
��� ������ ��������� �������� ������ ������� ��� ���� ���������� ��� ���������� ���� ��������������� ����
determined by one �������������������������������������-observer variability was excelent for 
LVI (к=0.88).(17) The median LVI focus number was 2.5 (IQR 1-�������������������������������
���������� ������ �������� ������;� �������� ���� ���� ������������ ��� ��������� ��� ���� ������;�
�������������������������;���������-3 LVI foci (n=21; 8.5%), and ≥4 LVI foci (n=15, 6.0%).  
Metastases 
Some 78 of 248 patients had metastases (Table 1), with a 5-year cumulative incidence of 
30.9% (95% CI 25.1%-36.8%) (Figure 2, Chapter 10.1). In patients treated with primary 
surgery (≥12 lymph node dissections) the median follow-up time was 3.3 years (IQR 1.8-5.3). 
In patients treated with surgery (<12 lymp node dissections) or endoscopic resection only, the 
median folow-up period was 5.5 years (IQR 4.9-7.7) The majority ��������������������������
only (49/78). �������������������������������������������������������������������������������
Parameter Total cohort (n=248) 





Median age, years (IQR) 65.6 (57.8-72.5) 



























in 47 patients and during folow-up in two patients. Six patients developed distant metastases 
only, al were treated with surgery for EAC (without LNM). Adequate lymph nodes (>12) were 
resected in only two of these six patients. Twenty-three patients developed both LNM and 
distant metastases. Surgery was performed in 22/23 patients, LNM was found in surgical 
resection specimen in 19 patients and during folow-up in three patients. One patient was 
treated with endoscopic resection only due to comorbidity, metastases were detected during 
folow-up. Of al patients who developed metastases during folow-up, the median interval 
between EAC diagnosis and detection of metastases was 1.9 years (IQR: 1.2-4.9).  
Risk factor analysis 
Univariable analysis 
The number of LVI foci was associated with presence of metastases. Tumors with 1 LVI focus 
had metastases in 37.5%, tumors with 2-3 LVI foci had metastases in 71.4% and tumors with 
≥4 LVI foci had metastases in 93.3% (Table 2). In contrast, 22% of patients without LVI 
developed metastases. 
Multivariable analysis  
���������� ������������ ������ �����������������������������������������hazard of developing 
metastases increased with 1.08 (95% CI 1.02-1.14) (Table 2). The presence of 2-3 LVI foci 
(SHR 3.39, 95% CI 2.10-5.47) and the presence of ≥4 LVI foci (SHR 3.81, 95% CI 2.37-6.10) 
were independent predictors for metastases compared to patients without LVI. In contrast, the 
presence of only one LVI focus was not significantly correlated with metastases after 
multivariable analysis. For every increase of tumor size with 10mm, the subdistribution hazard 
of developing metastases increased with 1.23 (95% CI 1.09-1.38). Poor differentiation grade 
was not an independent risk factor for metastases (SHR 0.98, 95% CI 0.65-1.50), this variable 
was therefore not incorporated into the prediction model.  
Prediction model development and validation 
The 5-year risk of developing metastases for different combinations of histopathological tumor 
characteristics is ilustrated in Table 3B. The prediction model with LVI incorporated as a 
dichotomous variable is presented in Table 3A.6 In Table 3B, the predicted score was 16.1% 
(95% CI 6.2-29.2) for patients with pT1b EAC ≥20mm, sm1 invasion depth without LVI, 
compared to 22.2% (95% CI 6.2-45.3) when one LVI focus is present, 37.0% (95% CI 16.0-
62.3) when 2-3 LVI foci are present and 47.1% (95% CI 21.1-72.9) ) when ≥4 LVI foci are 
present. Internal validation of the prediction model showed a good discriminative ability with a 
c-statistic of 0.81 (95% CI 0.74-0.87), which did not increase compared to the c-statistic of the 
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Table 3A�������������;��-year risk (%) of developing metastases for different combinations of 
������������������ ���������������� ��� ����� ����������� ��������������;� ���� ������������� ���
present or absent. 
Tumor size  Submucosal invasion 
����- ����� 
���������� ���������� 
sm1 5.9 (2.3-11.2) 15.7 (6.0-29.3) 
<20mm sm2 7.3 (2.6-13.8) 19.3 (6.3-36.8) 
sm3 14.1 (7.9-21.9) 34.7 (19.7-50.8) 
sm1 16.1 (6.2-29.2) 38.8 (17.0-61.4) 
≥20mm sm2 19.4 (8.6-32.2) 45.6 (20.8-67.9) 
sm3 35.2 (25.8-44.7) 70.1 (60.5-78.7) 
�����������������������;�����������������������������;��������������� 
Table 3B. �����������;��-year risk (%) of developing metastases for different combinations of 
������������������ ���������������� ��� ����� ����������� ��������������;� ���� incorporated as 
����������������������-3 LVI foci or ≥4 LVI foci. 
Tumor size Submucosal invasion 
����- ������ �����-3 LVI ≥4 
���������� ���������� ���������� ���������� 
sm1 5.9 (2.3-11.2) 10.9 (3.0-24.4) 19.5 (7.4-37.7) 25.7 (9.7-48.3) 
<20mm sm2 7.3 (2.6-13.8) 13.4 (3.8-30.1) 24.1 (8.6-44.2) 31.6 (11.0-55.5) 
sm3 14.1 (7.9-21.9) 26.3 (10.6-45.3) 43.5 (26.6-61.5) 54.4 (33.7-72.8) 
sm1 16.1 (6.2-29.2) 22.2 (6.2-45.3) 37.0 (16.0-62.3) 47.1 (21.1-72.9) 
≥20mm sm2 19.4 (8.6-32.2) 26.3 (8.4-51.0) 44.4 (20.2-66.2) 55.2 (26.4-77.9) 




��� ����� ������� ��� �� ��� ��� ���������� �������� ��������������� ��� ���� ��������� �����������
����������� ������������ ��� �������������� ���������� ���� �������� ��� ���� ������ ����� ����� ����
��������������������������������������������������������������������������������������������





���������-3 LVI foci and ≥4 LVI foci.6 �������������������������� �����������������������������




The more accurate this prediction is, the better a patient can be informed and the better the 
decision about (neo-)adjuvant therapy can be made.  
Remarkable is that the presence of only 1 LVI focus was not an independent predictor for 
metastases. The predicted 5-year metastases risk in patients with only 1 LVI focus is more in 
line with the risk in patients without LVI. One could argue that the presence of 1 LVI focus is 
negligible. 
To our knowledge, this is the first study that evaluates quantification of LVI in pT1b EAC. We 
could therefore not compare our results with previous studies. LVI has also been identified as 
a strong predictor for LNM in other cancer types.15, 18 The number of lymphatic tumor emboli 
was an independent predictor for LNM in early gastric cancer with LVI.15 The more lymphatic 
tumor emboli were present, the higher the LNM risk.15  
Despite the promising results of our study, it is unlikely that the application of the current model 
wil change clinical practice soon. The difference in predicted metastasis risk between the LVI 
foci groups is relatively smal and stil high in al scenarios. Although the metastases risk in 
patients with only 1 LVI focus is much lower than the risk in patients with 2-3 or ≥4 LVI foci, 
the advice for adjuvant treatment or active surveilance after ER wil probably not change 
based on the number of LVI foci. We are looking for a better risk assessment for metastasis 
to make active surveilance possible on the one hand. On the other hand, the presence of 
extensive LVI could be a reason to combine surgery with neo-adjuvant therapy. The better 
this risk assessment, the better we can apply tailored therapy for patients with pT1b EAC. 
Therefore, further research on LVI quantification is necessary to assess whether it is possible 
to identify a subgroup of patients with LVI positive tumors with a low or high risk of metastases. 
Our study is subject to certain limitation First, the retrospective design of our study could result 
in information and selection bias. There was no standard folow-up regime, which could have 
resulted in a different number of reported and actual number of metastases. Second, although 
the inter-observer agreement for LVI was excelent as presented in our previous study, 
differences in LVI foci between pathologists were not discussed in a consensus meeting.17 
Moreover, when multiple LVI foci were detected, it was uncertain whether these foci 
represented LVI in different vascular structures. It is very wel possible that multiple foci in the 
H&E section actualy represented tumor localization in the same vascular structure. Third, 
additional immunohistochemical staining was not performed in the assessment of LVI and this 
may improve LVI detection.19 Moreover, retraction artifacts related to tissue specimen 
preparation are difficult to distinguish from LVI in H&E slides.20 Fourth, endoscopic and 
surgical resection specimens were combined in the results of our study, which introduces 
heterogeneity. Sampling and processing of endoscopic and surgical resection specimens are 
different (2mm vs. 5mm) and this might introduce bias in histological interpretation. In addition, 
the number of LVI foci were counted in every available H&E slide. It might be that the number 
of LVI foci is higher when more slides are available in one patient. However, studies about this 
subject are lacking. The last limitation is that external validation of our prediction model was 
not performed. Although our sample size was large, it was stil not large enough to perform 
external validation. As a consequence, we do not know whether our model has adequate 
predictive value to be used in clinical practice. External validation is desirable when 
implementing it into daily clinical practice.  
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A major strength of our study is that al histopathological slides and tumor characteristics were 
reassessed by gastrointestinal pathologists. The incorporated tumor characteristics were valid 
without missing data. Another strength of the study is the cooperation with the Netherlands 
Cancer Registration, which enabled us to incorporate al eligible patients. 
To conclude, this prediction model suggests that quantification of LVI may further refine risk 
estimation in pT1b EAC. External validation of the model and more research regarding LVI 
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General discussion and future perspectives
Chapter 11.3
Conclusion








This thesis aims to provide insights in the incidence and risk of second and multiple primary 
tumors (MPTs) in the upper aerodigestive tract (UADT) in patients with esophageal squamous 
cel carcinoma (ESCC) and in patients with head and neck squamous cel carcinoma 
(HNSCC). The second aim of this thesis is to investigate whether screening for these MPTs 
should be recommended. The third aim of this thesis is to optimize clinical staging and 
endoscopic resection (ER) of early esophageal cancer (EC) and to develop a prediction model 
that estimates the risk of lymph node metastases (LNM) in individual patients with submucosal 
(pT1b) esophageal adenocarcinoma (EAC). 
Several aspects of EC are introduced in Part I of this thesis. Chapter 1.1 provides an overview 
of the epidemiology, clinical presentation, diagnosis and treatment of early EC, risk factors for 
LNM, the risk for second primary tumors (SPTs) in the UADT, endoscopic detection and ER 
techniques, and the prevention of esophageal strictures after ER. Chapter 1.2 describing the 
aims and outline of this thesis. 
Screening and diagnosis of second and multiple primary tumors in 
the upper aerodigestive tract 
Part II discusses the screening for and diagnosis of MPTs in the UADT in patients with ESCC 
and in patients with HNSCC.  
Esophageal squamous cell carcinoma and the risk of multiple primary tumors in the 
upper aerodigestive tract 
Chapter 2 describes a nationwide, retrospective cohort study in which the risk of synchronous 
and metachronous MPTs in the UADT in patients with primary ESCC is compared with the 
general population. Most studies about this topic are performed in the Asian population. Out 
of 9,058 included patients who were diagnosed with ESCC between 2000 and 2016, 476 
patients (5.3%) developed an SPT or MPTs in the UADT. Most MPTs were located in the head 
and neck region (49.5%) and were diagnosed synchronously with the primary tumor (60.4%). 
Compared with the general population, patients with ESCC had a significantly increased risk 
of developing both synchronous (SIR 10.95, 99% CI 9.40-12.53) and metachronous (SIR 4.36, 
99% CI 3.56-5.10) MPTs, with the highest risk of developing MPTs in the head and neck 
region. Approximately one in five patients with ESCC who survive longer than six months wil 
develop an SPT within 15 years. The high cumulative incidence suggests that screening for 
MPTs is of additional value. However, patients with high-stage ESCC have a poor prognosis 
and these patients might not benefit from screening programs since their prognosis is 
predominantly determined by ESCC. Diagnosing MPTs in these patients probably does not 
lead to any survival benefit. We therefore conclude that prospective screening studies are 
necessary to determine the true MPT incidence and to investigate the yield and benefit of 
screening for MPTs, taking the probability of ESCC survival into account.  
Chapter 3 describes a systematic review and meta-analysis of studies that performed 
screening for head and neck second primary tumors (HNSPT) in patients with ESCC. The 
purpose of the study was to investigate the yield of endoscopic screening for HNSPTs in 








HNSPT. A total of 12 studies were included in this systematic review and the total number of 
included patients was 6,483. The pooled prevalence of HNSPTs was 6.7% (95% CI: 4.9-8.4, 
range: 3.0-29.6%). Most HNSPTs were located in the hypopharynx (60.3%) and had a low 
tumor stage (85.3%). We conclude that the concept of endoscopic screening for HNSPTs in 
patients with ESCC is promising.  
Al included screening studies were performed in Japan. It is unknown whether the results of 
those studies are also applicable to the Western population. Therefore, more research is 
necessary to assess the HNSPT prevalence in the Western population. Additional research 
should also focus on the question which type of ESCC increases the risk of HNSPTs and the 
risk factors associated with HNSPT. 
In Chapter 4 we describe a systematic review and meta-analysis concerning screening for 
esophageal second primary tumors (ESPTs) in patients with HNSCC. Studies were included 
when screening of the esophagus was performed with Lugol chromoendoscopy (LCE). A total 
3,386 patients in 15 studies were included. The pooled prevalence of ESPTs was 15.2% (95% 
CI 11.4-19.0, range: 4.1-40.9%). Only three Western studies were included, in which the 
prevalence was 6.0% (95% CI: 2.3-9.7). In contrast, the prevalence in the 12 Asian studies 
was 17.7% (95% CI: 12.7-22.7). Patients with HNSCC located in the hypopharynx had the 
highest ESPT prevalence. The pooled prevalence in our review is higher than what has been 
reported in retrospective non-screening studies (1-6%). We conclude that there is strong 
evidence to perform esophageal screening with LCE in an Asian patient population. It is 
unknown whether this also applies to the Western population, since only three Western 
screening studies met our inclusion criteria. 
Based on the conclusions drawn from Chapter 4, we performed a prospective screening study 
to determine the incidence of synchronous ESPTs in patients with HNSCC in a Western 
country. This study is described in Chapter 5. Patients diagnosed with HNSCC in the 
oropharynx, hypopharynx, any other sub-location of the head and neck region in combination 
with active alcohol abuse, or patients with two HNSCCs regardless of sub-location, were 
eligible for inclusion. Al patients underwent screening esophagogastroduodenoscopy (EGD) 
with white light high resolution endoscopy (WLE), narrow-band imaging (NBI), and LCE by an 
experienced interventional endoscopist during the work-up for HNSCC. An ESPT was defined 
as ESCC or high grade dysplasia (HGD). During an inclusion period of 12 months, 85 patients 
were included and underwent screening EGD. An ESPT was pathologicaly confirmed in 5/85 
(5.9%) of patients. The detection rate of al (pre)malignant lesions, including LGD (n=3), was 
9.4%. Al ESPTs were detected in an early stage and could be treated with curative intent. In 
case of ESCC diagnosis, combined treatment with radiotherapy for both HNSCC and ESCC 
was performed. Esophageal lesions larger than 20 mm were predominantly seen in patients 
with ESPT. None of the ESPTs were detected with imaging techniques before EGD was 
performed. Therefore, we believe that screening for synchronous ESPTs in patients with 
HNSCC is promising. Screening should be first considered in high-risk patients (i.e. HNSCC 
located in the oropharynx and hypopharynx and patients with alcohol abuse). The combination 
of WLE and NBI is probably the most sensitive screening method. Although LCE can be 
performed, extra awareness is indicated in case of lesions smaler than 20mm because of the 




Endoscopic detection techniques 
Chapter 6 discusses the added value of LCE by describing three important phases of 
endoscopic treatment of early ESCC. This chapter has been published as an editioral referring 
to an article by Costa-Santos et al. which concluded that mucosal inspection with LCE before 
endoscopic resection is not associated with an increased complete lateral resection rate 
compared to inspection with NBI alone.1 
The first phase of endoscopic treatment of early ESCC is the detection of the lesion. It has 
been suggested that the accuracy in the detection of early ESCC is highest when NBI and 
LCE are combined. However, the specificity of NBI is superior to the other techniques.  
The second phase is the characterization of the lesion. LCE is able to highlight suspected 
lesions in the esophagus as Lugol voiding lesions (LVLs). These LVLs are present or not, but 
no further characterization of these lesions can be made besides gross morphology. In 
contrast, intraepithelial papilary capilary loop (IPCL) patterns visible with NBI can further 
characterize esophageal lesions.  
The third phase is lesion delineation. Costa-Santos et al. concluded that mucosal inspection 
with LCE before ER of ESCC or dysplasia was not associated with an increased complete 
lateral resection rate compared to inspection with NBI alone.  
Based on previous literature and the results of Costa-Santos et al., we conclude that for both 
NBI and LCE adequate expertise and experience on the part of the endoscopist is key in the 
detection, characterization, and delineation of esophageal lesions. Although NBI seems 
superior in terms of specificity and characterization of lesions, detection of lesions depends 
on the experience of the endoscopist. Recognition of specific IPCL patterns is crucial in NBI, 
while detection of LVL by LCE might be easier for an endoscopist with less experience. 
Endoscopic diagnosis and treatment of early esophageal cancer 
Part III discusses endoscopic diagnosis and treatment of early esophageal cancer and mainly 
focusses on esophageal adenocarcinoma (EAC).  
Endoscopic reassessment of cT2 esophageal adenocarcinoma 
Chapter 7 describes a multicenter prospective cohort study of patients with clinical T2 EAC. 
Clinical tumor stage of EAC is most often determined by endoscopic ultrasound (EUS), but 
the accuracy of EUS is low for tumor stages T1 and T2. This may result in overtreatment of 
T1 tumors which are overstaged as cT2.These patients unnecessarily undergo invasive 
treatment. The aim of this study was to assess the proportion of cT2 EAC downstaged to cT1 
after endoscopic reassessment (ERA) by an experienced interventional endoscopist.  
Patients with cT2N0M0 EAC were included in this study and underwent ERA. Fifteen out of 
25 (60%) included patients were downstaged from cT2 to cT1 EAC, whom al underwent ER. 
Twelve out of 15 patients underwent successful ER and al tumors proved to be stage pT1. 
Ten out of these 12 patients were treated with ER only, five within the curative criteria for ER. 
ER was unsuccessful in 3/15 patients due to tumor invasion in the muscle layer. In the 
remaining 10 out of 25 (40%) patients, ERA confirmed cT2 tumor stage. Overal, 15 out of 25 








features during ERA in detecting T2 EAC was 86% (95% CI 42-100) and the specificity was 
80% (95% CI 52-96). Based on Chapter 7, we concluded that in patients with cT2N0M0 EAC 
according to CT/EUS assessment, ERA by an experienced interventional endoscopist 
downstages about half of the cases to a cT1 EAC suitable for ER. ERA prevents unnecessary 
invasive adjuvant treatment in 40% of patients and has therefore a substantial clinical impact 
on the management of clinicaly diagnosed T2 EAC. We advocate that al cT2 staged EACs 
should be considered for ERA by an endoscopist with experience in ER of early EAC. 
Chapter 8 describes a retrospective, observational, cohort study of patients who underwent 
ESD for early esophageal and stomach cancer performed with propofol-remifentanil 
analgosedation without endotracheal intubation. We evaluated the safety of propofol sedation 
without endotracheal intubation and reported on endoscopy- and anesthesia-related 
complications. Out of 88 included patients, only three intra-procedural ESD-related 
complications occurred (3.4%). Intra-procedural anesthesia-related complications only 
occurred in two patients (2.3%), one of whom required conversion to endotracheal intubation. 
Based on Chapter 8, we concluded that propofol-based sedation without endotracheal 
intubation is safe for ESD procedures in the esophagus and stomach with low anesthesia-
related complication rates. In line with these observations and logistical and financial 
ramifications, propofol-remifentanil analgosedation without endotracheal intubation for ESD 
should be considered over general anesthesia. 
A disadvantage of ER of early EC is the high rate of post-resection strictures. A risk factor for 
stricture development is a large mucosal defect after ER (≥75% of the esophageal 
circumference). Chapter 9 describes the effectiveness of a treatment with topical Budesonide 
for the prevention of esophageal strictures after ER for esophageal cancer. This is a 
retrospective analysis of a prospective cohort study of patients who received topical 
budesonide after ER of EC. Forty-two patients who were treated with ER and topical 
budesonide were included in this study. A total of 18/42 (44.9%) patients developed a stricture. 
The pooled stricture rate was calculated for control groups in the literature, which was 75.3% 
(95% CI 68.8-81.9%). Comparable patients of our cohort had a lower stricture rate (47.8% vs. 
75.3%, p<0.01). We conclude that topical budesonide therapy after ER for early EC seems to 
be a safe and effective method in preventing strictures. The stricture rate after budesonide 
treatment is lower compared to the stricture rate of patients who did not receive a preventive 
treatment as reported in the literature. 
Once ER is performed, the decision to perform adjuvant treatment depends on histopathologic 
features in ER specimen and the risk of LNM. No clinical tool is available that combines the 
risk of different histopathologic features to predict the LNM risk on an individual basis. Chapter 
10.1 describes a multicenter retrospective cohort study of patients with submucosal (pT1b) 
EAC that underwent ER or primary surgery. We developed a prediction model that 
incorporates al accepted prognostic parameters to accurately predict the LNM risk on an 
individual basis. A total of 248 patients with pT1b EAC were included. We show that the 
cumulative incidence of developing metastases within 5 year after primary EAC treatment is 
30.9% (95% CI 25.1-36.8). The probability of developing post resection metastases can be 
estimated with a personalized prediction risk score incorporating tumor invasion depth, tumor 
size and lymphovascular invasion. For example, the predicted 5-year metastases risk in 
patients with T1b EAC <20mm, without LVI and submucosal invasion ≤500µm (sm1) is 5.9% 
(95% CI 2.3-11.2), compared to 70.1% (95% CI 60.5-78.7) in patients with T1b EAC ≥20mm, 
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with LVI and sm3. The prediction model demonstrated a good discriminative ability with a c-
statistic of 0.81 (95% CI 0.75-0.86). 
Chapter 10.2 describes whether quantification of LVI provides additional prognostic 
information for the development of metastasis in patients with pT1b EAC. LVI is classified in 
four categories based on LVI foci in resection specimens: no LVI, 1 LVI focus, 2-3 LVI foci, 
and ≥4 LVI foci. We show that more LVI foci was correlated with a higher risk of developing 
metastasis. The presence of only 1 LVI focus was not an independent predictor for 
metastases. For example, the predicted 5-year metastasis risk in patients with T1b EAC 
<20mm, sm1, LVI negative was 14.1% (95% CI 7.9-21.9), compared to 26.3% (95% CI 10.6-
45.3) when 1 LVI focus was present, 43.5% (95% CI 26.6-61.5) when 2-3 LVI foci were 
present, and 54.4% (95% CI 33.7-72.8) when ≥4 LVI foci were present. These results suggest 
that quantification of LVI may further refine risk estimation in pT1b EAC.  
In Part IV we summarize the main findings of this thesis in Chapter 11.1. Chapter 11.2 
includes the general discussion and recommendations for further research. The conclusion of 









General discussion and future perspectives 
Screening and diagnosis of second and multiple primary tumors in 
the upper aerodigestive tract 
The first aim of this thesis was to provide insights in the incidence and risk of second and 
multiple primary tumors (MPTs) in the upper aerodigestive tract (UADT) in patients with 
esophageal squamous cel carcinoma (ESCC), and in patients with head and neck squamous 
cel carcinoma (HNSCC). The second aim of this thesis was to investigate whether screening 
for these MPTs is recommended.  
Esophageal squamous cell carcinoma and the risk of multiple primary tumors in the 
upper aerodigestive tract 
Most retrospective studies about MPT incidence in the UADT in patients with ESCC have 
been performed in the Asian population. These studies reported MPT incidence rates up to 
19%.2-5 Comparable studies performed in a Western population reported MPT incidence rates 
up to 6%.6-8 
In Chapter 2, we assessed the incidence and risk of developing MPTs in the UADT and 
stomach in patients with ESCC in the Netherlands. Our cohort consisted of patients with ESCC 
registered in the National Cancer Registry of the Netherlands. In this study, the 15-year 
cumulative incidence of metachronous second primary tumors (SPTs) was 19.7%. The risk of 
developing both synchronous and metachronous MPTs in patients with primary ESCC was 
increased compared to the general population. Like in other studies, the head and neck region 
had the highest risk of developing MPTs.7, 9-11 This study is the largest study about MPT 
development in ESCC patients in Europe, with more than 9,000 patients included over a period 
of 16 years. Because this is a registry study, there is a possible underestimation of the true 
MPT incidence. Due to the retrospective design of the study, there was a substantial amount 
of missing data. In addition, we did not know whether MPTs were diagnosed during regular 
folow-up or as a result of patients symptoms. Because of these limitations, we could not report 
on specific risk factors for MPT development (e.g. smoking and alcohol) and no specific advice 
for time-interval for screening could be drawn from this study. Further research on this topic 
should consist of a prospective screening study. 
Because Chapter 2 showed that the MPT prevalence was highest in the head and neck 
region, the first step for further research should be a screening study for head and neck second 
primary tumors (HNSPTs) in patients with primary ESCC. The advantage of a prospective 
screening study is that several potential risk factors for HNSPT development can be recorded 
and screening can be performed systematicaly and homogeneous. One of the most important 
questions to answer is whether screening wil result in the detection of early stage HNSPTs 
and whether screening wil result in survival benefit. To achieve survival benefit, screening 
should be performed in patients that can be treated with curative intent for their ESCC. In 
addition, the folow-up time after screening should be long enough to investigate the effect of 
screening on patient survival.  
Screening for head and neck second primary tumors in patients with esophageal 
squamous cell carcinoma 
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In Chapter 3, we conducted a systematic literature search and meta-analysis of studies that 
performed endoscopic screening for HNSPTs in patients with ESCC. A total of 12 studies were 
included.12-23 The prevalence of HNSPTs in these studies ranged between 3.0% and 29.6%. 
Meta-analysis showed that the pooled prevalence of HNSPTs was 6.7% (95% CI 4.9-8.4). 
Most HNSPTs were located in the hypopharynx (60.3%). However, screening of the entire 
head and neck region was performed in only four of twelve included studies. We could 
therefore not determine which head and neck sub-location had the highest risk of developing 
SPTs. Most HNSPTs had a low tumor stage (85.3%). These low stage HNSPTs can be 
curatively treated and have an excelent prognosis.  
Although this systematic review suggests that screening for HNSPTs is promising, al 
screening studies were performed in Japan. Screening studies performed in a Western 
population are necessary to investigate the incidence of HNSPTs and to investigate whether 
screening is justified in only ESCC patients that can be treated with curative intent.  
Screening for esophageal second primary tumors in patients with head and neck 
squamous cell carcinoma 
In patients with HNSCC, the esophagus in particular is at increased risk of developing MPTs.24 
Early diagnosis and treatment of an esophageal second primary tumor (ESPT) may improve 
the overal outcome of patients with HNSCC.25, 26 In Chapter 4, we conducted a systematic 
literature search and meta-analysis of studies that performed endoscopic screening of the 
esophagus with Lugol chromoendoscopy (LCE) to detect ESPTs in patients with HNSCC. A 
total of 15 studies were included, of which 12 were performed in the Asian population and 
three in the non-Asian population.27-42 The pooled prevalence of ESPT was 15.2% (95% CI 
11.4-19.0). The ESPT prevalence was highest in patients with HNSCC located in the 
hypopharynx. More than 50% of ESPTs were low-stage and could be treated with curative 
intent.  
Based on Chapter 4, we recommend screening for ESPTs in an Asian patient population with 
HNSCC. A major limitation of this systematic review is that only three non-Asian studies were 
included, of which two studies were performed in Europe. It is therefore important to perform 
a prospective screening study in a Western population with HNSCC. 
This prospective screening study is described in Chapter 5. Eighty-five patients with an 
increased risk of ESPT development were included and underwent screening 
esophagogastroduodenoscopy (EGD), within two weeks after HNSCC diagnosis. EGD was 
performed with white light high resolution endoscopy (WLE), narrow-band imaging (NBI), and 
LCE. 
In Chapter 5, we found an ESPT incidence of 5.9% (95% CI 1.9-13.2). ESPT or low-grade 
dysplasia was found in one in ten patients. Al esophageal lesions were diagnosed at an early 
stage and could be treated with curative intent with either endoscopic resection (ER) or 
radiotherapy. Since none of the ESPTs were identified by other imaging techniques (i.e., MRI 
and/or CT-scan), we suggest that screening for ESPT by EGD is of added value for a selected 
group of patients with HNSCC. The combination of WLE and NBI is probably the most 
sensitive screening method. Although LCE can be performed, extra awareness is indicated in 
case of lesions <20mm because of the high rate of false positive lesions. 
and whether screening wil result in survival benefit. To achieve survival benefit, screening 
should be performed in patients that can be treated with curative intent for their ESCC. In 
addition, the folow-up time after screening should be long enough to investigate the effect of 
screening on patient survival.  
Screening for head and neck second primary tumors in patients with esophageal 
squamous cell carcinoma 
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However, before screening for ESPT can be implemented in daily clinical practice, further 
research on this topic should be conducted focusing on the folowing aspects:  
1. More studies with a larger patient cohort are necessary, preferably in a multicenter
setting. This would enable a solid risk factor analysis and identify a subgroup of
patients who are at high risk of developing ESPTs and would benefit most from
endoscopic screening.
2. Patient burden should be taken into account. This is an important parameter for the
decision whether screening should be performed. Screening EGD is an invasive
examination for patients. Although eight patients were treated for ESPT or low-grade
dysplasia in Chapter 5, three patients received an unnecessary endoscopic mucosal
resection (EMR) and no lesions were found in the other 74 patients.
3. Survival benefit should be taken into account. It is important to take HNSCC prognosis
into account since patients with poor prognosis wil probably not benefit from
screening, and screening wil not lead to survival benefit in these patients.
4. Screening for metachronous ESPTs should be performed to determine the optimal
timing of screening.
5. It is necessary to determine the cost-effectiveness of screening EGD.
Endoscopic detection techniques 
To continue the discussion whether LCE is stil necessary to date as pointed in Chapter 5, the 
added value of LCE is discussed further in Chapter 6. The added value of LCE is discussed 
by describing three different phases of endoscopic ESCC treatment. The first phase is the 
detection of ESCC. Based on previous literature, we conclude that accuracy rates of ESCC 
detection are highest when NBI and LCE are combined.43, 44 The second phase is the 
characterization of ESCC. Although LCE can easily highlight suspected dysplastic or 
neoplastic lesions in the esophagus, further characterization of the lesion cannot be made. In 
contrast, characterization of esophageal lesions with intraepithelial papilary capilary loop 
patterns is possible with NBI.45 The third phase is the delineation of ESCC before ER. 
According to Costa-Santos et al., defining lateral resection margins before ER of ESCC by 
LCE does not result in an increased complete lateral resection rate compared to NBI.1 
Based on previous literature, NBI seems superior to LCE in several aspects. However, key in 
the detection and treatment of ESCC is adequate expertise and experience of the endoscopist. 
In the near future, the role of LCE wil probably be pushed more to the background, in particular 
when artificial inteligence wil be implemented. 
Endoscopic diagnosis and treatment of early esophageal cancer 
The third aim of this thesis was to optimize clinical staging and ER of early esophageal cancer 
and to develop a prediction model that estimates the risk of lymph node metastasis (LNM) in 
individual patients with submucosal (pT1b) esophageal adenocarcinoma (EAC). 
Endoscopic reassessment of cT2 esophageal adenocarcinoma 
Clinical tumor stage of EAC is determined by endoscopic ultrasound (EUS) and/or CT-scan. 
The accuracy of these tools is low for stages T1 and T2.46, 47 This may result in overtreatment 
of patients who are overstaged as cT2 EAC, and therefore unnecessarily underwent invasive 
treatment, associated with increased risks and morbidity.48-51 Chapter 7 describes a 
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multicenter prospective cohort study of patients with cT2N0M0 EAC who underwent 
endoscopic reassessment (ERA) by an endoscopist with experience in ER of early EAC. In 
this study, we aimed to assess the proportion of cT2 EAC downstaged to cT1 after ERA.  
ERA downstaged about half of the cases to a T1 EAC, suitable for ER. In 40% of patients, 
unnecessary invasive adjuvant treatment was prevented. We conclude that ERA has a 
substantial clinical impact on the management of cT2 EAC. Al cT2 EAC should be considered 
for ERA by an experienced endoscopist. The results of Chapter 7 are in line with previous 
studies reporting that a substantial number of cT2 EAC are in fact pT1 EAC and can be treated 
with ER.48, 52 
A limitation of our study is the smal sample size of only 25 patients included over two years. 
However, we may have only included the tip of the iceberg because many patients with cT2 
EAC remain unnoticed. Participating study centers included patients who were referred by 
other non-expert hospitals. Endoscopists in non-expert hospitals are most often not trained to 
assess whether cT2 EAC is suitable for ER, and these patients are therefore not referred to 
an expert center for an attempt at ER. Although the smal sample size could limit the 
generalizability of our results, our results confirm the low accuracy of EUS in staging early 
EAC and show that ERA downstaged 60% of cT2 EAC, of which 80% were pT1 EAC. There 
are substantial implications of ERA for this patient group and we are therefore convinced that 
ERA by an experienced endoscopist can be implemented in daily clinical practice.  
Sedation during endoscopic resection  
In Chapter 8 we retrospectively evaluated the safety of propofol sedation without endotracheal 
intubation during endoscopic submucosal dissection (ESD) of esophageal and gastric tumors. 
We conclude that ESD can be safely performed with propofol-remifentanil analgosedation 
without endotracheal intubation. Intra-procedural anesthesia-related complications occurred 
in only 2.3% of patients and no post-procedural anesthesia-related complications were 
observed. Conversion to endotracheal intubation took place in only one patient and 93.2% of 
the patients were discharged the same day or the day after ESD.  
General anesthesia wil probably result in higher costs compared to propofol sedation. It 
requires additional facilities and an anesthesiologist.53 Patients cannot be discharged the 
same day as the ESD procedure and this wil result in longer hospital stay and additional 
costs.54-56 However, formal cost-effectiveness studies are needed to quantify potential 
savings.53  
A major advantage of our study is that al procedures were managed by a sedation practitioner 
who was present during the procedures. This sedation practitioner is a member of the 
anesthesiology department and is supervised by the anesthesiologist. Previous literature 
indicates that, compared to propofol sedation, the risk-benefit balance is in favor of general 
anesthesia.56 However, in these studies, no sedation practitioner was available during 
procedures with propofol sedation. It is therefore difficult to discern to what extent the training 
and experience of the sedation practitioner plays a decisive role in this equation. We conclude 
that propofol-remifentanil analgosedation without endotracheal intubation for ESD should be 
considered over general anesthesia when a sedation practitioner is available.  
A suggestion for further research is a randomized controled trial in which general anesthesia 
(performed by an anesthesiologist) is compared with propofol sedation (performed by a 
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sedation practitioner). This randomized controled trial should preferably be performed in a 
multicenter setting. In addition, patient satisfaction and cost-effectiveness analysis should be 
taken into account.  
Esophageal strictures after endoscopic resection 
A disadvantage of ER in the esophagus is the risk of developing esophageal strictures. This 
risk is especialy high when the mucosal defect of the esophageal circumference after ER is 
more than 75%.57 Although several methods to prevent these strictures have been 
investigated, the optimal preventive method is currently not known.  
In Chapter 9 we investigated the effectiveness of oral treatment with topical budesonide for 
the prevention of strictures after ER of esophageal cancer (both ESCC and EAC). We 
conclude that the use of topical budesonide is safe and effective in stricture prevention after 
ER. No side effects of budesonide are reported. The stricture rate of patients in our cohort 
(44.9%) was lower compared to the pooled stricture rate (75.3%) of patients who did not 
receive a preventive treatment as reported in the literature.58-66 Several studies, that 
investigated other methods to prevent strictures, reported a lower stricture rate compared to 
our study.58, 60-62 However, these methods include oral prednisolone and triamcinolone 
injections in the esophagus which are associated with many side effects.58, 67  
Limitations of our study include its retrospective design and the non-randomized study design 
without the availability of a control group. Prospective confirmation is needed, preferably 
through a randomized controled trial. In addition, topical budesonide was used off-label 
because it was not developed to prevent esophageal strictures. It seems likely that an 
orodispersible tablet designed for this indication could yield an even higher effect in the 
prevention of strictures. 
Lymph node metastasis in esophageal adenocarcinoma 
The prevalence of LNM in T1b EAC varies between 0-78%.68-72 Guidelines recommend 
additional surgical resection of the esophagus and loco-regional lymph node dissection when 
EAC invades the submucosa.73, 74 However, not every patient with pT1b EAC develops LNM 
and surgery is associated with morbidity, mortality, and decreased quality of life.49, 75 Individual 
risk factors associated with LNM have been described.68, 76, 77 However, little is known about 
how these risk factors interrelate and whether combining them may improve estimation of LNM 
risk. 
Chapter 10.1 presents a nationwide, retrospective cohort study of patients treated with ER or 
surgery for pT1b EAC. In this chapter, we established a prediction model that includes 
histopathological tumor characteristics and estimates the individual risk of metastases in 
patients with pT1b EAC. 
The 5-year cumulative incidence of metastasis in our cohort was 30.9% (95% CI 25.1-36.8%). 
After internal validation of the prediction model, the estimated risk of developing metastasis 
within five years after ER or primary surgery for pT1b EAC ranged between 5.9-70.1%, 
depending on different combinations of histopathological parameters. The prediction model 
demonstrated a good discriminative ability, with a c-statistic of 0.81 (95% CI 0.75-0.86).  
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Although such prediction model has not been previously reported, further research is 
necessary before this model can be implemented in daily clinical practice. Future studies 
should perform external validation of the prediction model because we could not perform this 
due to the lack of a validation cohort. Moreover, the current prediction model is mainly based 
on surgical data and we do not know whether this model can reliably be used to calculate LNM 
risk in patients treated with ER. Therefore, external validation should be performed on a cohort 
consisting of patients with pT1b EAC treated with ER. 
Since this was a retrospective study with possible selection and information bias, prospective 
confirmation is needed. To date, the decision to perform adjuvant therapy after ER of pT1b 
EAC, as stated in the ESGE guidelines, is based on less patient data than the current study. 
Moreover, no prediction model including different combinations of histopathological 
parameters is published to date. 
Another limitation of our study that needs to be tackled in future studies is that we did not 
perform additional immunohistochemical staining for the assessment of lymphovascular 
invasion (LVI) which may improve the detection of LVI.78  
In Chapter 10.2 we aimed to determine whether quantification of LVI provides additional 
prognostic information in patients with pT1b EAC. LVI was incorporated in the prediction model 
as no-LVI, 1 LVI focus, 2-3 LVI foci, or ≥4 LVI foci. We showed that the presence of more LVI 
foci in resection specimen of pT1b EAC was correlated with a higher risk of metastasis. 
Compared to the risk in LVI+ patients in the previous model, as described in Chapter 10.1, 
the metastasis risk in the current model is lower in case of 1 LVI focus and higher in case of 
2-3 LVI foci and ≥4 LVI foci.  
Despite the promising results of the prediction model, it is unlikely that the application of the 
this model wil change clinical practice soon. The difference in predicted metastasis risk 
between the LVI foci groups is relatively smal and the absolute risk is high in al scenarios. 
Although the metastasis risk in patients with only 1 LVI focus is much lower than the risk in 
patients with 2-3 or ≥4 LVI foci, the advice for adjuvant treatment or active surveillance after 
ER wil probably not change based on the number of LVI foci. On one hand, we are looking 
for a better risk assessment for metastasis to make active surveilance possible. On the other 
hand, the presence of extensive LVI could be a reason to combine surgery with neo-adjuvant 
therapy. The better this risk assessment, the better we can apply tailored therapy for patients 
with pT1b EAC. 
The same patient cohort was used for Chapter 10.1 and Chapter 10.2. Therefore, limitations 
of Chapter 10.2 also include its retrospective design, the lack of a validation cohort, and the 
fact that immunohistochemical staining for LVI assessment was not performed. Especialy the 
last limitation is important for a study focusing on LVI. Moreover, quantification of LVI in pT1b 
EAC has not been previously reported in the literature. More research regarding LVI 



















Patients with ESCC have an increased risk of developing MPTs compared to the general 
Dutch population. The MPT prevalence is highest in the head and neck region. For 
synchronous MPTS, the risk is approximately ten times higher. For metachronous MPTS, the 
risk is approximately four times higher.  
Based on a systematic review and meta-analysis, we conclude that the pooled prevalence of 
HNSPTs in ESCC patients is 6.7% (95% CI 4.9-8.4). Based on a second systematic review 
and meta-analysis, we conclude that screening for esophageal second primary tumors 
(ESPTs) in Asian patients with head and neck squamous cel carcinoma (HNSCC) is justified. 
The pooled ESPT prevalence in patients with HNSCC is 15.2% (95% CI 11.4-19.0).  
In a prospective screening study, we show that the ESPT incidence is 5.9% (95% CI 1.9-13.2) 
in patients with HNSCC in the Netherlands. Al detected esophageal lesions could be treated 
with curative intent. These lesions were not detected by other imaging techniques. We 
conclude that screening for ESPT by esophagogastroduodenoscopy is of added value for a 
selected group of patients with HNSCC. Narrow-band imaging seems superior to LCE in the 
detection and characterization of early ESCC. Adequate expertise and experience of the 
endoscopist is key in the detection and treatment of early ESCC. 
This thesis shows that endoscopic reassessment (ERA) of cT2N0M0 esophageal 
adenocarcinoma (EAC) downstages about half of the cases to a T1 EAC, suitable for 
endoscopic resection (ER). We conclude that ERA has a substantial clinical impact on the 
management of cT2 EAC, preventing overtreatment in 40% of patients. ERA of cT2N0M0 EAC 
should be implemented in daily clinical practice.  
In a retrospective study on the safety of propofol sedation without endotracheal intubation 
during endoscopic submucosal dissection (ESD) of esophageal and gastric tumors, we 
conclude that ESD can be safely performed with propofol sedation without endotracheal 
intubation.  
Based on comparisons with historical published data, oral treatment with topical budesonide 
after ER of esophageal cancer seems to be an effective method for preventing strictures. 
However, before topical budesonide can be implemented in daily clinical practice, a 
randomized controled trial on the effectivity of topical budesonide in stricture prevention is 
necessary.  
We established a prediction model that includes histopathological tumor characteristics and 
estimated the individual risk of metastasis in patients with pT1b EAC. We show that the 5 year 
cumulative incidence of metastasis after primary treatment of pT1b EAC is 30.9% (95% CI 
25.1-36.8). The estimated risk of developing metastasis within 5 years after ER or primary 
surgery of pT1b EAC ranges between 5.9% and 70.1%, depending on different combinations 
of histopathological parameters (tumor size, submucosal invasion depth and lymphovascular 
invasion [LVI]). In order to improve the prediction model, we quantified LVI as the total number 
of LVI foci and show that more LVI foci in pT1b EAC is correlated with higher rates of 
metastasis. We suggest that quantification of LVI could be useful for a more precise risk 
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Dit proefschrift heeft tot doel om inzicht te verschaffen in de incidentie en het risico op tweede 
en meerdere primaire tumoren (MPT’s) in de luchtwegen en het bovenste deel van het 
spijsverteringskanaal in patiënten met een plaveiselcelcarcinoom (PCC) in de slokdarm en in 
patiënten met een PCC in de hoofd-hals regio. Het tweede doel van dit proefschrift is om te 
onderzoeken of screening op deze MPT’s nodig is. Het derde doel van dit proefschrift is om 
de klinische stadiëring en endoscopische resectie (ER) van vroegcarcinomen in de slokdarm 
te optimaliseren en om een predictie model te ontwikkelen dat het risico op metastasen kan 
voorspelen in individuele patiënten met een submucosaal (pT1b) adenocarcinoom van de 
slokdarm. 
Slokdarmkanker wordt geïntroduceerd in Deel I van dit proefschrift. Hoofdstuk 1.1 geeft een 
overzicht van de epidemiologie, klinische presentatie, diagnose en behandeling van 
vroegcarcinomen in de slokdarm, risico factoren op lymfekliermetastasen, het risico op tweede 
primaire tumoren in de luchtwegen en het bovenste deel van het spijsverteringskanaal in 
patiënten met een PCC van de slokdarm en in patiënten met een PCC in de hoofd-hals regio, 
endoscopische detectietechnieken, ER technieken, en de preventie van slokdarmstricturen na 
ER. Dit hoofdstuk wordt gevolgd door Hoofdstuk 1.2 waarin de doelen en de opzet van dit 
proefschrift worden beschreven.  
Screening en diagnose van tweede en meerdere primaire tumoren in de luchtwegen en 
het bovenste deel van het spijsverteringskanaal 
Deel II beschrijft de screening en diagnose van MPT’s in de luchtwegen en het bovenste deel 
van het spijsverteringskanaal in patiënten met een PCC van de slokdarm en in patiënten met 
een PCC in de hoofd-hals regio.  
Plaveiselcelcarcinoom van de slokdarm en het risico op meerdere primaire tumoren in 
de luchtwegen en het bovenste deel van het spijsverteringskanaal 
Hoofdstuk 2 beschrijft een landelijke, retrospectieve, cohort studie waarin het risico op 
synchrone en metachrone MPT’s in de luchtwegen en het bovenste deel van het 
spijsverteringskanaal in patiënten met een primaire PCC van de slokdarm wordt vergeleken 
met de algemene populatie. De meeste onderzoeken over dit onderwerp zijn uitgevoerd in 
een Aziatische patiënten populatie. De studie beschreven in dit hoofdstuk werd uitgevoerd in 
samenwerking met de Nederlandse Kanker Registratie (IKNL). Van de 9058 geïncludeerde 
patiënten die gediagnosticeerd werden met een PCC van de slokdarm tussen 2000 en 2016 
ontwikkelde 476 patiënten (5,3%) een tweede primaire tumor of MPT’s in de luchtwegen en 
het bovenste deel van het spijsverteringskanaal. De meeste MPT’s waren gelokaliseerd in de 
hoofd-hals regio (49,5%) en werden synchroon gediagnosticeerd (60,4%). In vergelijking met 
de algemene populatie hadden patiënten met een PCC van de slokdarm een significant hoger 
risico op het ontwikkelen van zowel synchrone (SIR 10,95, 99% CI 9,40-12,53) als metachrone 
(SIR 4,36, 99% CI 3,56-5,10) MPT’s. De hoofd-hals regio had het hoogste risico op het 
ontwikkelen van MPT’s. De 15-jaar cumulatieve incidentie op het ontwikkelen van metachrone 
tweede primaire tumoren was 19,7% in de groep patiënten die langer leefden dan 6 maanden 
na diagnose van een PCC van de slokdarm. Dit betekent dat ongeveer 1 op de 5 patiënten 
met een PCC van de slokdarm die langer leeft dan 6 maanden een tweede primaire tumor 




screening op MPT’s nuttig kan zijn. Echter, patiënten met een hoog stadium PCC van de 
slokdarm hebben een slechte prognose en deze patiënten hebben waarschijnlijk geen 
voordeel van een screening programma omdat hun prognose al bepaald wordt door de 
slokdarmtumor. Het diagnosticeren van MPT’s in deze patiënten is waarschijnlijk niet klinisch 
relevant. We concluderen daarom dat prospectieve screeningstudies nodig zijn om de 
werkelijke incidentie van MPT’s te bepalen en om de opbrengst en het voordeel van screening 
op MPT’s te onderzoeken. Daarnaast dient rekening te worden gehouden met de overleving 
van patiënten met een PCC van de slokdarm.  
Zoals in Hoofdstuk 2 beschreven is het risico op MPT ontwikkeling het hoogst in de hoofd-
hals regio. Hoofdstuk 3 beschrijft een systematische review en meta-analyse van studies die 
screening hebben uitgevoerd op tweede primaire tumoren in de hoofd-hals regio in patiënten 
met een PCC van de slokdarm. Het doel van dit systematische review was om te onderzoeken 
wat de opbrengst van endoscopische screening op hoofd-hals tweede primaire tumoren is in 
patiënten met een PCC van de slokdarm. De primaire uitkomstmaat van deze studie was de 
gepoolde prevalentie van hoofd-hals tweede primaire tumoren. In totaal werden er 12 studies 
geïncludeerd in dit systematische review met in totaal 6483 geïncludeerde patiënten. Ale 
studies waren uitgevoerd in Japan. De gepoolde prevalentie van hoofd-hals tweede primaire 
tumoren was 6,7% (95% CI: 4,9-8,4, bereik: 3,0-29,6%). De meeste hoofd-hals tweede 
primaire tumoren waren gelokaliseerd in de hypopharynx (60,3%) en werden geclassificeerd 
met een laag tumor stadium (85,3%). Patiënten met een laag stadium hoofd-hals tumor 
kunnen curatief behandeld worden en deze patiënten hebben vaak een uitstekende prognose. 
We concluderen dat het concept van endoscopische screening op hoofd-hals tweede primaire 
tumoren bij patiënten met een PCC van de slokdarm veelbelovend is. Omdat ale 
geïncludeerde studies werden uitgevoerd in Japan, zou deze screening in Japan moeten 
worden gestandaardiseerd. Deze hoofd-hals screening zou dan moeten worden uitgevoerd 
tijdens de work-up en folow-up van een PCC van de slokdarm. Omdat ale geïncludeerde 
studies uitgevoerd werden in Japan is het noodzakelijk om Westerse screening studies uit te 
voeren, om te beoordelen wat de prevalentie is van hoofd-hals tweede primaire tumoren in 
een Westerse populatie. Daarnaast zijn er meer screeningstudies nodig om te onderzoeken 
welk type PCC van de slokdarm het risico op hoofd-hals tweede primaire tumoren verhoogt 
en om te onderzoeken welke risicofactoren verband houden met het ontstaan van hoofd-hals 
tweede primaire tumoren. 
In Hoofdstuk 4 beschrijven we een systematische review en meta-analyse over screening op 
slokdarm tweede primaire tumoren in patiënten met een PCC in de hoofd-hals regio. Studies 
werden aleen geïncludeerd als slokdarm screening werd uitgevoerd met Lugol 
chromoendoscopy (LCE). Er werden 15 studies geïncludeerd met in totaal 3386 
geïncludeerde patiënten. De gepoolde prevalentie van slokdarm tweede primaire tumoren, 
van ale geïncludeerde studies, was 15.2% (95% CI 11.4-19.0, bereik: 4.1-40.9%). Er waren 
maar 3 Westerse studies geïncludeerd, de gepoolde prevalentie van deze studies was 6.0% 
(95% CI: 2.3-9.7). Dit in tegensteling tot de gepoolde prevalentie van slokdarm tweede 
primaire tumoren in de 12 Aziatische studies, wat 17.7% (95% CI: 12.7-22.7) was. De 
prevalentie van tweede primaire tumoren was het hoogst in patiënten met een hoofd-hals PCC 
in de hypofarynx. De gepoolde prevalentie, zoals gerapporteerd in dit systematisch review is 
hoger dan de prevalentie die gerapporteerd is in retrospectieve, niet-screening studies (1-6%). 
We concluderen dat er een sterk bewijs is om slokdarmscreening uit te voeren met LCE in 
een Aziatische patiëntenpopulatie. We kunnen echter niet hetzelfde bevestigen voor een 
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Westerse patiëntenpopulatie omdat er maar drie Westerse studies werden uitgevoerd. Er zijn 
daarom meer Westerse screening studies nodig.  
Na de conclusies die we getrokken hebben uit Hoofdstuk 4, hebben we een prospectieve 
screening studie uitgevoerd om de incidentie van synchrone tweede primaire tumoren in de 
slokdarm te bepalen in patiënten met een hoofd-hals PCC in Nederland. Deze studie wordt 
beschreven in Hoofdstuk 5. Patiënten die gediagnosticeerd zijn met een hoofd-hals PCC in 
de orofarynx, hypofarynx, een andere hoofd-hals sub-locatie in combinatie met actief alcohol 
gebruik, of patiënten met twee PCC’s in de hoofd-hals regio ongeacht de sub-locatie, werden 
geïncludeerd in deze studie. Screening gastro duodenoscopie werd uitgevoerd met wit licht 
hoge resolutie endoscopie (WLE), ‘narrow-band imaging’ (NBI), en LCE door een ervaren 
interventie endoscopist tijdens de work-up voor een PCC in de hoofd-hals regio. Een tweede 
primaire tumor in de slokdarm werd gedefinieerd als een PCC of hooggradige dysplasie 
(HGD). Gedurende één jaar werden er in totaal 85 patiënten geïncludeerd die alen een 
screening gastro duodenoscopie ondergingen. Een tweede primaire tumor was pathologisch 
bewezen in 5/85 (5.9%) patiënten. Het detectie percentage van ale (pre)maligne laesies, 
inclusief laaggradige dysplasie (LGD) (n=3), was 9.4%. Ale tweede primaire tumoren werden 
gedetecteerd in een vroeg stadium en konden curatief behandeld worden met ER of 
radiotherapie. In de patiënt waarbij er een slokdarm PCC werd gediagnosticeerd kon 
gecombineerde behandeling met radiotherapie voor zowel hoofd-hals als slokdarm PCC 
worden uitgevoerd. Slokdarmlaesies groter dan 20 mm werden hoofzakelijk gezien in 
patiënten met een slokdarm tweede primaire tumor. Geen van deze tweede primaire tumoren 
werden gedetecteerd door beeldvormende technieken vóór gastro duodenoscopie was 
uitgevoerd. De studie suggereert daarom dat endoscopische screening van deze 
geselecteerde patiëntengroep van toegevoegde waarde was. Screening zou eerst moeten 
worden overwogen in hoog-risico patiënten (dat wil zeggen: een hoofd-hals PCC 
gelokaliseerd in de orofarynx of hypofarynx en patiënten met een hoofd-hals PCC die alcohol 
gebruiken). The combinatie van WLE en NBI is waarschijnlijk de meest sensitieve screening 
methode. Hoewel LCE ook kan worden uitgevoerd, is extra alertheid geïndiceerd in het geval 
van laesies kleiner dan 20 mm vanwege het hoge percentage vals-positieve laesies.  
Endoscopische detectietechnieken 
Hoofdstuk 6 beschrijft een “editorial” verwijzend naar Costa-Santos et al. In dit hoofdstuk 
wordt de toegevoegde waarde van LCE bediscussieerd door drie belangrijke fases te 
beschrijven in de behandeling van vroeg PCC’s in de slokdarm.  
De eerste fase is de detectie van de laesie. In de literatuur wordt vermeld dat de accuratesse 
van de detectie van vroeg PCC’s in de slokdarm het hoogst is als NBI en LCE gecombineerd 
worden. De specificiteit is echter superieur met NBI.  
De tweede fase is de karakterisering van de laesie. LCE kan verdachte laesies in de slokdarm 
markeren als “Lugol voiding laesies” (LVL’s). Deze LVL’s zijn aanwezig of niet, maar er kan 
geen verdere karakterisering van deze laesies worden gemaakt op grove morfologie na. 
Daarentegen kunnen intra-epitheliale papilaire capilaire lus (IPCL) patronen die zichtbaar zijn 
met NBI slokdarmlaesies verder karakteriseren. 
De derde fase is de afbakening van de laesie. Costa-Santos et al. concludeerde dat inspectie 




geassocieerd was met een verhoogde mate van voledige laterale resectie vergeleken met 
inspectie met aleen NBI. Gebaseerd op eerdere literatuur en de studie van Costa-Santos et 
al., concluderen we dat voor zowel NBI als LCE adequate expertise en ervaring van de 
endoscopist cruciaal is voor de detectie, karakterisering, en afbakening van slokdarm laesies. 
Alhoewel NBI superieur lijkt op het gebied van specificiteit en karakterisering van laesies, 
hangt de detectie van laesies af van de ervaring van de endoscopist. Herkenning van 
specifieke IPCL-patronen is cruciaal bij NBI, terwijl de detectie van LVL’s door LCE 
gemakkelijker lijkt voor een endoscopist met weinig ervaring.  
Endoscopische diagnose en behandeling van een vroeg carcinoom 
in de slokdarm 
Deel III beschrijft de endoscopische diagnose en behandeling van vroeg carcinomen in de 
slokdarm, de focus ligt hierbij op adenocarcinomen van de slokdarm.  
Endoscopische herbeoordeling van cT2 adenocarcinomen van de slokdarm 
Hoofdstuk 7 beschrijft een multicentrische, prospectieve cohort studie van patiënten met een 
klinisch T2 adenocarcinoom van de slokdarm. Het klinisch tumor stadium van een 
adenocarcinoom van de slokdarm wordt meestal bepaald door een endoscopische echo. De 
accuratesse van een endoscopische echo is echter laag voor tumor stadium T1 en T2. Dit zou 
kunnen resulteren in een overbehandeling van patiënten waarbij de tumor “overgestadieerd” 
is als T2 en deze patiënten ondergaan onnodige aanvulende invasieve behandeling. Het doel 
van deze studie was om de proportie van T2 adenocarcinomen van de slokdarm te bepalen 
die na endoscopische herbeoordeling door een ervaren interventie endoscopist beoordeeld 
worden als een T1 tumor. 
Patiënten met een T2N0M0 adenocarcinoom van de slokdarm werden geïncludeerd in deze 
studie en ondergingen een endoscopische herbeoordeling van de tumor. In 15 van de 25 
(60%) geïncludeerde patiënten werd de T2 tumor gedownstaged naar een T1 tumor, zij 
ondergingen alemaal een poging tot ER. Twaalf van de 15 patiënten ondergingen een 
succesvole ER en zij hadden alemaal een bewezen pT1 tumor. Tien van deze 12 patiënten 
werden aleen behandeld met ER, waarvan de ER curatief was in 5 patiënten. Een poging tot 
ER werd onderbroken in 3 van de 15 patiënten doordat de tumor ingroeide in de spierlaag. 
Endoscopische herbeoordeling bevestigde het T2 tumor stadium in de overige 10 van de 25 
(40%) patiënten. In totaal bleken 15 van de 25 cT2 adenocarcinomen van de slokdarm pT1 
stadium of prepT1 stadium te zijn. De sensitiviteit van de aanwezigheid van invasieve 
kenmerken van de tumor tijdens endoscopische herbeoordeling in het detecteren van een T2 
tumor was 86% (95% CI 42-100) en de specificiteit was 80% (95% CI 52-96).  
Gebaseerd op Hoofdstuk 7 concluderen we dat in patiënten met een cT2N0M0 
adenocarcinoom van de slokdarm (gebaseerd op een beoordeling met CT-scan of 
endoscopische echo), endoscopische herbeoordeling door een ervaren interventie 
endoscopist resulteert in het “downstagen” naar een T1 slokdarmtumor geschikt voor ER, in 
ongeveer de helft van de patiënten. 
Endoscopische herbeoordeling voorkomt onnodige invasieve aanvulende behandeling in 
40% van de patiënten en heeft daarom een substantiële klinische impact op de behandeling 
van T2 adenocarcinomen van de slokdarm. We pleiten ervoor dat ale T2 gestadieerde 
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adenocarcinomen van de slokdarm in aanmerking moeten komen voor een endoscopische 
herbeoordeling door een endoscopist met ervaring in ER van vroegcarcinomen in de 
slokdarm.  
Hoofdstuk 8 beschrijft een retrospectieve, observationele, cohort studie van patiënten die 
een endoscopische submucosal dissectie (ESD) hebben ondergaan voor vroegcarcinomen in 
de slokdarm of maag, uitgevoerd met propofol sedatie zonder endotracheale intubatie. We 
evalueren de veiligheid van propofol sedatie zonder endotracheale intubatie en rapporteren 
over endoscopie- en anesthesie gerelateerde complicaties. In drie van de 88 geïncludeerde 
patiënten heeft er een intra-procedurele ESD-gerelateerde complicatie plaatsgevonden. Intra-
procedurele anesthesie-gerelateerde complicaties vonden plaats in twee patiënten (2.3%), 
waarvan in één patiënt er een conversie naar endotracheale intubatie heeft plaatsgevonden. 
Gebaseerd op Hoofdstuk 8, concluderen we dat sedatie met propofol zonder endotracheale 
intubatie veilig is voor ESD procedures in de slokdarm en maag, met een laag aantal 
anesthesie-gerelateerde complicaties. In lijn met deze resultaten en logistieke en financiële 
consequenties, dient propofol sedatie zonder endotracheale intubatie voor ESD te worden 
overwogen in plaats van algemene anesthesie. 
Een nadeel van ER van vroeg carcinomen in de slokdarm is de hoge strictuur kans na de 
resectie. Een risicofactor voor strictuur ontwikkeling is een mucosaal defect van ≥75% van de 
circumferentie van de slokdarm na ER. Hoofdstuk 9 beschrijft de effectiviteit van een 
behandeling met topicale Budesonide op de preventie van slokdarmstricturen na een ER van 
een vroeg carcinoom in de slokdarm. Het betreft een retrospectieve analyse van een 
prospectieve cohort studie van patiënten die topicale budesonide hebben gekregen na ER 
van slokdarmkanker. Tweeënveertig patiënten die behandeld werden met ER en topicale 
budesonide werden geïncludeerd in deze studie. In totaal ontwikkelden 18/42 (44.9%) 
patiënten een strictuur. Het gepoolde strictuur percentage was berekend voor controle 
groepen (zonder Budesonide behandeling) uit de literatuur, wat 75.3% (95% CI 68.8-81.9%) 
was. Vergelijkbare patiënten uit ons cohort hadden een lager strictuur percentage (47.8% vs. 
75.3%, p=0.007). We concluderen dat een behandeling met topicale budesonide na ER van 
slokdarmkanker een veilige en effectieve methode lijkt te zijn in het voorkomen van 
slokdarmstricturen. Het strictuur percentage na behandeling met Budesonide is lager in 
vergelijking met het strictuur percentage van patiënten die géén preventieve behandeling 
hebben gekregen na ER, gerapporteerd in de literatuur.  
Zodra ER is uitgevoerd, hangt de beslissing om aanvulende behandeling uit te voeren af van 
de histologische kenmerking van het ER-preparaat en het risico op lymfekliermetastasen. Er 
is geen klinische “tool” beschikbaar die het risico van verschillende histologische kenmerken 
combineert om het risico op lymfekliermetastasen te voorspelen in individuele patiënten. 
Hoofdstuk 10.1 beschrijft een multicentrische, retrospectieve cohort studie van patiënten met 
een submucosaal (pT1b) adenocarcinoom van de slokdarm die ER of primaire chirurgie 
hebben ondergaan. We hebben een voorspelingsmodel ontwikkeld dat ale geaccepteerde 
prognostische parameters bevat om het risico op metastasen op individuele basis nauwkeurig 
te voorspelen. In totaal werden er 248 patiënten met een pT1b adenocarcinoom van de 
slokdarm geïncludeerd. We laten zien dat de cumulatieve incidentie op het ontwikkelen van 
metastasen binnen 5 jaar na de primaire behandeling van een adenocarcinoom van de 
slokdarm 30,9% (95% CI 25,1-36,8) is. De kans op het ontwikkelen van metastasen na 
resectie kan worden geschat met een gepersonaliseerde voorspelingsrisico score die de 








voorspelde risico op metastasen binnen 5 jaar na primaire behandeling is bijvoorbeeld 5,9% 
(95% CI 2,3-11,2) in patiënten met een T1b adenocarcinoom van de slokdarm <20mm, zonder 
LVI en sm1 diepte invasie, vergeleken met een risico van 70,1% (95% CI 60,5-78,7) in 
patiënten met een T1b adenocarcinoom van de slokdarm ≥20mm, met LVI en sm3 diepte 
invasie. Het voorspelingsmodel had een goede accuratesse met een c-statistic van 0,81 (95% 
CI 0,75-0,86).  
Hoofdstuk 10.2 beschrijft of kwantificatie van LVI aanvulende prognostische informatie geeft 
op het ontwikkelen van metastasen in patiënten met een pT1b adenocarcinoom van de 
slokdarm. LVI is geclassificeerd in 4 categorieën gebaseerd op het aantal LVI foci in het 
resectie preparaat: geen LVI, 1 LVI focus, 2-3 LVI foci, en ≥4 LVI foci. We laten zien dat de 
aanwezigheid van meer LVI foci gecorreleerd is met een hoger metastasen risico. De 
aanwezigheid van slechts één LVI focus was geen onafhankelijke voorspeler voor 
metastasen. Het voorspelde 5-jaars metastasen risico is bijvoorbeeld 14,1% (95% CI 7,9-
21,9) in patiënten met een T1b adenocarcinoom van de slokdarm <20mm, sm1 diepte invasie 
en geen LVI, in vergelijking met 26,3% (95% CI 10,6-45,3) als één LVI focus aanwezig is, 
43,5% (95% CI 26,6-61,5) als 2-3 LVI foci aanwezig zijn, en 54,4% (95% CI 33,7-72,8) als ≥4 
LVI foci aanwezig zijn. Deze resultaten suggereren dat kwantificatie van LVI de risicoschatting 
in pT1b EAC verder kan verfijnen. 
In Deel IV vatten we de belangrijkste bevindingen van dit proefschrift samen in Hoofdstuk 
11.1. Hoofdstuk 11.2 omvat de algemene discussie gevolgd door de aanbevelingen voor 












AE adverse event 
ASA American Society of Anesthesiologists 
BE Barrett’s esophagus 
BMI body mass index 
CI confidence interval 
CRT chemoradiotherapy 
CT computed tomography 
dCRT definitive chemoradiotherapy 
df degree of freedom 
EAC esophageal adenocarcinoma 
EBD endoscopic baloon diltion  
EC esophageal cancer 
EGD esophagogastroduodenoscopy 
EGJ esophagogastric junction 
EMR endoscopic mucosal resection 
EoE eosinophilic esophagitis  
ER endoscopic resection  
ERA endoscopic reassessment 
ESCC esophageal squamous cel carcinoma 
ESD endoscopic submucosal dissection 
ESGE European Society of Gastrointestinal Endoscopy 
ESPT esophageal second primary tumors 
EUS endoscopic ultrasound 
F female 
FFPE formalix-fixed paraffin-embedded 
FE fixed-effects 
FNA fine needle aspiration 
GEJ gastroesophageal junction 
GI gastro-intestinal 
H&E hematoxylin and eosin stained 
HGD high grade dysplasia 
HGIN high grade neoplasia 
HN head and neck 
HNSCC head and neck squamous cel carcinoma 
HNSPT head and neck second primary tumor 
HR hazard ratio 
HPV human papiloma virus 
I2 inconsistency index 
IQR interquartile range 







LCE  lugol chromoendoscopy 
LGD  low grade dysplasia 
LGIN  low grade neoplasia 
LNM  lymph node metastasis 
LVI  lymphovascular invasion 
LVL  lugol voiding lesions 
M  male 
MBM  multiband mucosectomy 
MINORS Methodological Index for Non Randomized Studies 
MPT  multiple primary tumor 
MRI  magnetic resonance imaging 
NBI  narrow band imaging 
NCR  Netherlands Cancer Registry  
nCRT  neo-adjuvant chemoradiotherapy  
PET  positron emission tomography 
PGA  polygycolic acid sheet 
prepTstage pre-treatment pathological tumor stage 
prepNstage pre-treatment pathological node stage 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
Pro  prospective 
pt  patient 
pTN-stage pathological tumor and node stage 
PVV  positive predictive value 
PY  pack years 
RCT  randomized controled trial 
Rel  relevance 
Retro  retrospective 
RFA  radiofrequency ablation  
RSS  Ramsay Sedation Scale 
SCC  squamous cel carcinoma 
SHR  subdistribution hazard ratio  
SIR  standardized incidence ratio 
SE  standard error 
SP  sedation practitioner  
SPT  second primary tumor 
Tis  carcinoma in situ 
TNM  Tumor Node Metastasis 
UADT  upper aerodigestive tract 
 
WLE  white light (high resolution) endoscopy  
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